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 Several classes of antimetabolites have been developed for the treatment of cancer, including 
numerous inhibitors of nucleotide biosynthesis.  N-(phosphonacetyl)-L-aspartate (PALA) and 
hydroxyurea (HU) are two antimetabolites that inhibit nucleotide biosynthesis; PALA inhibits de novo 
pyrimidine synthesis and HU inhibits the conversion of ribonucleotide diphosphates to 
deoxyribonucleotide diphosphates.  Due to the similar mechanisms, it was thought that cancer cells would 
respond similarly to HU and PALA treatment.  However, studies in this dissertation revealed strikingly 
different responses to either HU or PALA treatment in HCT116 cells.  A cytoprotective S-phase arrest 
was activated upon HU treatment while PALA treatment failed to activate the S-phase checkpoint, 
  
 
 
resulting in p53-dependent apoptosis.  The checkpoint effector kinase, Chk1, was not significantly 
phosphorylated during PALA treatment due to a failure to recruit ATR, the upstream kinase, to chromatin 
sites.  The post-translational modifications of p53, phosphorylation of serines 46 and 392, suggested that 
PALA treatment promotes the accumulation of a transcriptionally active p53 while HU does not.  ChIP 
analysis showed that p53 bound to pro-apoptotic promoters, therefore activating p53-dependent apoptosis 
during PALA treatment.  To gain more insight into these differential cellular responses, we developed a 
tandem-affinity purification (TAP) tagged p53 cell line in which a TAP tag was inserted into the C-
terminus of the endogenous p53 genetic locus through homologous recombination.  This technology 
allows purification of p53 with its protein binding partners at endogenous expression levels.  The tagged 
p53 accumulated and bound to promoters in response to DNA damage similar to the untagged p53, 
suggesting that the TAP tag did not interfere with the normal cellular functions of p53.  Using mass 
spectrometry, we can identify the different p53 protein binding partners in response to PALA or HU 
treatment.  We can also determine the variable pattern of post-translational modifications on different 
drug-stabilized p53 and determine which modifications are responsible for promoting apoptosis versus 
cytoprotective arrest.  We can then exploit the identified proteins and post-translational modifications in 
the development of new chemotherapeutic agents.   
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Chapter 1: Overview and Introduction 
 
Development of Cancer Chemotherapy  
The origin of cancer chemotherapy dates back to World War I, when soldiers whom were 
exposed to mustard gases experienced dramatic symptoms, including significant bone marrow 
depression (Krumbhaar and Krumbhaar, 1919).  Many years after this initial observation the 
biological action of mustard gases was investigated and it was found that proliferating cells are 
selectively vulnerable to mustard gases (Gilman and Philips, 1946). An initial clinical trial with a 
patient with non-Hodgkin lymphoma resulted in a dramatic anti-tumor effect with the use of 
mustard gas (Gilman, 1963).  This experience with mustard gas was instrumental in the 
development of the concept that drugs could be administered systemically to induce tumor 
regression.     
The next major advance in cancer chemotherapy was the development of antifolates.   
Syndey Farber made the discovery that administering folic acid to children with acute 
lymphoblastic leukemia (ALL) stimulated the proliferation of the cancer cells (Farber et al., 
1947).  This observation led to the development of aminopterin, a folic acid antagonist.  
Aminopterin induced remission in children suffering from ALL, the first time that induction of a 
temporary remission from cancer by drug was observed (Farber and Diamond, 1948).  The 
concept of targeted therapeutics designed to inhibit cellular division led to the beginning of 
modern chemotherapy.   
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Antimetabolite development began to focus on DNA and RNA precursors in the early 
1950‟s with the development of the purine analog 6-mercaptopurine (Hitchings and Elion, 1954), 
which was shown to have anti-cancer activity  in mice with acute leukemia (Hitchings and Elion, 
1954; Skipper et al., 1954). Pyrimidine analogs were also developed, the first being 5-
fluorouracil, which was shown to inhibit the growth of transplanted tumors in mice 
(Heidelberger et al., 1957; Heidelberger et al., 1958).  5-FU is one of the oldest 
chemotherapeutic agents that is still in use for the treatment of several human cancers including 
colorectal, breast, stomach and pancreatic cancers, suggesting that this field of chemotherapy 
drugs is still very much alive.   
 
A novel inhibitor of de novo pyrimidine synthesis 
N-(phosphonaceytl)-L-aspartate (PALA) was synthesized in the search for specific 
inhibitors of nucleotide synthesis.  Unlike 5-FU which requires cellular metabolism to convert it 
to its active form, 5-fluorodeoxyuridine monophosphate (FdUMP), which inhibits thymidylate 
synthase, PALA directly binds to and inhibits the second enzyme in de novo pyrimidine 
synthesis, aspartate transcarbamylase (Fig 1-1) (Collins and Stark, 1971).  This enzyme consists 
of five subunits, two catalytic subunits and three regulatory subunits (Kantrowitz and Lipscomb, 
1988).  The end product of pyrimidine synthesis, cytidine triphosphate, interacts with the 
regulatory subunit decreasing the catalytic activity through negative feedback.  Adenosine 
triphosphate also interacts with the regulatory subunit exerting the opposing effect, stimulating 
the catalytic activity of the enzyme (Gerhart and Pardee, 1962; Pardee and Yates, 1956).  These 
feedback mechanisms maintain balanced levels of purines and pyrimidines in the cell for 
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Figure 1-1. De novo pyrimidine and purine nucleotide synthesis pathway.  Inhibition of the 
enzymes in this pathway by HU and PALA is indicated by red T-bars.  AT, aspartate 
transcarbamylase and RR, ribonucleotide reductase. 
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nucleotide synthesis.  The catalytic subunit binds L-aspartate and carbamyl-phosphate catalyzing 
the formation of carbamyl-L-aspartate, the first precursor committed exclusively to the 
biosynthesis of pyrimidines (Fig 1-2) (Reichard and Hanshoff, 1956). 
Ultraviolet difference spectroscopy of the catalytic of subunit of E. coli aspartate 
transcarbamylase with various substrates demonstrated that the enzyme binds the transition state 
of the reaction more tightly than the substrates (Collins and Stark, 1969).  The enzyme-carbamyl 
phosphate complex binds the inhibitor succinate more tightly than the natural substrate L-
aspartate because it allows the conformational shift required for the reaction to occur without 
colliding with the carbamyl-phosphate.  A model of the transition state of the aspartate 
transcarbamylase reaction was created on the basis of these observations in which the enzyme 
converts a portion of the electrostatic binding energy of L-aspartate into energy needed to force 
the two substrates together (Fig 1-2) (Collins and Stark, 1969).  Using this model, PALA was 
synthesized as a transition state analog designed by combining structural features of the 
substrates (carbamyl phosphate and L-aspartate) and of the product (carbamyl-L-aspartate) of the 
aspartate transcarbamylase reaction (Fig 1-2) (Collins and Stark, 1971). 
PALA simultaneously interacts with aspartate transcarbamylase at the binding sites for 
carbamyl-phosphate and L-aspartate with a Ki of 0.162 M (Cohen and Schachman, 1986; 
Collins and Stark, 1971).  It is a competitive inhibitor with carbamyl-phosphate at the catalytic 
subunit of the enzyme.  Due to the ordered sequence of the reaction, carbamyl phosphate must 
first be bound to aspartate transcarbamylase in order for L-aspartate to bind; an excess of L-
aspartate does not relieve PALA inhibition (Collins and Stark, 1971).  Ultraviolet difference 
spectroscopy of PALA and aspartate transcarbamylase produced the same spectrum as was 
observed with carbamyl-phosphate and succinate, thus indicating that PALA inhibits the enzyme  
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Figure 1-2. The chemical reaction catalyzed by aspartate transcarbamylase. 
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in a conformation closely resembling that associated with the transition state (Collins and Stark, 
1971).   
Initial studies with PALA in mammalian cells showed that PALA blocked proliferation 
and was cytotoxic.  These effects were completely reversed with the addition of the nucleoside 
uridine indicating that PALA specially inhibits de novo pyrimidine synthesis (Swyryd et al., 
1974). These initial studies suggested that PALA might have a clinical use in inhibiting cellular 
proliferation.  In mice bearing transplanted tumors, PALA treatment delayed tumor growth and 
caused a partial regression.  The most sensitive of these tumors was the Lewis lung carcinoma, a 
tumor that is refractory to most antiproliferative agents (Johnson et al., 1976).  Doses of PALA 
which delayed the growth of Lewis lung carcinoma depleted the uracil and cytosine levels in the 
tumor without having an effect on the pyrimidine pools of liver, spleen or lung, indicating the 
specificity of PALA for rapidly proliferating cancer cells (Moyer and Handschumacher, 1979).  
This specificity was strictly found for solid tumors, including Lewis lung carcinoma, B16 
melanoma and colon carcinoma 26, while L1210 and P388 leukemia are virtually insensitive to 
PALA (Johnson et al., 1976; Tsuboi et al., 1977).  The spectrum of sensitivity of PALA to 
several experimental cancers inversely correlated with the cellular content of aspartate 
transcarbamylase.  Interestingly, slow growing solid tumors in culture had lower levels of 
aspartate transcarbamylase than the fast growing leukemic cells (Johnson et al., 1978).  This 
implies that PALA would potentially be an important drug for the slow growing, often drug 
refractory, solid human carcinomas.  
 The depletion of pyrimidine pools by PALA is considered to be essential for its antitumor 
activity.  After 5 hours of PALA treatment in L1210 cells, UTP and CTP pools decreased to 10% 
of the control while ATP pools increased to 120% of control and GTP pools remain unchanged 
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(Moyer et al., 1982).  Subsequently, DNA synthesis was 80% inhibited as measured by pulse 
labeling with 
3
H-guanosine.  Mice bearing transplanted tumors from L1210 cells were treated 
with PALA for 24 hours and showed similar trends and mirrored what was observed in Lewis 
lung carcinoma (described above); there were large decreases in CTP and GTP pools to 30-40% 
of the control, while ATP pools increased and GTP did not change (Moyer and 
Handschumacher, 1979; Moyer et al., 1982).          
  
Clinical Evaluations of PALA 
 As a result of the promising preclinical antitumor effects of PALA, Phase I clinical trials 
were conducted in the late 1970‟s.  In the first clinical trial, thirty-six patients were included, the 
majority of whom had either colon or lung cancer (Erlichman et al., 1979).  All patients received 
a daily 15 minute intravenous infusion for a total of five consecutive days repeated every three 
weeks due to the rapid renal excretion of PALA with a plasma elimination t1/2 of 4.6 hours.  
Dose limiting skin and gastrointestinal toxicities were observed at the highest doses.  Only one 
patient with metastatic colon carcinoma showed signs of a clinical response to PALA after 8 
months of treatment; in this patient, lung metastases decreased by more than 50% and several 
liver lesions also decreased in size (Erlichman et al., 1979).  Phase II trials conducted in patients 
with colon, rectal or non-small cell lung cancer did not demonstrate significant antitumor 
activity, preventing further trials with PALA as a single agent (Carroll et al., 1980; Casper et al., 
1980; Van Echo et al., 1980). 
Experiments focusing on a possible combination therapy with PALA and other drugs 
began shortly after the completion of Phase II trials with PALA alone.  When thymidylate 
synthetase is inhibited with 5-FU the conversion of dUMP to thymidylate is blocked causing an 
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accumulation of dUMP, which may interfere with FdUMP further binding and inhibiting 
thymidylate synthetase (Moran et al., 1979).  If dUMP accumulation after 5-FU treatment could 
be prevented with the use of PALA, the inhibition of FdUMP on thymidylate synthetase might 
be enhanced.  This hypothesis was tested; a 12-18 hour pretreatment with PALA followed by a 
two hour incubation with 5-FU increased FdUMP levels more than two fold and decreased 
dUMP levels three fold when compared to 5-FU alone in sarcoma cells (Liang et al., 1982). 
Encouraging experimental data led to a Phase I clinical trial consisting of 16 patients who 
received a 24-hour transfusion of PALA followed by an IV bolus of 5-FU daily for 5 days.  This 
cycle was repeated every 28 days.  Side effects included hair loss, diarrhea, skin rash, 
myelosuppression and dose-limiting gut toxicity (Meshad et al., 1981).  One patient who was 
previously resistant to 5-FU responded to the combination treatment. A subsequent Phase II 
clinical trial with 57 patients treated with the same regimen concluded that 14% of the patients 
with the diseases responded to the drug combination.  Of the responding patients, one with colon 
cancer and two with breast cancer had previously failed to respond to 5-FU alone.  Although the 
outcome of the trials showed some promise, it was concluded that there was minimal advantage 
of PALA treatment in combination with 5-FU (Weiss et al., 1982).   
Other drug combinations attempted to augment the incorporation of FUTP into RNA 
after administration of 5-FU, an alternative mechanism of the drug.  When thymidine was 
administered before 5-FU in humans, it was shown to increase the half life of 5-FU by more than 
five-fold, an effect due to competition between 5-FU and thymidine at dihydropyrimidine 
dehydrogenase, the rate limiting process for 5-FU elimination (Woodcock et al., 1980).  
Subsequently, a Phase II clinical trial of the combination of FU, PALA, and thymidine was 
conducted in 37 patients with colorectal cancer.  The dosing regimen consisted of an IV infusion  
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of PALA administered on day 1 followed by an IV infusion of thymidine 24 hours later on day 2 
directly followed by an IV infusion of 5-FU.  Treatment was repeated every four weeks 
(O'Connell et al., 1984).  Although primary toxicities of leucopenia and ataxia were noted, there 
was a 27% response rate to this combination therapy over the historical response rate of 17% 
obtained after therapy with 5-FU alone.  The dose-limiting leucopenia toxicity of the regimen 
prevented increasing the dosage of 5-FU. 
Clinical trials using PALA in combination with other drugs, including methotrexate, ara-
C and dipyridamole, continued until the mid 1990‟s but none resulted in any appreciable 
advantage in the treatment of cancer (Grem et al., 1988; Kemeny et al., 1989; Markman et al., 
1987).    
 
Hydroxyurea, a classic inhibitor of deoxynucleotide synthesis 
 Hydroxyurea, HU, was first synthesized in Germany by Dresler and Stein in 1869 (Fig 1-
3) (Dresler and Stein, 1869).  One hundred years after its original synthesis, it was discovered 
that HU inhibits ribonucleotide reductase, inhibiting the conversion of the four ribonucleotide 
diphosphates into deoxyribonucleotide diphosphates, the rate limiting step in the biosynthesis of 
DNA (Fig 1-1) (Krakoff et al., 1968).  Mammalian and Escherichia coli ribonucleotide reductase 
consists of four subunits, two pairs of dimers, R1 and R2 (Reichard and Ehrenberg, 1983). Two 
active sites are formed at the interface between the R1 and R2 subunits.  Each active site contains 
two sulfhydryl groups from the R1 subunit and a stable tyrosyl radical and two nonheme irons 
from the R2 subunit.  Ribonucleotides bind to the R1 subunit and the sulfhydryl groups, tyrosyl 
radicals and nonheme irons participate in the reduction of the ribonucleotides (Atkin et al., 1973; 
Brown et al., 1969; Reichard, 1993).  There are multiple levels of regulation of ribonucleotide  
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Figure 1-3. The chemical structure of hydroxyurea 
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reductase activity in place to obtain a balanced supply of dNTPS.  Each R1 subunit contains two 
regulatory sites; one binds ATP activating the enzyme or dATP inactivating it, while the other 
binds effector molecules (ATP, dATP, dTTP or dGTP) altering the substrate specificity (Brown 
and Reichard, 1969; Reichard, 1987).  HU scavenges the tyrosyl free radical, reducing it to a 
normal tyrosine residue, inhibiting the enzymatic activity of ribonucleotide reductase (Reichard 
and Ehrenberg, 1983).  The –NH-OH segment of HU was shown to be essential for inhibition as 
detected in human recombinant holoenzyme-based in vitro assays (Shao et al., 2005).  Using 
electron paramagnetic resonance, the inhibitory reaction between HU and purified R2 subunit of 
ribonucleotide reductase from mouse and E. coli was determined to be a one-electron transfer 
from HU to the tyrosyl radical (Lassmann et al., 1992).  Studies with ribonucleotide reductase 
purified from Chinese hamster ovary cells demonstrated that HU noncompetitively inhibits the 
enzyme with a Ki of 0.08 mM for CDP reduction, 0.13 mM for ADP reduction and 0.07 mM for 
GDP reduction (Lewis and Wright, 1978). There are several other types of ribonucleotide 
reductase inhibitors (Reviewed in (Shao et al., 2006)).  Other inhibitors that also scavenge the 
tyrosyl free radical include trimidox, nitric oxide and didox.  Triapine chelates the iron groups in 
the R2 subunit inhibiting the enzyme.  The R1 subunit is also a drug target.  Caracemide and 
cisplatin inactivate the sulfhydryl groups and there are also several nucleoside analogs that bind 
to and inhibit the R1 subunit including, gemcitabine, tezacitabine and cytarabine.  
 The mechanism of action of HU was first linked to decreased nucleotide pools in E. coli 
(Neuhard, 1967).  Further analysis in mouse embryonic fibroblast 3T6 cells showed that, after 10 
minutes of HU treatment, dCTP, dGTP and dATP pools had decreased to 40% of the control 
while dTTP pools increased to 150% of the control (Bianchi et al., 1986).  Thymidine 
incorporation into DNA was inhibited after 10 minutes of HU treatment indicating that the 
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decreases in nucleotide pools effectively inhibited DNA synthesis.  When HU was given to 
animals, a marked leukopenia and anemia resulted, suggesting that HU might be active against 
leukemia (Rosenthal et al., 1928).  Similar results were obtained when U251 human glioblastoma 
cells were treated with HU; after 2 hours dATP, dGTP and dCTP pools decreased while dTTP 
pools increased (Ostruszka and Shewach, 2003).  Interestingly, after 24 hours of HU treatment, 
dATP pools remain decreased to 1% of the control while dGTP were 40% of control and both 
dCTP and dTTP pools increased to 175% of control.   In 1963, HU was found to be active in 
L1210 mouse leukemia, doubling the life span of the treated mice (Stearns et al., 1963).  This 
study resulted in clinical trials on patients with various types of cancer. 
 
Clinical Evaluations of HU 
 Initial clinical trials of HU began in the 1960s in patients with a range of tumors.  Patients 
with solid tumors experienced minimal improvement, while patients with chronic myelogenous 
leukemia, CML, experienced a decrease in leukocyte counts, a decrease in splenomegaly and an 
improvement in anemia (Fishbein et al., 1964; Thurman et al., 1963).  A clinical trial focused on 
patients with CML administered a dose of 50 mg/kg/day of HU in two divided doses until the 
white blood cell count was 40% of the pretreated value, with the average length of treatment 
being ten days.  The treatment of HU effectively controlled all nine patients with CML, but 
continuous therapy was required to maintain remission.  Four of the nine patients were 
previously not responsive to busulfan, which led to the Federal Food and Drug Administration 
approving HU for the use in CML refractory to busulfan therapy (Kennedy and Yarbro, 1966).  
Subsequent trials proved that HU can be used as a primary therapy for CML and is currently 
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used in crises to rapidly reduce the number of white blood cells (Kennedy, 1972; von Bubnoff 
and Duyster, 2010).  
 When Chinese hamster ovary cells were treated with HU prior to or after IR treatment, 
the effects of radiation were more cytotoxic when compared to IR alone as measured by colony 
formation assays, implying HU is a radiosensitizing agent (Sinclair, 1968).  Clinical trials began 
in 1969 for the combination treatment of head and neck carcinoma with IR and HU.  Twenty 
patients received HU every third day with simultaneous treatment with IR over a period from 
three to ten weeks, while another 20 patients received IR with a placebo.  Following the 
treatment with irradiation, patients continued receiving HU for six to eight weeks.  Excluding the 
patients that underwent surgery, 6 out of the remaining 11 patients who received the combination 
therapy went into complete remission, while 2 out of the 11 patients who received placebo went 
into remission (Richards and Chambers, 1969).  Several other clinical trials all demonstrated HU 
in combination with IR treatment is more beneficial than IR treatment alone in the treatment of 
head and neck carcinoma; HU and IR is clinically used to treat such cancers.                
 Other combination treatments with HU have been investigated but are currently not in 
clinical use.  HU in combination with ara-C has been shown to enhance the cellular metabolism 
to the active metabolite ara-CTP (Robichaud and Fram, 1987).  A phase II clinical trial in which 
21 patients with non-Hodgkin‟s lymphoma treated with HU for six days followed by a three day 
infusion of ara-C resulted in 43% treated patients going into partial or complete remission 
(Schilsky et al., 1987).  In combination with 5-FU, HU improved the survival of mice with 
L1210 mouse leukemia compared with treatment of either alone, although a clinical trial on 
patients with colon cancer showed only modest improvement (Lokich et al., 1975; Moran et al., 
1982). 
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 Currently, HU is also approved for the treatment of melanoma and inoperable, metastatic 
or recurrent ovarian cancer.  Interestingly, HU is also used to treat the painful crises of sickle cell 
anemia, decreasing the need for blood transfusions (Platt et al., 1984).  HU has been shown to 
increase fetal hemoglobin in patients with sickle cell anemia.  The increased level of fetal 
hemoglobin limits sickle-cell hemoglobin polymerization, which is responsible for the painful 
episodes (Rodgers, 1992).         
 
Cellular events induced by nucleotide synthesis inhibitors 
 Although PALA is not clinically used due to limiting efficacy at maximal tolerated doses, 
HU and PALA were shown to efficiently reduce tumor growth and in some cases even induce 
remission.  The cellular and molecular mechanisms responsible for growth arrest and kill by 
nucleotide synthesis inhibitors have been investigated.  This section will summarize what is 
presently known and how this dissertation research adds to the current understanding of the 
cytotoxicity induced by this class of antimetabolites.   
 Previous studies demonstrated that when fibroblasts with a functional p53 are treated 
with PALA, a G1 arrest results whereas cells lacking p53 were able to progress into S-phase after 
treatment, therefore indicating that p53 contributes to the G1 checkpoint (Yin et al., 1992).  In 
contrast to the p53-dependence of the PALA-induced cell cycle arrest, HU caused arrest in early 
S-phase regardless of the p53 status, suggesting that fibroblasts respond differently to various 
types of nucleotide synthesis inhibitors (Linke et al., 1996).  This concept raised a question 
which was central to this dissertation, namely, how do cancer cells molecularly respond to 
treatment with different nucleotide synthesis inhibitors?  The data suggesting p53 is not required 
for the apparent S-phase checkpoint activated by inhibitors of dNTP synthesis also raises the 
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question of whether p53 is involved in the cellular response to HU.  The molecular events of the 
G1 arrest induced by PALA treatment were shown to include p53 accumulation, p21 activation 
and hypophosphorylation of Rb (Linke et al., 2003).  Analysis of metaphase chromosomes 
demonstrated that PALA treatment did not cause chromosomal aberrations and did not cause 
DNA damage, yet p53 still accumulated.  This led to the idea that p53 could detect levels of 
nucleotide pools, activating the G1 checkpoint when pools become unbalanced (Linke et al., 
2003).  If this is true, how does this explain the observation that regardless of p53 status, HU 
treated cells arrest in early S-phase?  Can p53 only detect nucleotide pools imbalances when 
pyrimidine or purine synthesis is inhibited and not when all dNTP synthesis is inhibited?  The 
observed arrest induced by PALA treatment was not universal across all cell lines; out of five 
fibroblast cell lines studied that had wild-type p53, two arrested in S-phase while the other three 
underwent a functional G1 arrest (Agarwal et al., 1998).  Those cells that arrested in S-phase 
exhibited reduced BrdU staining and a three-fold decrease in thymidine incorporation, both 
suggesting that the arrested cells are not efficiently synthesizing DNA.  This was not observed in 
fibroblasts lacking a functional p53; these cells continued synthesizing DNA and entered mitosis, 
suggesting p53 is inhibiting DNA synthesis during an arrested S-phase (Taylor et al., 1999).  
Synthesizing DNA in the presence of limited pyrimidine pools resulted in apoptosis as observed 
from positive staining in the TUNEL assay, DNA laddering, cytochrome c release, and cleavage 
of caspases 3 and 9 (Agarwal et al., 2006).  Cells containing a wild-type p53 that arrested in S-
phase appeared to be protected from cellular death by MIC-1 (macrophage inhibitory cytokine 
1), a member of the TGF- superfamily. A follow-up study addressed how p53 is stabilized 
during PALA treatment and suggested that when normal actively dividing fibroblasts are treated 
with PALA, reversible DNA damage occurs activating ATR and subsequent phosphorylation of 
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Chk1 and p53, leading to p53 accumulation, MIC-1 induction and S-phase arrest (Hastak et al., 
2008).  There appear to be contradictions on what checkpoint, if any, is activated in p53 
competent cells treated with PALA.  Some studies indicate p53 activates the G1 checkpoint 
(Linke et al., 1996) while others suggest p53 activates the S-phase checkpoint (Agarwal et al., 
1998).  The reason for this discrepancy is not clear.  This dissertation work is aimed at clarifying 
this field and understanding the molecular activities of p53 during PALA and HU treatment.  
 HU was identified to be an S-phase specific drug when Chinese hamster ovary cells 
traversing through S-phase were killed during HU treatment while the non-S-phase cells 
accumulate at the G1-S boundary of the cell cycle and survived (Sinclair, 1965).  Flow cytometry 
analysis of G1 synchronized Chinese hamster ovary cells released into HU for 10 hours 
demonstrated that cells accumulated at the G1/S border, with approximately 10% cells entering 
S-phase as compared to the control (Tobey and Crissman, 1972).  After HU was removed, the 
cells entered S-phase synchronously and divided 6 hours later.  These experiments led to the use 
of HU as a synchronization agent that has been a very valuable approach for generating an S-
phase enriched cell population.  In the early characterization of cell-cycle checkpoints, HU was 
often used for this reason, as well as to understand how incomplete DNA replication is detected 
by cellular mechanisms.  A screen for Schizosaccharomyces pombe mutants that failed to arrest 
in the cell-cycle, and therefore initiated mitosis when DNA replication was blocked by HU, 
identified five genes named hus (hydroxyurea sensitive) 1-5, (Enoch et al., 1992).  The analyses 
of these mutants in yeast have led to the discovery of what is now known as the S-phase 
checkpoint.  It is now understood that HU activates the protective S-phase checkpoint and this 
compound is commonly used as a tool to study this cell cycle checkpoint, raising the question of 
whether other drugs that inhibit the synthesis of nucleotides will also activate this checkpoint, 
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which has been almost exclusively characterized with the use of HU.  The S-phase checkpoint is 
described in detail in the introduction of the next chapter. 
  
Focus of this Dissertation 
 Through the course of this dissertation, we investigated the cellular responses resulting 
from treatment with nucleotide synthesis inhibitors.  The precedent literature suggested that 
PALA and HU treatment would activate the same molecular event within the cell, the protective 
ATR activated S-phase arrest.  As described in Chapter 2, we determined that when human colon 
carcinoma HCT116 cells are treated with PALA or HU, both of which inhibited enzymes within 
the nucleotide synthesis pathways and thus, slowing the progress of the replication fork, the 
cancer cells respond differently at the molecular level.  PALA is cytotoxic to the tumor cells, 
while HU is cytoprotective, preventing further tumor cell growth with little immediate 
cytotoxicity.  The cellular signaling resulting from drug treatment is strikingly different, although 
both drugs cause a slowed S-phase and robust accumulation of p53.  The differences in the 
molecular response of HCT116 cells to HU and PALA will be described.  During these studies, 
we have developed a HCT116 cell line in which one allele of the p53 gene has been 
endogenously modified with a tandem affinity purification (TAP) tag.  This cell line will be very 
useful in investigating the role of p53 in the cellular events leading to the cytotoxic versus 
cytoprotective response after treatment with these nucleotide synthesis inhibitors.  The 
development and functional characterization of this cell line is detailed in Chapter 3.  The 
implications of the results presented here will be discussed in Chapter 4.   
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Chapter 2: Differential Cellular Responses to Nucleotide Synthesis Inhibitors 
 
Introduction 
 This Chapter will investigate the cellular and molecular responses of human colon cancer 
cells to different inhibitors of nucleotide synthesis.  The role of p53 in the signaling pathways 
activated by the drugs as well as the possible mechanisms causing the observed responses will 
also be addressed.  The following introduces the tumor suppressor p53, its cellular functions and 
the molecular events involved in the S-phase checkpoint.  
 
The Tumor Suppressor p53 
Structure of p53 
 p53 was discovered in 1979 as a phosphoprotein that co-immunoprecipitated with the 
simian virus large T antigen after SV40 infection and traveled at 53,000 Daltons on sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (Lane and Crawford, 1979).  
p53 was originally hypothesized to have oncogenic properties after a temperature sensitive 
mutant of the SV40 large T-antigen gene was found to cause p53 accumulation after a 
temperature shift suggesting that p53 was involved in SV40-mediated transformation (Linzer et 
al., 1979).  It is now know that the accumulation of p53 under these conditions reflects 
inactivation of p53 function by binding to the large T-antigen.  p53 was later identified as a 
tumor suppressor after the loss of p53 was found to promote cancer.  This was first reported in 
1984 when p53 was inactivated by a retroviral insertion into a leukemia virus-transformed mouse 
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cell line (Wolf and Rotter, 1984).  p53 was cloned shortly afterwards, allowing experimental 
manipulation of the gene and investigation of the consequences of such manipulations (Oren and 
Levine, 1983).   
 The p53 gene is located on the short arm of human chromosome 17 (17p13) and consists 
of 11 exons spanning approximately 20 kb of DNA (Benchimol et al., 1985; Lamb and 
Crawford, 1986).  The p53 protein consists of 393 amino acids organized into four functional 
domains (Fig 2-1).  The amino terminus of p53 contains two acidic transactivation domains, 
amino acids 1-42 and 43-60 (Fields and Jang, 1990).  Activation of gene transcription by p53 is 
facilitated through the binding of several transcription factors at the amino terminus of p53 
including the TATA binding protein (TBP) and TBP associated factors (TAFs) (Seto et al., 1992; 
Thut et al., 1995).  One nuclear export sequence is located within the transactivation domain at 
amino acids 12-27 containing two serine residues (serine 15 and serine 20), which are known to 
be phosphorylated after DNA damage, resulting in nuclear retention of p53 (Zhang and Xiong, 
2001).  Downstream from the transactivation domain there is a proline rich domain (amino acids 
64-92), which contains five repeats of the src homology 3 (SH3) binding motif PXXP where P 
represents proline and X any other amino acid (Walker and Levine, 1996).  This region has been 
linked to p53-mediated apoptosis and appears to be dispensable for transactivation and cell 
growth arrest (Sakamuro et al., 1997).  Amino acids 102-292 constitute the DNA binding domain 
that enables p53 to bind to specific DNA sequences (Kern et al., 1991).  This domain of p53 
specifically binds to the consensus binding sequence (p53 response element, p53RE) within gene 
promoters that contains two copies of the 10 bp motif 5′-PuPuPuC(A/T)(T/A)GPyPyPy-3′ 
separated by 10-13 bps where Pu is a purine base and Py is a pyrimidine base (el-Deiry et al., 
1992).  There are four conserved regions within the DNA binding domain responsible for  
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Figure 2-1. Structure of the p53 protein.  Map of the functional domains of the p53 protein, 
the amino-acid residues spanning each domain are indicated below the domain name.  p53 
consists of two amino terminal acidic transactivation domains (TAD), a proline rich (PRD), a 
central DNA binding domain (DBD), a flexible linker (L), a tetramerization domain (4DE) 
followed by the C-terminal regulatory domain (CTRD).  The nuclear export sequence (NES) and 
nuclear localization signals (NLS) are also noted. 
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contacting the minor and major grooves of the DNA within the p53-binding site.  The DNA 
binding domain contains the majority of mutation hotspots in human cancer; the most frequently 
occurring mutations are in the peptides that make the closest contacts with DNA, explaining why 
many p53 mutants are unable to bind DNA (Cho et al., 1994). 
 The C-terminal region of p53 contains a flexible linker connecting the central core 
domain to the oligomerization domain, a 32 amino acid peptide required for the formation of 
tetramers, which are the form of p53 that bind to DNA (Fig 2-1) (Kraiss et al., 1988).  Each 
monomer contains a turn, a -strand, a second turn and an -helix.  Two monomers form a dimer 
in which the -helix is anti-parallel to the -strand in the corresponding monomer.  Tetramers 
are formed by two dimers interacting through their -helices and therefore the p53 tetramer is 
known as a dimer of dimers (Jeffrey et al., 1995).  This tetramerization is required for efficient 
p53 transactivation in vivo and subsequent growth suppression (Pietenpol et al., 1994).  A 
nuclear export sequence (NES) is located at amino acids 340-351 within the oligomerization 
domain and tetramerization masks the NES resulting in nuclear retention of p53 (Stommel et al., 
1999).  The extreme C-terminal basic domain, amino acids 363-393, was initially thought to be a 
negative regulator of sequence specific binding (Hupp and Lane, 1995).  It was shown that DNA 
binding increased when the C-terminus of p53 was blocked with an antibody.  This view has 
recently changed with the discovery that p53 binds nonspecifically to DNA via the C-terminal 
domain (CTD) and then slides along the DNA searching for p53 consensus sequences and 
therefore the CTD promotes DNA binding (McKinney et al., 2004).  There are three known 
nuclear localization signals within p53, one located in the flexible linker sequence and the other 
two within the CTD (Addison et al., 1990; Shaulsky et al., 1990). 
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Accumulation and Stabilization of p53 by Post Translational Modifications 
 p53 is rapidly turned over in unstressed cells through its interaction with MDM2, a RING 
family type E3 ligase, which promotes poly-ubiquitination and proteasomal degradation (Honda 
et al., 1997).  After the genotoxic stress of IR-induced DNA damage, p53 protein levels 
increased, apparently due to a post-translational mechanism.  (Kastan et al., 1991).  Post-
translational modifications (PTMs) of p53 play a role in p53 accumulation by uncoupling the 
interaction between MDM2 and p53 thereby inhibiting its degradation (Shieh et al., 1997).  
PTMs of p53 have been extensively investigated; modifications can include phosphorylation, 
acetylation, methylation, ubiquitination, neddylation and/or sumoylation (Reviewed in (Toledo 
and Wahl, 2006)).  After different cellular stresses, PTMs are thought to act as a barcode 
dictating the multiple cellular functions of p53.  This section will address the phosphorylation 
sites which were investigated in this dissertation work.  Figure 2.2 summarizes the known PTMs 
of p53. 
 
Serine 15 
 The role of serine 15 phosphorylation in p53 biology appears to be complex.  
Phosphorylation of serine 15 is not required for p53 accumulation or transcriptional activation 
but enhances subsequent phosphorylations on neighboring residues (Fuchs et al., 1995).  
Nonetheless, MDM2 interacts with amino acids 18-23 of p53, therefore phosphorylation at serine 
15 undoubtedly promotes p53 accumulation by alleviating this inhibitory interaction (Shieh et 
al., 1997).  This residue lies within a nuclear export signal and when phosphorylated, results in 
nuclear retention of p53 (Zhang and Xiong, 2001).  After IR, phosphorylation of serine 15 
increases the ability of p53 to recruit and associate with the transcriptional coactivator proteins 
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Figure 2-2. Post-translational modifications of p53.  A map of the post translational 
modifications of p53 where each residue known to be modified is shown. Phosphorylation (P) 
sites are indicated in yellow, acetylations (A) in pink, ubiquitination (U) in grey, methylation 
(M) in as blue and neddylation (N) in green.  
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CBP and p300 (Lambert et al., 1998).  The acetyltransferase activity of p300 recognizes the C-
terminal domain of p53 as a substrate and acetylates it at lysines 373 and 382 enhancing the 
sequence-specificity of p53 binding to DNA (Gu and Roeder, 1997).  Several kinases have been 
linked to phosphorylation of serine 15, including ATM, ATR, AMPK, DNA-PK, ERK, p38 and 
CDK9 (Reviewed in (Toledo and Wahl, 2006)). In this dissertation we are most interested in the 
activity of ATR, which is known to phosphorylate serine 15 after IR and UV treatment and is 
involved in the S-phase checkpoint (see below) (Tibbetts et al., 1999).      
 
Serine 20 
 Phosphorylation of serine 20 also aids in p53 accumulation and nuclear retention in a 
similar fashion as was described for serine 15 phosphorylation.  It is also not required for p53 
stabilization and activation (Chehab et al., 1999).  Chk1, among several other kinases, have been 
identified to be capable of phosphorylating serine 20 and, rather surprisingly, other than 
facilitating p53 stabilization, no further functions of this modification have been elucidated 
(Shieh et al., 2000).   
 
Serine 37 
 Phosphorylation at serine 37 after UV and IR treatment appears to be important in p53-
dependent transcription.  Mutating this serine residue to an alanine significantly impairs the 
transactivating ability of p53 in a MDM2-luciferase reporter assay (Dohoney et al., 2004).  
Sequence-specific DNA binding of p53 is also enhanced when serine 37 is phosphorylated.  The 
phosphorylation of serine 37 was shown to stimulate the interaction between p53 and the 
transcriptional coactivators p300 and PCAF which acetylate p53 at lysine 382 and lysine 320, 
respectively, activating the sequence-specific DNA-binding of p53 (Sakaguchi et al., 1998).           
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Serine 46  
 Phosphorylation of serine 46 has been implicated in p53 dependent apoptosis.  When this 
residue is mutated to an alanine, cells have a reduced ability to induce apoptosis after UV 
treatment when compared to cells containing wild-type p53.  Phosphorylation of p53 at serine 46 
by the kinase HIPK2 induces the p53 dependent transcription of p53AIP1, a protein known to 
induce apoptosis by disrupting the mitochondrial membrane potential (D'Orazi et al., 2002; Oda 
et al., 2000).  One study demonstrated that the phosphorylation status of serine 46 dictates the 
promoter selection of p53 (Mayo et al., 2005). Thus, during mild VP16-induced DNA damage, 
serine 46 is not phosphorylated and p53 thereby activates the transcription of MDM2 inducing 
the autoregulatory feedback loop.  After extensive VP16-induced DNA damage, serine 46 is 
phosphorylated and the transcriptional activation by p53 becomes more extensive, for instance, 
PTEN transcription is activated favoring apoptosis (Mayo et al., 2005).  
 
Serine 392   
 Thermodynamic studies demonstrated that phosphorylation of serine 392 significantly 
enhanced tetramer stability, possibly through hydrogen bonds between the phosphorylated 
residue and the N-terminal region of p53 (Sakaguchi et al., 1997).  DNA binding and 
transcription activation of p53 is also enhanced after phosphorylation of serine 392 during UV 
treatment (Hupp et al., 1992; Keller et al., 2001).   All of these effects of phosphorylation of 
serine 392 appear to be important for the anti-proliferative activity of p53.  When SV3T3 mouse 
cells were transfected with p53 containing an alanine at this residue, this mutant p53 was unable 
to suppress colony formation as compared to cells transfected with wild-type p53 (Milne et al., 
1992).  
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Transcriptional Regulation by p53 
 As described in the previous section, p53 contains a DNA binding domain which 
specifically binds the p53 response element (p53RE) within promoter regions of various genes, 
and a C-terminal domain, which has been shown to non-specifically bind DNA and then 
coordinate the linear search of DNA for p53REs (el-Deiry et al., 1992; McKinney et al., 2004).  
This section will further explain how p53 regulates gene transcription from binding to the p53RE 
to transcriptional elongation. 
 
p53 Response Element 
 The p53RE contains two copies of the 10 bp motif 5′-PuPuPuC(A/T)(T/A)GPyPyPy-3′ 
separated by 10-13 bps where Pu is a purine base and Py is a pyrimidine base (el-Deiry et al., 
1992).  However, p53 is somewhat promiscuous when binding to promoters.  It has been shown 
that tetrameric p53 is able to recognize, bind and transactivate genes from noncanonical 
consensus sequences containing only half of the consensus sequence (Jordan et al., 2008).  
Overall, the literature suggests that different p53RE have different binding affinities for p53.  A 
study using a red-white p53 reporter system in Saccharomyces cerevisiae measured the ability of 
p53 to transactivate the reporter gene from various p53REs.  It was shown that there is as much 
as a 1000-fold difference between the transactivation from weaker p53RE to stronger p53RE.  
The upstream p21 p53RE had the highest affinity, while the p53RE within the BAX promoter 
had the weakest affinity (Inga et al., 2002). In vitro thermodynamic studies using fluorescence 
anisotropy to measure the ability of purified p53 to bind to fluorescein labeled p53RE 
oligonucleotides agreed with the yeast model, demonstrating that the upstream p21 p53RE has 
greatest affinity and the promoters of other p53-regulated cell cycle genes, cyclin G, 14-3-3 and 
  
26 
 
GADD45 also have higher binding affinity than the proapoptotic genes PUMA, BAX and 
p53AIP (Weinberg et al., 2005).  Post translational modifications of p53 and p53 binding 
partners also contribute to the diversity of the transcriptional response.  For instance, the 
phosphorylation of serine 46 discussed above has been shown to selectively induce p53 to 
transactivate the pro-apoptotic gene p53AIP (Oda et al., 2000).  The ASPP family of proteins 
bind to p53 and promote transactivation of the pro-apoptotic gene bax; this is not observed with 
the cell cycle regulator p21 (Samuels-Lev et al., 2001).  The control of genes transactivated by 
p53 is an enormously complex process for which multiple p53 post translational modifications 
and protein interactions with binding partners effect promoter selectivity.   
 
Transcriptional Initiation 
 Prior to transcriptional initiation the chromatin around a promoter must be modified to 
open the chromatin structure allowing the general transcriptional initiation machinery to bind to 
the DNA.  The role of p53 in this process is intricate.  After p53 has bound to the p53RE, histone 
acetyltransferases (HATs) are recruited to acetylate the histones surrounding p53 (Lill et al., 
1997).  One such HAT that is recruited to promoters is p300/CBP following the interaction of 
CBP with the transactivation domain of p53.  Not only does p300/CBP acetylate the histones 
bound to DNA in the vicinity of p53, it also acetylates the CTD of p53 increasing the activation 
of gene transcription (Gu and Roeder, 1997).  After the opening of chromatin, the general 
transcription machinery can be recruited to form the preinitiation complex (PIC).  p53 is known 
to act with several components of the PIC to initiate transcription.  The assembly of complexes 
containing p53, TBP, the TBP associating factors (TAF), TAFII60, TAFII40 and TAFII250 can 
activate transcription.  When leucine 22 and tryptophan 23 residues of p53 that have been shown 
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to interact with the transcriptional machinery, were mutated to alanine, the transcriptional 
activity of the complex decreased (Thut et al., 1995).   
 The composition of the PIC required for transcriptional activation differs between gene 
loci as well as the stress stimuli.  Two examples of this are the p21 and FAS promoters.  Prior to 
any cellular stress, p53 is poised at the p21 promoter along with components of the PIC, TBP 
and paused RNA polymerase (Espinosa et al., 2003).  After UV stress, increased levels of p53 
leads to completion of the transactivation process by p53-dependent recruitment of TAFII250 and 
stimulating the phosphorylation of serine 2 in the C terminal domain (CTD) of the paused RNA 
polymerase, converting it to the elongation form.  In contrast, the FAS promoter does not contain 
a TATA box.  Prior to any stress, p53 is also poised but the levels of paused RNA polymerase 
are significantly lower than found at the p21 promoter (Espinosa et al., 2003).  After UV 
treatment, p53 levels increase recruiting HATs and TAFII250 to the promoter.  There is no net 
loss of paused RNA polymerase at the promoter after the appearance of the elongation form, 
suggesting that the initiation and elongation rates were similar.  The difference between these 
two promoters demonstrate that cell cycle genes, such as p21, are poised for rapid transcriptional 
activation after cellular stress while the transcriptional activation of the proapoptotic gene Fas is 
slower due to the lower levels of RNA polymerase poised at the promoter.  Once RNA 
polymerase is loaded onto the promoter and transcription is initiated, transcription of FAS 
remained constant because there is no net loss of paused RNA polymerase while p21 
transcription fluctuates due to varying levels of loaded RNA polymerase (Espinosa et al., 2003). 
 
Transcriptional Elongation    
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 After RNA polymerase is cleared from the promoter, its processivity is facilitated by 
several elongation factors, some of which interact with p53.  The phosphorylation of serine 392 
of p53 is often implicated in complexes with elongation factors and, as described above, this 
phosphorylation promotes oligomerization of p53 and subsequent DNA binding (Hupp et al., 
1992; Sakaguchi et al., 1997).  During the discovery that casein kinase 2 (CK2) is able to 
phosphorylate serine 392 of p53 after UV treatment, p53 was found to be in a complex with 
subunits from the FACT (facilitated chromatin transcription) complex, a known elongation factor 
(Keller et al., 2001). The human p-TEF (positive transcription elongation factor) is responsible 
for converting the paused RNA polymerase to elongating polymerase through phosphorylation at 
serine 2 in the carboxy terminal domain (Marshall et al., 1996).  The Cdk9 kinase is the 
component of p-TEF responsible for phosphorylating serine 5 of the CTD of RNA polymerase 
(Ramanathan et al., 2001; Zhu et al., 1997).  Cdk9 is known to interact with p53 and 
phosphorylate it at serine 392; the stabilized p53 then promotes transcription of Cdk9, thereby 
promoting transcriptional elongation in a feed-forward system (Claudio et al., 2006).      
 
Transcriptional Repression 
 A less studied role of p53 is transcriptional repression.  After binding to certain 
promoters,  p53 interacts with mSin3a recruiting HDAC1 (histone deactetylase), which removes 
the acetyl moieties from the chromatin causing the chromatin to close around the promoter, 
repressing transcription (Murphy et al., 1999).  The physical binding of p53 to promoters may 
occlude the binding of other transcription factors required for transcriptional activation.  This is 
observed during hypoxic stress: under these conditions p53 binds to the alpha-fetoprotein 
promoter, inhibiting the binding of the transcriptional activator HNF3 and, hence, repressing 
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transcription (Lee et al., 1999).  Although the mechanism of transcriptional repression is not 
understood yet, p53 binds to the Rad51 promoter repressing transcription of this protein critical 
to homologous recombination during DNA damage (Arias-Lopez et al., 2006).  As will be 
discussed below, this repression is of interest for this dissertation.     
 
p53 Dependent Apoptosis 
 It was first shown that p53 was involved in the apoptosis pathway when tumor cells null 
for p53 underwent spontaneous cell death after the introduction of a wild-type p53 by 
transfection (Yonish-Rouach et al., 1991).  Bax was found to be a direct transcriptional target of 
p53 and the first example of a proapoptotic gene directly regulated by p53 (Miyashita and Reed, 
1995).  The restoration of p53 in murine leukemia cells caused an increase of Bax mRNA and 
protein levels (Selvakumaran et al., 1994).  Since then several other pro-apoptotic genes have 
been identified that are regulated by p53, including p53AIP1, APAF1, Caspases 1, 6 and 10, 
FAS, PUMA, DR4 and DR5.  Upon binding to the promoters of these genes, p53 activates 
transcription, thereby promoting the downstream components of the apoptosis cascade 
(Reviewed in (Riley et al., 2008)). 
 Evidence for a role of p53 in the regulation of apoptosis that was independent of 
transcription was first hypothesized after transcriptionally inactive mutants of p53 were found to 
induce cell death (Haupt et al., 1995).  After DNA damage, p53 translocates to the surface of 
mitochondria prior to the release of cytochrome c from the mitochondrial intramembrane space 
and caspase 3 cleavage in the cytosol, suggesting that p53 has a direct role in the intrinsic 
pathway of apoptotic signaling (Marchenko et al., 2000).  Once at mitochondria, p53 specifically 
binds to the Bcl-2 family proteins.  The interaction between p53 and Bak releases the anti-
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apoptotic inhibitory protein Mcl-1 from complexes with Bak, allowing oligomerization of Bak 
and subsequent cytochrome c release from the mitochondria (Leu et al., 2004).  Similarly, p53 
also interacts with Bax releasing the anti-apoptotic protein Bcl-xl from Bax-Bcl-xl complexes 
and promoting Bax oligomerization and cytochrome c release (Chipuk et al., 2004).  The anti-
apoptotic proteins Bcl-xl and Bcl-2 are also modulated by p53 within mitochondria.  The DNA 
binding domain of p53 binds to Bcl-xl and Bcl-2 inhibiting their anti-apoptotic activity, again 
facilitating the release of the central mediator of the intrinsic pathway, causing cytochrome c 
release (Mihara et al., 2003; Tomita et al., 2006). 
 
p53 senses cellular stresses induced by chemotherapeutic agents 
 Due to the several roles of p53 in response to chemotherapeutic agents, the question arose 
as to what cellular changes p53 could detect after such treatments.  Most cellular responses have 
been studied in response to IR or UV; much less is known about the p53 response to nucleotide 
pool deprivations.  Ionizing radiation, camptothecin and bleomycin directly and rapidly induce 
DNA strand breaks, promoting the accumulation of significant levels of p53 within one hour of 
treatment.  Cells electroporated with DNaseI or the restriction enzyme AluI also accumulated 
p53, leading to the conclusion that DNA strand breaks initiate p53-dependent signaling pathways 
(Nelson and Kastan, 1994).  Further analyses showed that only one single DNA strand break per 
cell was sufficient to induce a p53 dependent growth arrest (Huang et al., 1996).   
 The concept that p53 could sense nucleotide levels and then would become stabilized was 
first proposed by Linke et al. (Linke et al., 1996).  In their experiment, treating WS1 embryonic 
skin cells containing a wild-type p53 with antimetabolites inhibiting different parts of de novo 
pyrimidine and purine synthesis resulted in a G1 cell cycle arrest.  In cells null for p53 the effect 
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did not occur and cells slipped into early S-phase and then arrested.  Interestingly, dNTP 
biosynthesis inhibitors caused arrest in early S-phase regardless of p53 status.  This dissertation 
addresses the question of what role, if any, does p53 have in the S-phase checkpoint.  In the 
studies of Linke and colleagues, the G1 arrest was reversed upon the addition of the limiting 
nucleotides and no apparent DNA damage was detected by metaphase chromosome analysis, 
therefore, the p53 dependent arrest was not caused by DNA damage.  This was a central paper to 
this dissertation in that it demonstrated the accumulation of p53 in response to deoxynucleotide 
deficiencies promoted cell cycle arrest.  This unique p53 dependent cell cycle arrest caused by 
nucleotide depletion is of substantial importance because if cells are allowed to divide in the 
presence of limiting nucleotides, chromosome breakages could arise due to incomplete DNA 
replication, putting the genome at risk of becoming highly unstable and tumorigenic (Linke et 
al., 1996).   
 
p53 mutations and cancer 
 In approximately 50% of human cancers p53 is mutated, making it the most commonly 
mutated gene in human malignancies (Vogelstein, 1990).  As described above, p53 is capable of 
triggering apoptosis or growth arrest, both of which aid in maintaining genome stability.  Due to 
the involvement of p53 in these pathways protecting the cell from tumorigenesis, extensive 
research has been done to further understand mutant p53 and its cellular effects.  The majority of 
p53 mutations in human cancers disrupt the ability of p53 to bind to DNA (Kato et al., 2003).  In 
a study including 280 tumors containing p53 with somatic base substitution mutations, 98% of 
the mutations fell within a 600 base pair region of p53 encompassing exons 5 through 8 (amino 
acids 110-307).  Out of the 280 analyzed, 227 were from solid tumors.  Colon, esophagus, breast 
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and non-small cell lung cancer containing the most mutations (Hollstein et al., 1991).  In 
heterozygous cells, a mutant p53 allele can alter the function of the wild-type p53 allele, have a 
dominant negative effect on wild-type p53, or results in gaining new oncogenic properties 
independent of the wild-type p53 (Baker et al., 1989).  Analysis of tumors containing allelic 
deletions in the short arm of chromosome 17, specifically the region encoding p53, showed that 
the remaining allele contained point mutations indicative of loss of heterozygosity (Baker et al., 
1989).  Upon co-translation of mutant p53 and wild-type p53, mutant p53 was found to 
oligomerize with wild-type p53, driving it to a mutant phenotype characteristic of a dominant 
negative effect (Milner and Medcalf, 1991).  Transfection of mutant p53 into p53 null tumors 
resulted in lethal tumors, demonstrating that mutant p53 may gain oncogenic properties (Wolf et 
al., 1984).        
 
DNA Replication 
 DNA replication in eukaryotic cells is an intricate process; this section will serve as a 
brief overview of the main proteins that are present at replication forks during an unperturbed S-
phase (See Figure 2-3).  Replication is initiated at multiple origins along the DNA in mammalian 
cells as was shown by audioradiography of chromosomal DNA fibers isolated from Chinese 
hamster fibroblasts (Huberman and Riggs, 1966).  The origins are marked by the formation of 
pre-replicative complexes (preRC) in G1.  The origin recognition complex (ORC) binds to the 
preRC as well as the additional replication factors, including Cdc6, Cdt1 and minichromosome 
maintenance helicase complex (MCM2-7) (Bell and Stillman, 1992).  Initiation of DNA 
synthesis is regulated by two protein kinases: S-phase specific cyclin-dependent kinase (S-CDK) 
and Cdc7-Dbf4 (DDK).  The exact mechanisms of how these kinases enhance the initiation of 
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Figure 2-3. Model of eukaryotic DNA synthesis.  Modifications of the origin of replication 
complex (ORC) by S-CDK and DDK initiates DNA replication.  MCM helicase unwinds the 
DNA allowing access to replisome proteins.  Replication protein A (RPA) binds to and stabilizes 
the ssDNA during DNA synthesis.  The replication clamp PCNA is loaded onto the complex by 
RCF forming a complex with pol.  The leading strand is indicated by the continuous arrow 
while the lagging strand is indicated by the discontinuous arrows. 
 
 
ORC MCM
Cdc
6
Cdt1
DDK
S-CDK
GINS
MCM
RPA
PCNA
Pol
RCF
Cdc45
Pol
Pole
  
34 
 
replication in eukaryotes remain to be elucidated but it is thought that they are involved in 
promoting the assembly of the active helicase CMG complex, consisting of Cdc45, MCM and 
GINS (Moyer et al., 2006).  DDK was shown to phosphorylate the N-terminus of MCM4 in 
Saccharomyces cerevisiae (Sheu and Stillman, 2006).  A mutant of MCM4 with the N-terminus 
removed was able to progress through S-phase in the absence of DDK indicating that the 
phosphorylation of MCM4 by DDK relieves an inhibitory activity (Sheu and Stillman, 2010).  
During S-phase, fired origins consist of two replication forks moving away from the origin in 
opposing directions as the DNA is unwound by the MCM helicase allowing access to replisome 
proteins including DNA polymerase- primase, replicative DNA polymerase- and polymerase-
ewhich elongate the primers, and Cdc45 (Aparicio et al., 1997; Aparicio et al., 1999).  As the 
DNA is unwound by MCM2-7 helicase and DNA is replicated by the components of the 
replisome, the replication protein A (RPA) binds and stabilizes the ssDNA as was observed by 
colocalization of the RPA subunits with newly synthesized DNA (Dimitrova and Gilbert, 2000). 
 
The S-phase Checkpoint 
 The accurate completion of DNA replication is of utmost importance for maintaining 
genomic stability and preventing carcinogenesis.  Although DNA damage can occur throughout 
all phases of the cell cycle, cells are most susceptible to genotoxic stress during S-phase and M-
phase. The S-phase checkpoint is in place to inhibit progress through S-phase and the subsequent 
mitosis when the conditions for accurate DNA replication have not been met.  This checkpoint 
would then allow time for DNA repair, recombination or apoptosis (Kastan and Bartek, 2004; 
Zhou and Bartek, 2004).         
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Function of the S-phase Checkpoint 
 The function of the S-phase checkpoint is to maintain functional replication forks in 
times of replication perturbations, to ensure successful chromosome replication. This was shown 
in yeast when kinase dead mutants of the yeast homolog to mammalian ATR (Ataxia 
telangiectasia mutated and Rad3 Related), mec1, had a significant increase in the rate of 
replication fork breakdown during HU treatment which led to replication fork collapse and 
generation of lethal double strand breaks.  When the yeast effector kinase homologous to human 
checkpoint effector kinase, Chk1, was put under the control of a Gal promoter allowing 
induction by galactose, non-induced cells were unable to recover from HU treatment, resulting in 
a decrease in viability.  This suggests that DNA damage is caused by stalled replication forks 
which are not stabilized through Chk1 signaling and this is catastrophic for the cell (Tercero et 
al., 2003).  The RecQ helicase BLM and the homologous recombination protein Rad51 are 
proteins within the ATR-Chk1 signaling cascade that have both been implicated in the restart of 
stalled replication forks after the removal of HU (Davies et al., 2007; Petermann et al., 2010).  
The S-phase checkpoint regulates BLM and Rad51 so that stalled replication forks are not 
restarted in the presence of replicative stress, which could possibly lead to replication fork 
collapse (see below) and subsequent catastrophic DNA damage.   
 In order to explain the mechanisms in which the S-phase checkpoint stabilizes stalled 
replication forks, it is necessary to discuss the remodeling of the stalled replication fork 
structures prior to the restart of S-phase events, which remain largely speculative (summarized in 
Fig 2-4).  One central model is that when a replication fork encounters a lesion in the template 
DNA, the leading and lagging strand unwind and pair with the newly replicated sister strand,  
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Figure 2-4. Pathways for restart of stalled replication forks.  Consequences of a collision of a 
replication fork with a single strand interruption (1) or a lesion (A) are shown.   After collision 
with a lesion, the stalled replication fork can become stabilized by pairing with the newly 
synthesized strand forming a Holliday Junction (AB)  Pathway F, E, D and C all show 
possible outcomes of the Holliday junction.  Pathway E resolves the lesion through Rad51-
mediated homologous recombination and BLM-mediated resolution of double Holliday 
junctions.  The other pathways stabilize the stalled replication without repair of the lesion and F 
results in a double strand break due to collapse of the replication fork by DNA junction-
processing enzymes (G).  Collision with a single strand interruption also results in double strand 
break due to replication fork collapse.  Rad51-mediated homologous recombination and 
resolution of the Holliday junction by BLM repairs the damage allowing replication restart.  
Leading strand is represented in blue and lagging strand is represented in red. DNA junction-
processing enzymes are represented by black triangles and exonucleases are represented as a .     
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creating a four-stranded DNA structure, termed fork regression.  This resembles a Holliday 
junction commonly found during recombination (AB).  The fork regression can be reversed by 
branch migration (ABC), or can undergo exonuclease degradation (ABD) and the 
replication fork will be restored to its original conformation.   The newly paired sister strand can 
also be used as a substrate for homologous recombination to repair the lesion (ABE).   If a 
replication fork encounters a single strand interruption in the template DNA, the fork collapses, 
generating a double strand break (12).  A similar structure results if the regressed fork is 
resolved by DNA junction-processing enzymes which ultimately breaks the fork into a double 
strand break ((ABFG)).  These structures can be repaired by strand invasion of the 
double-strand end into the corresponding sister chromatid followed by homologous 
recombination (234).  (Reviewed in (Atkinson and McGlynn, 2009; Budzowska and 
Kanaar, 2009; Petermann and Helleday, 2010; Weinert et al., 2009)).  The proteins involved in 
the current model of replication fork recovery are part of the S-phase checkpoint and will be 
discussed in detail below.  The phosphorylation and recruitment of the majority of the proteins 
during the S-phase checkpoint efficiently recruit and modulate the functions of BLM and Rad51 
at the stalled replication fork.    
 
Activation of the S-phase Checkpoint 
 The initial groundbreaking research that defined the S-phase checkpoint was done in the 
yeast Saccharomyces cerevisiae in the presence of hydroxyurea (HU).   Human homologs of the 
checkpoint proteins discovered in yeast have since been identified and the area of research has 
expanded into mammalian cells.  HU is an important tool in studying the S-phase checkpoint in 
both mammalian and yeast systems.  ATM (Ataxia telangiectasia mutated) and ATR are 
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members of the phosphatidylinositol kinase-related protein family and are essential for cell cycle 
checkpoint signaling in the presence of DNA damage or of stalled replication forks (Reviewed in 
Durocher and Jackson, 2001; Shiloh, 2001).  The overexpression of kinase-inactive ATR in 
fibroblasts from Ataxia Telangiectasia (AT) patients sensitizes cells to UV, IR and HU treatment 
and abolishes the activation of the checkpoint, thus implicating ATR in the S-phase checkpoint 
(Cliby et al., 1998; Wright et al., 1998).  ATR exists in a complex with ATR-interacting protein 
(ATRIP) and colocalizes to nuclei after UV and HU treatment.  ATRIP and ATR are mutually 
dependent on each other in human cells, that is, if one is deleted or knocked-down, expression of 
the other diminishes and cell cycle checkpoint control is lost (Cortez et al., 2001).   
 Electron microscopy analyses of the DNA structures accumulating during HU treatment 
in S. cerevisiae demonstrated that cells exhibit normal replication forks when treated with HU 
but sustain very slow DNA synthesis at a rate of 50 base pairs per a minute.  Interestingly, there 
is an increase of about 100 nucleotides of single stranded DNA (ssDNA) present at replication 
forks during HU, a substantially larger ssDNA fragment  when compared to those in untreated 
cells, a fact that has led to the  suggestion that the increase of ssDNA may activate the S-phase 
checkpoint (Sogo et al., 2002).  Replication protein A (RPA) has been known to coat ssDNA 
within mammalian and yeast cells; when RPA was mutated in S. cerevisiae, the S-phase cell 
cycle checkpoint was defective allowing progression through S-phase into G2 after UV treatment 
(Longhese et al., 1996; Wold, 1997).  Recruitment of ATR and ATRIP to nuclear foci depends 
on the presence of RPA which stimulates ATRIP binding to ssDNA (Zou and Elledge, 2003).  A 
substrate of ATR is Chk1, which is phosphorylated in response to UV and HU treatment (Liu et 
al., 2000).  Interestingly, this phosphorylation was shown to be dependent on the presence of 
  
39 
 
RPA lending evidence to the concept that RPA-coated ssDNA is the molecular trigger initiating 
the S-phase checkpoint (Zou and Elledge, 2003).     
 
S-phase Checkpoint Signaling 
 After nuclear localization of ATR and ATRIP and binding of this complex to RPA-
coated ssDNA, ATR phosphorylates a series of proteins and recruits them to the stalled 
replication fork in mammalian cells (Fig 2-5).  Activation of the checkpoint is thought to require 
the recruitment of the Rad9-Rad1-Hus1 (9-1-1) complex and the Rad17-replication factor C 
complex (RCF)-dependent loading of Rad9 onto the chromatin (Weiss et al., 2003; Zou et al., 
2002).  The 9-1-1 complex is a PCNA-related complex that is thought to sense DNA damage and 
the recruitment of the 9-1-1 complex to sites of DNA damage is independent of ATR, suggesting 
that it may enable ATR to recognize the damaged DNA (Volkmer and Karnitz, 1999; Zou et al., 
2002).  TopBP1 (Topoisomerase II beta binding protein 1) is recruited to stalled replication forks 
by Rad9 (Greer et al., 2003).  ATR kinase activity is activated through the interaction of TopBP1 
and ATRIP and the direct contact between TopBP1 and the PRD (PIKK phosphoinositide 3-
kinase related kinase Regulatory Domain) of ATR (Mordes et al., 2008).  ATRIP further 
stimulates the kinase activity of ATR resulting in autophosphorylation of ATR, phosphorylation 
of ATRIP and the RPA32 subunit (Cortez et al., 2001; Unsal-Kacmaz and Sancar, 2004).  Rad9 
and Rad17 are also phosphorylated by ATR (Furuya et al., 2004; Zou et al., 2002).  The above-
mentioned series of localization and phosphorylation events are the current standing model of 
ATR activation. 
 Like ATR, the main S-phase checkpoint effector kinase Chk1 is an essential gene and 
deletion of either results in an embryonic lethal phenotype in mice, indicating an irreplaceable 
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Figure 2-5. The signaling involved in the S-phase checkpoint.  Long lengths of RPA-coated 
single-stranded DNA activates the checkpoint signaling.  RPA-dependent binding of ATRIP  to 
DNA and interaction with TopBP1 activates ATR kinase activity.  ATR phosphorylates several 
key checkpoint proteins, including Chk1 which is dependent on the presence of Claspin.  
Phosphorylated and activated Chk1 is the central kinase in the S-phase checkpoint.  
Phosphorylation of signaling proteins by Chk1 leads to recruitment of these proteins to the 
stalled replication fork and subsequent replication fork stabilization.       
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role for both kinases in development (Brown and Baltimore, 2000; Takai et al., 2000).  Activated 
ATR phosphorylates Chk1 at serines 317 and 345 in response to HU and subsequently activates 
Chk1 as detected by the phosphorylation of the known Chk1 substrate Cdc25C (Zhao and 
Piwnica-Worms, 2001).  Phosphorylation of serine 345 is required for Chk1 activation and is 
dependent on phosphorylation of serine 317 (Lopez-Girona et al., 2001; Walker et al., 2009).  
Phosphorylation of Chk1 also requires other nuclear proteins, for instance through the interaction 
of Tipin and RPA, Timeless binds to Tipin recruiting the adaptor molecule Claspin which then 
facilitates the phosphorylation of Chk1 by ATR (Kemp et al., 2010).  Claspin is required for 
ATR-dependent Chk1 phosphorylation (Chini and Chen, 2003; Kumagai and Dunphy, 2000).  
Activated Chk1 phosphorylates downstream proteins including p53 at serine 20, BRCA2, Rad51, 
Cdc25C, 53BP1 and FANCE (Bahassi et al., 2008; Sanchez et al., 1997; Shieh et al., 2000; 
Sorensen et al., 2005; Tripathi et al., 2008; Wang et al., 2007).  The implications of these 
phosphorylations will be discussed in the next section. 
    Chk1 is not the only substrate of ATR in the S-phase checkpoint.  ATR phosphorylates 
BLM at threonines 99 and 122 during HU-induced stalled replication forks (Davies et al., 2004).  
Mutant forms of BLM transfected into BLM -/- cells in which these residues have been changed 
to alanine fail to recover from the replication blockade following HU and arrest in G2/M, 
demonstrating that the phosphorylation of BLM by ATR is required for proper recovery from S-
phase arrest.  BRCA1 is phosphorylated by ATR during HU or UV treatment and this 
phosphorylation is independent of ATM (Chen, 2000; Gatei et al., 2001).  Serine 15 of p53 is 
phosphorylated by ATR after IR, UV or HU treatment.  Kinase inactive mutants of ATR 
interfere with phosphorylation of p53 in late S-phase during IR treatment and completely 
suppress p53 phosphorylation after UV treatment, supporting the obligatory role of ATR in the 
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S-phase checkpoint (Tibbetts et al., 1999). During replication-mediated double strand DNA 
breaks induced by camptothecin, ATR phosphorylates H2AX (H2AX) an event required to 
recruit DNA repair proteins Mre11, Rad50 and NSB1 (MRN) (Furuta et al., 2003).   It is now 
known that although ATM and ATR have overlapping targets, ATM is the kinase involved in the 
G1/S and G2/M checkpoint signaling after IR treatment while ATR is activated after UV 
treatment and is involved in the S-phase checkpoint (Reviewed in (Cimprich and Cortez, 2008; 
Kastan and Bartek, 2004)).       
 
BLM and p53 
 Plasmid based assays in E. coli show that when a replication fork encounters a lesion and 
stalls, the leading and lagging strand of DNA replication uncouple and DNA synthesis continues 
on the lagging strand, generating ssDNA gaps which may activate homologous recombination 
(Pages and Fuchs, 2003).  In 1990, prior to the identification of BLM in mammalian cells, RecQ 
was characterized as a 3′ to 5′ DNA helicase in E. coli.  It was shown to initiate homologous 
recombination and unwind a broad range of DNA substrates representative of structures 
generated during recombination or replication including 3′ and 5′ ssDNA overhangs, 4-way 
junctions and 3-way junctions, thus implicating RecQ in repair of stalled replication forks 
(Harmon and Kowalczykowski, 1998; Umezu et al., 1990).  The mammalian homolog of RecQ 
is BLM, which is the gene product mutated in and causative of Bloom‟s syndrome.  Cells from 
Bloom Syndrome patients exhibit chromosomal instability due to an elevated rate of sister-
chromatid exchange suggesting that a protein involved in recombination is mutated in these cells 
(Chaganti et al., 1974).  BLM selectively recognizes Holliday junctions, a four-way DNA 
junction, and promotes the branch migration of these junctions, thereby preventing homologous 
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recombination of the regressed fork from occurring (Karow et al., 2000).  It has been 
hypothesized that, when replication forks stall, Holliday junctions may arise and resolution of 
these structures would result in a double-strand DNA break that is repaired by homologous 
recombination returning the replication fork to its original structure (Sharples et al., 1999).  p53 
has been shown to bind to BLM modulating the associated helicase activity (Yang et al., 2002).  
By inhibiting the resolution of the Holliday junctions at stalled replication forks, modulation of 
BLM by p53 prevents the collapse of the replication fork, further DNA damage, and the threat of 
tumorigenesis.  Interestingly, BLM is required for efficient localization of p53 to stalled 
replication forks during HU (Sengupta et al., 2003).  Once recruited, p53 is found to bind to and 
inhibit the pro-recombinogenic protein Rad51 as well as inhibiting BLM helicase activity.  This 
inhibition is thought to stabilize stalled replication forks by inhibiting unnecessary 
recombination.  It is also thought that the presence of p53 recruits other proteins to the stalled 
replication fork, so that the necessary homologous recombination can occur after the replication 
stress has been resolved to reinitiate the replication fork, allowing for an accurate S-phase to 
continue (Sengupta et al., 2003).   
 
Rad51 
 The double strand breaks resulting from replication fork collapse and resolution of the 
fork regression are a lethal form of DNA damage that can be repaired error-free by homologous 
recombination using the undamaged sister chromatid as a template (Johnson and Jasin, 2000; van 
Gent et al., 2001).  Homologous recombination is tightly regulated in the S-phase checkpoint to 
prevent further DNA damage during replicative stress.  Expression of Rad51 is induced in late S-
phase and G2 and binds to single stranded DNA during the initial steps of homologous 
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recombination (Benson et al., 1994; Flygare et al., 1996).  Rad51 possesses DNA-dependent 
ATPase activity which catalyzes the homologous pairing and strand exchange of the sister 
chromatid during homologous recombination leading to the formation of a Holliday junction as a 
DNA intermediate (Baumann et al., 1996).  When Chk1 was inhibited with either UCN-01 or 
caffeine during HU treatment, an increase in double strand breaks and Rad51 nuclear DNA foci 
formation resulted, suggesting that Chk1 modulates Rad51 function (Sorensen et al., 2005).  
Chk1 phosphorylates Rad51 at threonine 309 during HU treatment.  When this residue is 
mutated to alanine, cells are more sensitive to HU treatment, indicating that phosphorylation of 
Rad51 by Chk1 is required for survival after replication stress.  Importantly, less than 1% of 
Chk1 was found to immunoprecipitate with Rad51 during HU treatment in cells containing a 
Chk1 mutant where serines 317 and 345 are mutated, preventing ATR phosphorylation and 
activation of Chk1.  That is, if Chk1 phosphorylation is blocked it cannot form a complex with 
Rad51.  Therefore the ATR dependent activation of Chk1 and subsequent nuclear localization 
and phosphorylation of Rad51 is important for survival after replication–stress induced DNA 
damage (Sorensen et al., 2005).  
  When p53 was transfected into normal human fibroblast cells along with wild-type 
Rad51, the homologous recombination frequency decreased compared to cells containing only 
Rad51, suggesting that the direct binding of p53 to Rad51 inhibits the homologous 
recombination activity of Rad51 (Linke et al., 2003; Sturzbecher et al., 1996).  Rad51 and p53 
both co-localize to stalled replication forks induced by HU and their interaction inhibits the 
Rad51-driven homologous recombination at the stalled replication fork, maintaining genome 
integrity by stabilizing the stalled replication fork (Sengupta et al., 2003; Yoon et al., 2004). 
During VP16-induced DNA damage, p53 binds to the Rad51 promoter, repressing transcription 
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of Rad51, indicating that p53 controls homologous recombination when the genome integrity is 
compromised at two levels; through protein-protein interactions and through transcriptional 
repression (Arias-Lopez et al., 2006).   
 
BRCA2 
 In vitro kinase assays demonstrated that Chk1 phosphorylates BRCA2 at threonine 3387 
(Bahassi et al., 2008).  This phosphorylation was found to be required for the nuclear localization 
of Rad51 after DNA damage.  Interestingly, when the Chk1 phosphorylation site of BRCA2 is 
mutated, there is a significant increase in Rad51 binding to BRCA2 after IR treatment 
comparable to the levels observed in untreated cells with wild-type BRCA2.  After cells were 
cotransfected with BRCA2 and either a wild-type Rad51 or mutated Rad51 at the residue 
phosphorylated by Chk1, the mutant form associated with BRCA2 after UV treatment while the 
wild-type form did not.  Together these studies suggest a model of Rad51 control by Chk1 where 
BRCA2 binds Rad51 under normal cellular conditions and upon the generation of DNA damage, 
Chk1 phosphorylates BRCA2 and Rad51 releasing Rad51 allowing for Rad51 to localize to sites 
of DNA damage within the nucleus (Bahassi et al., 2008). 
 
53BP1 
 53BP1 was identified as a p53 binding partner in a two-hybrid yeast screen and was later 
found to rapidly localize to the nucleus after exposure to DNA DSB-inducing agents, implicating 
53BP1 in the cellular response to DSBs (Iwabuchi et al., 1994; Schultz et al., 2000).  Initially, 
53BP1 was found to be required for the nuclear localization of BLM and p53 during HU 
treatment in an ATR-Chk1 dependent fashion (Sengupta et al., 2004).  Co-immunoprecipitation 
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studies demonstrated that, during HU treatment, 53BP1 forms a complex with Rad51 and BLM 
(Tripathi et al., 2008).   Phosphorylation of 53BP1 by Chk1 enhanced the interaction between 
53BP1 and Rad51.  In a study on defects in cells lacking BLM, it was shown that BLM enhances 
the localization and interaction of 53BP1 and Rad51 during HU-induced replication stress.  The 
heterotrimeric complex ultimately inhibits Rad51 as was shown by a decrease in homologous 
recombination as measured by fluorimetric assay where a homologous recombination substrate is 
transfected and homologous recombination results in an emission of green fluorescence.  This 
assay also included a mutated BLM where the residue that ATR phosphorylates is mutated to an 
alanine and the homologous recombination frequency increases, indicating that this 
phosphorylation is required for the anti-recombinogenic activity of BLM (Tripathi et al., 2008). 
 
Reversal of the S-phase Checkpoint 
 After DNA damage has been repaired or the replication stressor is resolved, the S-phase 
checkpoint must be turned off to allow cells to continue replication for an accurate completion of 
S-phase.  The serine/threonine phosphatase Wip1, also called PPM1D, is the protein responsible 
for dephosphorylating Chk1, attenuating the S-phase checkpoint (Lu et al., 2005). Wip1 was first 
identified in a screen for genes induced by IR treatment in WBM Burkitt lymphoma cells.  While 
comparing mRNA Wip1 transcript levels between the WBM cells containing a wild-type p53 to 
several cell lines with varying p53 status from null to mutated, a clear correlation was observed 
between p53 status and induction of Wip1 mRNA.  Thus, the newly discovered gene was name 
Wip1, wild-type p53-induced phosphatase (Fiscella et al., 1997).  More than ten years later p53 
was found to bind to the Wip1 promoter, transactivating the transcription of Wip1 after UV  
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IR treatment.  Transcription of Wip1 is p53 dependent; in cells without p53 there are very low 
levels of Wip1 mRNA (Rossi et al., 2008).   
 Wip1 is a member of the PP2C phosphatase family.  The Wip1 sequence shows region-
specific homology at the three conserved regions among the PP2C family of phosphatase and is 
dependent on Mg
2+
 and insensitive to the inhibitor okadaic acid, all characteristics of the PP2C 
family (Fiscella et al., 1997).  Phosphatase assays demonstrated that Wip1 dephosphorylates 
Chk1 at serine 345 but not at serine 317 and that this dephosphorylation decreases Chk1 kinase 
activity by more than two fold (Lu et al., 2005).  Similarly, Wip1 was found to dephosphorylate 
p53 at serine 15.  Wip1 was knocked down with siRNA in U2OS cells: Wip1-tet on cells, or 
overexpressed following tetracycline induction and then treated with UV and the percentage of 
3
H-thymidine incorporated in DNA was measured.  In the absence of Wip1 there was 70% 
reduction of incorporation, while cells overexpressing Wip1 incorporated more 
3
H-thymidine 
than the control cells, indicating Wip1 attenuates the S-phase checkpoint as observed by an 
increase in DNA synthesis in the presence of Wip1 (Lu et al., 2005).          
 
Focus of this Chapter 
 The experiments presented in this chapter address the molecular and cellular response of 
human colon cancer HCT116 cells to nucleotide pool deficiencies induced by nucleotide 
synthesis inhibitors.  Treatment with PALA and HU resulted in slowed S-phase progression and 
p53 accumulation, yet the cellular consequences of pyrimidine deficiencies versus dNTP 
deficiencies were very different.  For example, ATR was not recruited to the chromatin during 
PALA treatment, resulting in a deficient S-phase checkpoint, and cells subsequently underwent 
p53-dependent apoptosis.  During HU treatment the S-phase checkpoint was found to be intact 
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and as a result, cells were protected from the nucleotide deficiencies.  The observations that the 
PTMs of p53 were asymmetrically opposed during the two treatments and that p53 was bound to 
pro-apoptotic promoters during PALA treatment, led us to hypothesize that p53 has a central role 
in determining the cytotoxic versus cytoprotective response to nucleotide pool deficiencies.    
 
Materials & Methods 
Drug Solutions  
 Solutions of HU (Sigma) and PALA (National Cancer Institute) were made by dissolving 
the drug in phosphate-buffered saline (PBS) containing 1.06 mM KH2PO4, 155.17 mM NaCl, 
2.97 mM Na2HPO4-7H2O, pH 7.4.  VP16 (Sigma) was dissolved in DMSO then diluted in PBS 
prior to use.  DDATHF (Eli Lilly) was dissolved in 0.2 M Tris-Cl, pH 8.9.  HU was made fresh 
prior to every use and PALA and DDATHF stocks were made and stored at -80ºC until use.     
 
Cell Culture 
 Human colon carcinoma HCT116 p53 +/+ and p53 -/- cells were generously provided by 
Dr. Bert Vogelstein (John Hopkins University).  They were grown in RPMI 1640 
(Invitrogen/Life Technologies) supplemented with 10% dialyzed fetal bovine serum (dFBS) in a 
humidified atmosphere of 5% CO2 at 37ºC.  Go/G1 synchrony was achieved by plating cells at a 
high density of 2.5 x 10
6
 cells/T-25 flask, allowing them to reach confluency (approximately 72 
hours) feeding once after 48 hours, and holding them at confluence for an additional 48 hours.  
Cells were released from postconfluent synchrony by replating at low density of 2 x 10
6
 cells/10 
cm
 
dish.     
 
Western Blotting 
  
49 
 
Cellular Lysate preparation 
 HCT116 cells were plated at 8 x 10
5
 cells/10 cm dishes and allowed to adhere for 24 
hours prior to drug treatment.  Stock solutions of drug were made as previously described, filter 
sterilized through a 0.22 M syringe filter, and added to the appropriate volume of RPMI 1640 
containing 10% dFBS to achieve the working drug concentrations.  After the time point was 
reached, cells were washed with cold PBS once and scraped into PBS containing 1x protease 
inhibitor complete mixture (Roche).  Cells were pelleted by centrifugation at 4,000 x g for 5 
minutes at 4ºC and lysed in 10x volumes of lysis buffer containing 62.5 mM Tris, pH 6.8, 5% 
glycerol, 2% SDS, 5% 2-mercaptoethanol, 0.2 mM Na3VO4, 10 mM NaF, and 1x protease 
inhibitor complete mixture (Roche Applied Science).  The samples were passed through a 22 
gauge needle ten times and debris was pelleted by centrifugation at 10,000 x g for 10 minutes at 
4ºC.  Protein concentrations were determined using the Bradford assay against a standard of 
bovine serum albumin (BSA) according to manufacturer‟s (Bio-Rad) instructions.  Lysates were 
aliquoted and stored at -80ºC.     
 
SDS PAGE and Immunoblotting 
 Laemmli sample buffer (Bio-rad) was added to 25 g of total cellular protein and the 
solution was boiled for 5 minutes.  Proteins were resolved by electrophoresis on 5%, 7.5%, 10% 
or 15% SDS-polyacrylamide gels, at 150 V in running buffer containing 25 mM Tris base, 250 
mM glycine and 0.1% SDS.  Immobilon-P polyvinylidene fluoride membrane (PVDF) was 
activated in 100% methanol for 2 minutes prior to use.  The gel and PVDF membrane were 
equilibrated in cold transfer buffer containing 25 mM Tris base and 192 mM glycine for 15 
minutes.   Proteins were transferred to the PVDF membrane for one hour at 100 V using a wet 
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transfer.  Following transfer the membrane was immersed into 100% ethanol for 15 seconds and 
dried for 15 minutes.  Non-specific protein binding was blocked in either Starting Block Buffer 
(Pierce) or a Blotto solution containing 5% milk, 0.1% Tween 20, 0.01 M Tris, pH 7.4, 0.15 M 
NaCl for 1 hour at 25ºC with gentle rocking. Blots were washed three times for five minutes 
each with TBS-T containing 0.5 M Tris pH 7.5, 0.14 M NaCl, 2.7 mM KCl, 0.05% Tween 20 at 
25ºC with vigorous rocking then incubated with primary antibody diluted in Starting Block 
Buffer or 5% milk and TBS-T for 16 hours at 4ºC with gentle rocking.  Primary antibodies were 
polyclonal phospho-Chk1 (S317, S345) both at 1:1000 (Cell Signaling Technology, #2344, 
#2341), polyclonal Chk1 at 1:1000 (Cell Signaling, #2345), monoclonal p21 at 1:100 
(Calbiochem Ab-1, OP64) monoclonal beta Actin at 1:5000 (Abcam, #8226), monoclonal p53 at 
1:100 (Calbiochem Ab-6, OP43), polyclonal Wip1 at 1:1000 (Santa Cruz H-300, sc-20712), 
polyclonal BLM at 1:500 (Santa Cruz C-18, sc-7790),  polyclonal ATR at 1:1000 (Santa Cruz H-
300, sc-28901), polyclonal trimethyl-Histone H3 (Lys4) at 1:1000 (Upstate, 07-473), polyclonal 
phospho p53 (S15, S20, S37, S46, S392) all at 1:1000 (Cell Signaling, #9284, #9287, #9289, 
#2521, #9281) and polyclonal PARP (Cell Signaling, #9542), cleaved PARP (Asp214) (Cell 
Signaling, #9541), cleaved Caspase-9 (Asp330) (Cell Signaling, #9501), cleaved Caspase-7 
(Asp198) (Cell Signaling, #9491) all at 1:1000, monoclonal phospho-H2AX (S139) at 1:1000 
(Millipore JBW301, #16-193).  Following three TBS-T washes as described above, the 
membranes were incubated for 1 hour at 25ºC with secondary antibodies conjugated to 
horseradish peroxidase (Pierce) diluted in Starting Block Buffer or 5% milk and TBS-T and 
complexes were detected by enhanced chemiluminescence using the Supersignal West Pico 
Chemiluminescent Substrate Kit or SuperSignal West Dura Extended Duration Substrate Kit 
(Pierce).  For the p53 post-translational modification blot, 25 g of cell lysates were probed for 
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p53 and the densities of the corresponding p53 signals were measured with a FluorChem SP 
Imager (Alpha Innotech).  The amount of protein required to be loaded for each treatment lane 
was calculated from the obtained densities and a second gel was set up so that equal amounts of 
p53 were present in every lane by loading different volumes of the different samples.  
 
Chromatin Immunoprecipitation (ChIP) 
Formaldehyde cross-linking and chromatin shearing 
 The ChIP assay was adapted from Bronder et al (Bronder and Moran, 2003).  
Approximately 1 x 10
7
 cells per condition were crosslinked at room temperature with 1% 
formaldehyde for 10 minutes, the reaction was then quenched for 5 minutes by the addition of 
0.125 mM glycine.  Cells were washed twice with PBS, scraped, washed in buffer I containing 
10 mM HEPES pH 7.5, 0.5 mM EGTA pH 7.5, 10 mM EDTA pH 8.0, 0.25% Triton X-100, then 
in buffer II containing 10 mM HEPES pH 7.5, 0.5 mM EGTA pH 7.5, 1 mM EDTA pH 8.0, 200 
mM NaCl.  All ChIP buffers contained 1 g/mL aprotinin, 1 g/mL leupeptin, 1 g/mL 
pepstatin, 1 mM PMSF, 0.2 mM Na3VO4 and 10 mM NaF.  Cells were lysed in lysis buffer 
containing 25 mM Tris pH 7.5, 5 mM EDTA pH 8.0, 150 mM NaCl, 1% Triton X-100, 0.1% 
SDS, 0.5% Na Deoxycholate.  Aliquots of 2 x 10
6  
cells in 600 L lysis buffer were sonicated 
with a Diagenode bath bioruptor for a total of 20 minutes with consecutive duty cycles of 30 
seconds on, 30 seconds off at 4ºC (5 minute cycles repeated a total of 4 times). These conditions 
were found to yield DNA fragments less than 1000 bp in size.   
 
Immunoprecipitation 
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 Lysates corresponding to 2 x 10
6 
cells were precleared for 1 hour at 4ºC with a 50% 
slurry of protein G-Sepharose (Amersham Biosciences) beads previously blocked with 8 g of 
BSA and either 5 g of sonicated lambda DNA or 6 g of sonicated salmon sperm DNA, then 
incubated with 2 g p53 Ab-6 (Calbiochem) antibody or 2 g IgG (Millipore) antibody 
overnight.  Antibody-protein-DNA complexes were captured by the addition of 30 L of 50% 
blocked protein G-Sepharose bead slurry for 1 hour at 4ºC.  Beads were pelleted at 4,500 x g for 
5 minutes at 4ºC and the supernatant from the IgG immunoprecipitation was saved and the DNA 
contained within was referred to as input DNA.  Beads were washed extensively twice with 
RIPA buffer (150 mM NaCl, 50 mM Tris pH 8.0, 0.1% SDS, 0.5% Na Deoxycholate, 1% NP-
40), once with High Salt Buffer (500 mM NaCl, 50 mM Tris pH 8.0, 0.1% SDS, 1% Na 
Deoxycholate), once with LiCl Buffer (250 mM LiCl, 50 mM Tris pH 8.0, 0.5% Na 
Deoxycholate, 1% NP-40), and twice with TE (10 mM Tris pH 8.0, 1 mM EDTA pH 8.0) for 10 
minutes each at 4ºC rotating end-over-end.  Protein-DNA complexes were eluted with elution 
buffer (2% SDS, 10 mM DTT, 0.1 M NaHCO3) while rotating end over end at 25ºC for 15 
minutes and the cross-links were reversed by the addition of 0.2 M NaCl and incubation at 65ºC 
overnight.  DNA was treated with 10 g of RNase for 30 minutes at 37ºC and with 20 g 
Proteinase K in 10 mM Tris pH 7.5, 5 mM EDTA pH 8.0, 0.25% SDS for 1 hour at 42ºC, 
phenol-chloroform extracted, ethanol-precipitated and dissolved in 100L TE.  
 
Quantitative PCR (Q-PCR) 
 Quantitative PCR was performed with 1 L of input DNA or ChIP DNA for each 25 L 
reaction containing 12.5 L Quantitect SYBR Green PCR Master Mix (Qiagen) and 0.3 M of 
each primer.  The sequences of the primers flanking the p53 binding sites of the analyzed 
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promoters can be found in Table 2-1.  The amplification conditions were 95ºC for 15 minutes, 40 
cycles of 95ºC for 45 seconds, for the noted Tm of each primer set in Table 2.1 for 45 seconds, 
72ºC for 45 seconds with a plate read, and concluding with a 5 minute extension at 72ºC and a 
melting curve from 45ºC to 100ºC.  Absolute quantities were calculated using a standard curve 
ranging from 100 ng to 0.8 ng of input DNA.    
 
One Parameter Flow Cytometry 
 Cells were synchronized as previously described.  At indicated times cells were collected 
by trypsinization, centrifuged at 300 x g and washed twice in PBS.  Cells were resuspended in 
propidium iodide fluorochrome stain containing 50 g/mL propidium iodine, 0.1% Triton X-
100, 7 K-units/mL ribonuclease B in 3.2 mM sodium citrate buffer at a density of 1 x 10
6
 
cells/mL.  Cell solutions were wrapped in foil and stored at 4ºC in the dark until analysis, up to 
48 hours.  Prior to analysis, cells were filtered through a 35 m nylon mesh to obtain a single cell 
suspension.  Flow cytometry was performed on a Beckman Coulter Elite XL-MCL single-laser 
flow cytometer.   
Growth Rescue with deoxyribonucleotides   
 Inosine and deoxyadenosine (AdR) (Sigma) were dissolved in PBS.  Deoxyguanosine 
(GdR) (Sigma) was dissolved in PBS and 10% the total volume of 1N NaOH was added to aid in 
solubilization.  HCT116 cells were plated in 12-well plates at 2.4 x 10
4
 cells/well and allowed to 
adhere overnight.  Triplicates were plated for every drug treatment.  Filter-sterilized drugs were 
added to RPMI 1640 supplemented with 10% dFBS and HEPES/MOPS buffer containing 20 
mM HEPES, 10 mM MOPS, pH 7.4 to obtain the working concentration and added to the plated 
cells for 72 hours.  Cells were fed after 48 hours with fresh drug-containing medium.  Cells were 
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Table 2-1. Sequence of primers used in ChIP assays to quantitate the levels of p53 residence 
at various promoters.  The sense and antisense primers are denoted next to the specific 
promoter.  The melting temperature (Tm) of each primer set follows the primers.   
  
Promoter Sense Primer Antisense Primer Tm
p21 5′ RE 5′-CTTTCCACCTTTCACCATTCC-3′ 5′-AAGGACAAAATAGCCACCAGC-3′ 53ºC
Rad51 5′-CCTCGAACTCCTAGGCTCAGA-3′ 5′-CCGCGTCGACGTAACGTAT-3′ 54ºC
WIP1 5′-ACGCCTGATTTGTGTGGTGG-3′ 5′-ACGCAGCCCGCCGAATCCG-3′ 55ºC
PUMA 5′-TGGGGGTGTGGATCTGTG-3′ 5′-AAGTCAGGACTTGCAGGCG-3′ 55ºC
FAS 5′-GCGGACAGGAATTGAAGCGGAAG-3′ 5′-GGACCTTTGGCTTGGCTTGTCA-3′ 58ºC
PIG3 5′-CCTTTCTCTTCTCTTAGCAGCACC-3′ 5′-GTGCGATTCTAGCTCTCACTTCAAGG-3′ 55ºC
BAX 5′-GCTCATGCCTGTAATCCCAGCG-3′ 5′-ACCTGGATCTAGCAATATAGCCCACG-3′ 58ºC
AIP1 5′-ATCTCTGGATGGGTAGGAGG-3′ 5′-GTTCATGTCAGGGAGGTGC-3′ 53ºC
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trypsinized and counted with the Beckman Coulter Z1 Coulter Particle Counter.  For the purine 
nucleotide rescue of HU treatment, the above solutions were used scaled up to 10 cm plates for 
lysate preparation.  
 
Co-immunoprecipitation  
 HCT116 cells were grown in RPMI 1640 supplemented with 10% dFBS.   Cells were 
plated at 3 x 10 cells/15 cm dish and allowed to adhere overnight.  Twenty-four hours after drug 
treatment plates were washed once with PBS and then scraped in 2 mL modified RIPA buffer 
containing 50 mM Tris-HCl pH 7.4, 1% NP40, 0.25% Na deoxycholate, 1mM EDTA pH 8.0.  
All buffers contained 1 g/mL aprotinin, 1 g/mL leupeptin, 1 g/mL pepstatin, 1 mM PMSF, 
0.2 mM Na3VO4 and 10 mM NaF.  Cells were lysed through gentle rocking for 15 minutes at 
4ºC.  Cell debris was pelleted at 14,000 x g for 15 minutes at 4ºC.  Protein concentration of the 
supernatant was determined with the Bradford assay as previously described.  BLM was 
immunoprecipitated from 0.75 mg of total protein with 1 g polyclonal BLM antibody (Santa 
Cruz C-18, sc-7790) adding 4 M NaCl to obtain a final concentration of 100 mM NaCl.  The 
volume of the above solution was raised to 750 L with CO-IP buffer containing 50 mM Tris-
HCl pH 7.5, 15 mM EGTA pH 7.5, 100 mM NaCl, 0.1% Triton X-100 and was incubated on ice 
for 90 minutes with occasional inverting.  Nonspecific aggregates were pelleted by 
centrifugation at 14,000 x g for 10 minutes at 4ºC.  The supernatant was incubated for 60 
minutes while rotating end over end with 50 L 50% protein G bead slurry that was previously 
washed three times with Co-IP buffer.  Beads were pelleted by centrifugation at 4,500 x g at 4ºC 
for 1 minute and washed three times with 500 L CO-IP buffer, with three tube inversions 
between washes.  The beads were resuspended in 25 L sample buffer containing 62.5 mM Tris-
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Cl pH 6.8, 5% glycerol, 2% SDS, 5% 2-mercaptoethanol and boiled for 5 minutes.  Beads were 
pelleted by centrifugation at 4,500 x g at 4ºC for 1 minute and the supernatant was stored at -
20ºC until further analysis by western blot, as described above.  Prior to loading on to a 
polyacrylamide gel, samples were boiled for 5 minutes and 1 L 0.4% bromophenol blue was 
added to each sample.         
 
Reverse Transcriptase Quantitative PCR 
 Total RNA was isolated using the TRIzol reagent according to manufactures instructions 
(Invitrogen).  RNA (1 g) was treated with 10 units of DNase I (Invitrogen) for 15 minutes at 
25ºC in a 100 L volume reaction containing 10 mM Tris HCl (pH 8.4), 2 mM MgCl2 and 5 mM 
KCl.  DNase I was inactivated for 10 minutes at 65ºC with 2.5 mM EDTA (pH 8).  RNA was 
precipitated with the addition of 1/10
th
 the total volume of 3 M NaOAc and 2.5 times the total 
volume of 100% ethanol overnight at -80ºC.   The integrity of the RNA was verified on a 1% 
agarose gel containing ethidium bromide.  cDNA was synthesized from 2 g RNA using random 
hexamers in the Superscript III First-Strand Synthesis System according to the manufacturer‟s 
instructions (Invitrogen).  Quantitative PCR was performed with 1 L cDNA in a 25 L reaction 
containing 12.5 L Quantitect SYBR Green PCR Master Mix (Qiagen), 0.3 M of each primer 
in a three-step amplification plus melt-curve as described previously.  Primers to measure the 
Wip1 transcript were 5′-TGCCGCCGCCGTTCCTCCGTG-3′ (sense) and 5′-
GCCCCGAATGATGACCACACT-3′ (antisense); primers to measure -actin as the normalizing 
control were 5′-CACGAAACTACCTTCAACTCC-3′ (sense) and 5′-
TCATACTCCTGCTTGCTGATCC -3′ (antisense).     
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RNA Interference 
 HCT116 cells were plated at 1.5 x 10
5
 cells/well in a 6-well plate, in 2 mL of RMPI 1640 
with 10% dFBS and 1% pen/strep, and were allowed to adhere overnight.  siRNA (Wip1 
siGENOME SMARTpools or non-targeting siRNA pool #1, Dharmacon) was resuspended to a 
concentration of 20 M in 1x siRNA buffer containing 60 mM KCl, 0.2 mM MgCl2 and 6 mM 
HEPES pH 7.5.  siRNA was diluted to 2 M in the above mentioned 1x siRNA buffer and an 
equal volume of serum free RPMI 1640 was added.  Dharmafect reagent #2 was diluted down to 
0.2% in serum-free RPMI 1640.  Both sets of solutions were incubated at 25ºC for 5 minutes and 
then mixed together and incubated for another 20 minutes at 25ºC.  RPMI 1640 with 10% dFBS 
was added to the transfection solutions to a final siRNA concentration of 100 nM.  Each well 
received 2 mL of the transfection-medium and after 24 hours the transfection medium was 
removed and replaced with RPMI 1640 containing 10% dFBS and 100 U/mL of penicillin and 
100 mg/mL of streptomycin replaced the transfection medium.  The 24 hour drug treatment 
began 48 hours after transfection. 
 
Chromatin Fractionation 
 Cells were synchronized at Go/G1 as previously described and chromatin fractionation 
was performed as previously described (Mendez and Stillman, 2000).  Synchronized HCT116 
cells were released at 2 x 10
6
 cells/10 cm dish containing 10 mL.  24 hours after drug treatment, 
cells were washed with PBS once and scraped into PBS containing 1x complete protease 
inhibitor mixture (Roche).  Cells were pelleted at 1000 x g for 5 minutes at 4ºC.  The pellet was 
resuspended in Buffer A containing 10 mM HEPES pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.34 
M Sucrose, 10% glycerol, 1 mM DTT, and Triton X-100 was added to obtain a final 
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concentration of 0.1%.  All buffers contained 0.5 g/mL aprotinin, 0.5 g/mL leupeptin, 0.5 
g/mL pepstatin, 0.1 mM PMSF, 2 mM Na3VO4 and 10 mM NaF.  Cells were incubated on ice 
for 8 minutes and nuclei were pelleted by low speed centrifugation at 1300 x g for 5 minutes at 
4ºC.  The supernatant was saved as the cytosolic fraction.  The nuclei were washed twice with 
Buffer A and lysed with 50 L for ND treatment, 40 L for HU and 30L for PALA (volumes 
which were previously determined to yield equal nuclear fractions from control and drug treated 
cells) of buffer B containing 3 mM EDTA pH 8.0, 0.2 mM EGTA pH 7.5, 1 mM DTT and 
incubated on ice for 30 minutes.  The chromatin was pelleted at 1700 x g for 5 minutes at 4ºC 
and the insoluble nuclear fraction supernatant was saved.  The pellet was washed twice with 
buffer B and resuspended in 40 L for ND and 25 L for HU and PALA samples of 1x sample 
buffer containing 62.5 mM 1 M Tris pH 6.8, 10% glycerol, 2% SDS and 10% 2-mercaptoethanol 
and sonicated at 4ºC with the Diagenode bioruptor for a total of 15 minutes with consecutive 
duty cycles of 30 seconds on, 30 seconds off (5 minute cycles repeated a total of 3 times).  All 
fractions were aliquoted and stored at -80ºC.         
 
Clonogenic Survival 
 For colony formation assays, HCT116 p53 +/+ and HCT116 p53 -/- cells were plated at 
150 cells/10 cm dish and allowed to adhere for 5 hours.  Cells were then incubated with RPMI 
medium containing 10% dFBS and a range of HU or PALA concentrations for 24 hour.  Plates 
were replenished with fresh RPMI with 10% dFBS medium the following day and every 2-3 
days for a total of 8 days.  For the adapted version of the colony formation assay, HCT116 cells 
were synchronized as previously described and released into drug for 24 or 48 hours.  Adherent 
and floating cells were collected and plated at 100 cells/60-mm
2
 dish and allowed to attach 
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overnight. Plates were replenished with fresh RPMI with 10% dFBS medium the following day 
and every 2-3 days.  After 8 days in both assays, colonies were fixed with methanol, stained with 
5% Wright-Giemsa reagent and all visible colonies were counted manually. 
 
Results 
 The experiments presented in Chapter 2 address the question of whether treatment of 
HCT116 cells with different nucleotide synthesis inhibitors result in similar cellular responses.  
Besides p53 stabilization and slowed S-phase progression, the cellular responses to HU and 
PALA treatment are strikingly different.  The results presented herein suggest that PALA 
treatment fails to recruit ATR to the chromatin resulting in a p53-dependent apoptosis while HU-
treatment activates a S-phase checkpoint that is cytoprotective. 
 
Cell Cycle Effects of Nucleotide Synthesis Inhibitors 
Both HU and PALA stabilize p53 and minimally activate p21 transcription 
 Given the significant role p53 plays in a multitude of cellular responses within the cell, 
the ability of nucleotide-deprived cells to promote the accumulation of p53 was investigated.  
HCT116 cells were treated with HU, PALA or the positive control DNA damaging agent VP16 
for 24 hours and lysates were then western blotted to determine the effect on p53 accumulation.  
All three drug treatments led to the accumulation of p53.  VP16 and PALA treatment resulted in 
the highest accumulation of p53, but p53 levels after HU were also quite high (Fig 2-6).  The 
activation of p21 was investigated by immunoblotting to determine if the accumulated p53 was 
promoting transcription of this critical cell cycle inhibitor.  As expected VP16 caused significant 
p21 activation; p21 activation by PALA treatment was very low but still clearly detectable, while  
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Figure 2-6. Nucleotide deficiencies promote p53 accumulation with minimal p21 activation.  
This figure shows a western blot analysis of p53 and p21 levels in asynchronous HCT116 cells 
exposed to 10 M VP16, 1.5 mM HU or 100 M PALA for 24 hours.  Total cell lysate protein 
(25 g) was subjected to SDS-PAGE and immunoblotted with antibodies against p53, p21 or -
Actin.  VP16 was used as the positive control for p53 accumulation and p21 activation.  Protein 
loading was assessed with -Actin.  
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HU treatment resulted in minimal p21 activation, even though a significant amount of p53 
stabilization was seen in all three drug treatments (Fig 2.6).  The poor transcriptional activation 
of p21 after HU was expected from previous work in Prives‟ laboratory, but that observed after 
PALA treatment was surprising but reproducible.  Previously in our lab, Julie Bronder observed 
a similar defect in p21 transcription during treatment of HCT116 cells with DDATHF, an 
antifolate de novo purine synthesis inhibitor.  In her studies, p53 was bound to p53RE sites at the 
p21 promoter but, due to the lack of PTMs on p53 and the closed chromatin structure of the 
promoter, transcription was not activated (Bronder and Moran, 2003).  To determine if the 
minimal activation of p21 transcription during HU treatment was due to failure of p53 to bind to 
the p21 promoter or events downstream of binding to the p53REs in the p21 promoter, a ChIP 
experiment was performed, with DDATHF included as a control for a nucleotide synthesis 
inhibitor exhibiting a similar p21 defect as HU.  After DDATHF and HU treatment, 
approximately threefold more p53 was detected at the upstream p53RE of the p21 promoter than 
was seen in the no drug control.  There was over a five-fold enrichment of p53 at the p21 
promoter during PALA treatment and VP16 resulted in a four-fold enrichment of p53 bound at 
this promoter (Fig 2-7).  The inability of the p53 that accumulated in HU-treated cells to 
transactivate p21 in spite of binding at the p21 (Mattia et al., 2007) promoter had previously been 
observed in Carol Prives‟ laboratory (Gottifredi et al., 2001), but the mechanism for this effect is 
still not clear.   
 
The post translational modifications of stabilized p53 after nucleotide synthesis inhibition 
 The PTMs of the p53 that accumulated in HCT116 cells during the treatments with HU, 
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Figure 2-7. Nucleotide deficiencies induce p53 binding at the p21 promoter.  ChIP 
analysis of p53 enrichment  at the p21 promoter in asynchronous HCT116 cells after 24 
hours of drug treatment.  p53-DNA complexes were immunoprecipitated from crosslinked 
cells and p21 promoter levels were quantitated with Q-PCR.  Non-specific binding was 
detected by parallel immunoprecipitations with IgG.  VP16 served as a positive control.  
Standard error is depicted by the bars from one biological repeat with triplicate Q-PCR 
samples.  The same trend was observed in subsequent biological repeats.  Vehicle was PBS, 
VP16 was used at 10 M, HU was used at 1.5 mM, PALA was used at 100 M and 
DDATHF was used at 10 M. 
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 PALA, and VP16 were examined by loading an equivalent amount of p53 for all conditions on a 
gel and immunoblotting with phospho-specific peptide antibodies. VP16 caused robust 
phosphorylation at all the serine residues examined as was expected from previous literature for 
such a strong inducer of the DNA damage response.  The phosphorylation profile of the p53 
stabilized during HU treatment was very different to that of the p53 stabilized during PALA 
treatment.  Interestingly, PALA treatment did not promote significant phosphorylation at serine 
20 and induced only low levels of phosphorylation at serine 15, two of the most commonly 
phosphorylated serines on p53.  HU promotes efficient phosphorylation of these residues.  On 
the other hand serines 37, 46 and 392 were significantly phosphorylated during PALA treatment 
compared to that observed following HU treatment (Fig 2-8).  The different pattern of post 
translational phosphorylations of p53 that resulted after PALA treatment and HU treatment 
suggested that the upstream regulators of p53 may differ as well was the cellular activities of the 
accumulated p53.  
 
HU and PALA-treated cells undergo a prolonged cell cycle arrest in S-phase 
 The observation that p21 is not being robustly activated during HU and PALA treatment 
suggested that perhaps these two treatments are promoting cell cycle arrest in a different phase of 
the cell cycle other than the G1/S or G2/M checkpoint.  G1 synchronized HCT116 cells were 
released into drug-containing medium and cells were then stained with propidium iodide after 24 
hours and analyzed by flow cytometry.  Under these synchronization conditions, ~97% of the 
cell population was in G1 immediately after release from synchrony with the remaining ~3% in 
G2 (Fig 2-9).  The VP16 control caused a G2/M cell cycle arrest, which was expected from 
previous literature (Smith et al., 1994).  Both HU and PALA treatment bypassed the G1/S  
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Figure 2-8. The post-translational modifications of the p53 that accumulate in HU- and 
PALA-treated cells are substantially different.  This figure shows a western blot analysis of 
the post-translational modifications of p53 in asynchronous HCT116 cells after 24 hours of drug 
treatment.  An initial western blot was performed with 25 g of total protein to quantitate total 
p53 levels and then a second gel was run with differing volumes of lysates from the different 
conditions so that equivalent amounts of p53 were loaded and immunoblotted with antibodies 
specific for p53 phosphorylated at serine 15, 20, 37, 46, 392. Vehicle was PBS, HU was used at 
1.5 mM, PALA was used at 100 M and VP16 was used at 10 M.  
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Figure 2-9.  Synchronized HCT116 cells bypass the G1 checkpoint and accumulate in S-
phase upon nucleotide deficiencies.  HCT11 cells were synchronized in G0/G1 by holding at 
confluence for 48 hours and released into drug containing medium at a low density for 24 hours.  
Cells were stained with PI and cell-cycle progression was monitored by flow cytometry.           
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checkpoint, an observation that was consistent with the low levels of p21 in these conditions, and 
accumulated in S-phase (Fig 2-9).  This suggested that the low levels of p21 activated during 
PALA did not arrest the cells at the G1/S border and that this checkpoint was not active.  
Compared to the vehicle, the HU and PALA treated cells moved through the cell cycle at a much 
slower rate and accumulated in early to mid S-phase. 
 
 S-phase Specific Events Resulting after Nucleotide Pool Imbalance 
HU and PALA treatment promote a differentially phosphorylated Chk1  
 The phosphorylation of Chk1 is an event commonly used as definitive of the activation of 
the S-phase checkpoint (Lopez-Girona et al., 2001; Zhao and Piwnica-Worms, 2001).  Since 
both HU and PALA treated cells arrested in S-phase, the phosphorylation status of Chk1 was 
investigated to determine if this checkpoint was being activated.  VP16 and HU treatment 
resulted in a robust phosphorylation of Chk1 at serine 345, while PALA treatment did not (Fig 2-
10).  This was quite surprising.  Minimal phosphorylation of Chk1 was observed following 
PALA treatment over that in the untreated control.  A concentration-dependence study was 
performed to determine whether the Chk1 phosphorylation difference observed after HU and 
PALA was an artifact of the drug concentrations used.  The concentration range for HU was 0.15 
mM to 3 mM, 1.5 mM being the working concentration.  Chk1 phosphorylation is detectable at 
0.5 mM HU and was maximal at 3 mM (Fig 2-11).  PALA concentrations from 10 M to 500 
M did not cause appreciable Chk1 phosphorylation when compared with 1.5 mM HU or  10 
M VP16.  Hence, substantial Chk1 phosphorylation following any reasonable dose of PALA 
was not occurring, while the phosphorylation occurring during HU treatment was robust (Fig 2-
11).        
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Figure 2-10. Chk1 is not phosphorylated at serine 345 upon PALA-induced pyrimidine 
deficiencies.  This figure shows a western blot analysis of phosphorylated Chk1 at serine 345 
and total Chk1 levels in asynchronous HCT116 cells exposed to 10 M VP16, 1.5 mM HU or 
100 M PALA for 24 hours.  Total cell lysate protein (25 g) was subjected to SDS-PAGE and 
immunoblotted with antibodies against phospho-Chk1 serine 345 or total Chk1.  HU was used as 
the positive control for stalled replication forks and VP16 served as a DNA-damage control.   
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Figure 2-11. Concentration dependency of HU- or PALA-induced Chk1 phosphorylation 
and p53 accumulation.  This figure shows a western blot analysis of levels of accumulated p53, 
total and phosphorylated Chk1 at serine 345 in asynchronous HCT116 cells treated with drug for 
24 hours.  Equal levels of total protein (25g) were loaded in each lane.  Vehicle was PBS, HU 
was used at 0.15 mM to 3 mM, PALA was used at 10 M to 500 M and VP16 was used at 10 
M.  HU at 1.5 mM was used as a positive control for the concentration dependency of PALA 
treatment.  Protein loading was assessed with-Actin.  
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 A time course was also performed to determine if the 24 hour time point used above 
possibly missed a transient Chk1 phosphorylation during PALA treatment.  Cells were 
synchronized in G1 and released into drug, then lysates were made at various time points to allow 
an enriched S-phase cellular population to be studied (Fig 2-12).  Interestingly, a low level and 
transient phosphorylation of Chk1 was observed during PALA-induced pyrimidine imbalances.  
At 24 hours, Chk1 is heavily phosphorylated at serine 345 in HU and remained phosphorylated 
throughout the 48 hour time point (Fig 2-13).  Throughout this period, the HU-treated cultures 
were found to be in a slowed S-phase by flow cytometry (Fig 2-12). The level of transient Chk1 
phosphorylation observed during PALA treatment was much lower than that observed during 
HU treatment and, again, was observed only at time points corresponding to slow passage 
through S-phase (Figs 2-12, 2-13).  Chk1 phosphorylation was detected as early as 12 hours after 
HU treatment while the low levels of Chk1 phosphorylation was first detected at 24 hours in 
PALA treated cells.  Another interesting difference is the amount of accumulated p53 present 
during both of the drug treatments.  During PALA treatment, p53 stabilization was detectable by 
12 hours and was still substantial at 48 hours.  During HU treatment, p53 stabilization was 
undetectable at 12 hours, a lower level of p53 had accumulated at 24 hours and this level 
decreased with time thereafter (Fig 2-13).   The different levels of accumulated p53 that 
resulted from HU- and PALA-treatment suggested that p53 could be playing a role in the 
differential Chk1 phosphorylation.  To address this question the p53 isogenic HCT116 cell lines 
were used to examine the possible p53 dependency of Chk1 phosphorylation.  In HCT116 p53-/- 
cells, Chk1 phosphorylation at both serines 345 and 317 was partially restored during PALA 
treatment when compared to HCT116 p53 +/+ cells.  The phosphorylation levels did not reach 
those observed during HU, but they were significantly higher than what was observed in the   
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Figure 2-12. HU and PALA treatment slow S-phase progression.  HCT116 cells were 
synchronized at G0/G1 and released into drug containing medium for the indicated times, stained 
with PI and their DNA content was analyzed by flow cytometry.  Approximately 1 x 10
6
 
synchronized cells were collected and saved for the 0 hr time point prior to releasing the 
remainder into drug. Vehicle was PBS, HU was used at 1.5 mM, PALA was used at 100 M.  
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Figure 2-13. The time course of Chk1 phosphorylation and p53 accumulation after HU- or 
PALA-induced nucleotide deficiencies. This figure shows a western blot analysis of total and 
phosphorylated Chk1 at serine 345 in G0/G1 synchronized HCT116 cells released into drug for 
the indicated times. Equal levels of total protein (25 g) were loaded in each lane.  Vehicle was 
PBS, HU was used at 1.5 mM, PALA was used at 100 M and the VP16 control was used at 10 
M for 24 hours. Protein loading was assessed with -Actin. 
 
  
VP16    ND    HU    PALA   ND   HU   PALA    ND  HU   PALA  ND    HU  PALA 
24 hours
p53
-Actin
p-S345 Chk1
Chk1
12 hours 36 hours 48 hours
  
72 
 
presence of p53, suggesting that the presence of p53 is preventing the phosphorylation of Chk1 
(Fig 2-14).  HU inhibits the synthesis of both purine and pyrimidine deoxyribonucleotides and 
PALA solely inhibits the synthesis of pyrimidines.  The Chk1 phosphorylation deficiency 
observed during PALA treatment may be a result of the fact that the pyrimidine pools are being 
affected with no effect on purines while HU is causing an overall deficiency in all of the 
deoxyribonucleotide pools.  To indirectly determine if the Chk1 phosphorylation deficiency in 
PALA was due to the asymmetric effect on purine and pyrimidine nucleotide pools, HU treated 
cells were supplemented with 2-deoxyadenosine (AdR) and 2-deoxyguanosine (GdR), precursors 
of purine nucleotides.  Prior to the supplementation, studies were performed with the purine 
inhibitor DDATHF, and the purine deoxynucleotides, to optimize the concentrations required to 
fully rescue the purine synthesis inhibition.  The salvage metabolite inosine was used as a 
positive control for full rescue of DDATHF treatment.  DDATHF treatment alone resulted in a 
90% suppression of the growth of HCT116 cells compared to the no drug control.  
Supplementation of medium with 100 M inosine or by addition of both 100 M AdR and GdR 
rescued the cell growth caused by 10 M DDATHF treatment (Fig 2-15A).  Hence, these 
concentrations of extracellular AdR and GdR allowed support for growth by salvage and they 
were used to study the effect of HU suppression of deoxypyrimidine pools in the presence of 
exogenously supplied deoxypurines.  The level of Chk1 phosphorylation did not decrease during 
HU treatment in the presence of purine deoxynucleotides, suggesting that the deficiency in Chk1 
phosphorylation during PALA treatment is not due to deoxypurine/pyrimidine pool imbalances 
(Fig 2-15B).   
 
HU and PALA treatment slows S-phase progression  
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Figure 2-14.  p53 dependency of Chk1 phosphorylation.  This figure shows a western blot 
analysis of total and phosphorylated Chk1 at serines 317 and 345 and accumulated p53 in 
asynchronous HCT116 p53 +/+ and HCT116 p53 -/- cells exposed to drug for 24 hours. Equal 
levels of total protein (25 g) were loaded in each lane.  Vehicle was PBS, HU was used at 1.5 
mM, PALA was used at 100 M and the VP16 control was used at 10 M. Protein loading was 
assessed with -Actin 
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Figure 2-15. Differences in Chk1 phosphorylation is not due to the pool of nucleotides being 
inhibited. A, Growth rescue of DDATHF treatment with deoxyribonucleotides or inosine to 
determine  concentrations for partial rescue of purine deoxyribonucleotides during HU treatment.  
HCT116 cells were treated with 10 M DDATHF alone or supplemented with either 100 M 
inosine or 100 M AdR and 100 M GdR for 72 hours.  Cells were trypsinized and counted with 
the Beckman Coulter Z1 Coulter Particle Counter.  Each bar indicates the mean of three plates 
within a single experiment, and standard deviation is shown.  B, Western blot analysis of total, 
phosphorylated Chk1 at serine 345, accumulated p53, and cleaved PARP1 in asynchronous 
HCT116 cells exposed to drug for 24 hours.  Purine deoxyribonucleotides were rescued during 
HU treatment by supplementation with 100 M AdR and 100 M GdR.  Equal levels of total 
protein (25 g) were loaded in each lane.  Vehicle was PBS, HU was used at 1.5 mM, PALA 
was used at 100 M and the VP16 control was used at 10 M. Protein loading was assessed with 
-actin.   
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 The differences in the time course and degree of Chk1 phosphorylation in HU and PALA 
suggested that fundamentally different cellular processes were occurring during the two drug 
treatments (Fig 2-13).  The flow cytometry performed on the treated cells after 24 hours was 
expanded to a full time course.  G1-synchronized cells were immediately released into drug and 
the adherent cells were collected after different time points and stained with propidium iodide.   
Neither HU nor PALA-treated cell populations were blocked at the G1 checkpoint and the 
majority of both populations progressed into S-phase at a slower rate than the untreated cells.  
Both populations progressed into S-phase very slowly, but eventually completed transit through 
S-phase.  Starting at 12 hours the cells began to enter S-phase and by 48 hours they were almost 
completely out of S-phase, whereas untreated HCT116 cells appeared to progress at a much 
faster rate, transiting through one or more S-phases within 24 hours.  PALA-treated cells 
progressed through S-phase at a somewhat faster rate, approximately 12 hours ahead of HU 
treated cells.  At the 48 hour time point, they are completely out of S-phase while HU cells are in 
the latter half of S-phase.  There was a noticeable accumulation of cells in G2/M in both drug 
treatments that was not observed in untreated cell populations.  By 72 hours the cells are 
asynchronous and the flow cytometry cell cycle histograms appeared identical (Fig 2-12).     
 
p53 Binds to BLM during Both HU and PALA treatment 
 Because Chk1 phosphorylation was not observed during PALA treatment, other S-phase 
specific events were investigated to define the scope of the difference in the cellular responses to 
HU and PALA.  Previous studies have demonstrated the interaction of BLM and p53 during the 
S-phase checkpoint (Sengupta et al., 2003; Yang et al., 2002).  BLM was immunoprecipitated 
from HCT116 cells that were treated with either HU or PALA for 24 hours.  This 
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immunoprecipitate was analyzed by western blot to determine if p53 was interacting with BLM.  
Both HU and PALA treatment stimulated the binding of p53 to BLM (Fig 2-16).  Equivalent 
amounts of BLM were immunoprecipitated from both drug treated lysates, but slightly more p53 
was found associated with BLM during PALA treatment, consistent with the higher levels of p53 
in PALA-treated cells (see input lanes, Fig 2-16).  Minimal BLM was pulled down in the 
untreated lysates, but p53 was still found in this pellet, suggesting that BLM and p53 associate in 
unstressed cells as well as in cells depleted of nucleotides.  Only a small fraction of total cellular 
p53 immunoprecipitated with BLM under the experimental conditions, suggesting that the 
stabilized p53 has other roles besides modulating BLM function, in the cellular response to HU 
and PALA treatment (Fig 2-16).      
 
Enrichment of p53 at the Rad51 promoter is stimulated by PALA treatment 
 p53 has been shown to bind to the Rad51 promoter inhibiting the transcription of this 
pro-recombinogenic protein during the S-phase checkpoint (Arias-Lopez et al., 2006).   The 
observation that only a small fraction of total cellular p53 was binding to BLM suggested that 
p53 was involved in other cellular processes, and therefore the residence of p53 at the p53RE in 
the Rad51 promoter after 24 hours of HU and PALA treatment was measured by ChIP.  PALA 
treatment caused more than a threefold enrichment of p53 at this promoter over the no drug 
treatment.  HU treatment did not elevate the levels of p53 at the Rad51 promoter (Fig 2-17).  
Thus, HU-stabilized p53 is not inhibiting the transcription of Rad51 while p53 that is 
accumulated during PALA treatment is bound at the promoter suggesting that it is negatively 
regulating the transcription of Rad51.  It has been suggested that induction of apoptosis in cells 
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Figure 2-16. BLM and p53 interact during HU- or PALA-induced nucleotide deficiencies.  
This figure shows a western blot analysis of the interaction between p53 and BLM after 24 hours 
of HU- or PALA- induced nucleotide pool deficiencies in asynchronous HCT116 cells.  BLM 
was immunoprecipitated from 750 g protein from whole cell lysates with the p53 antibody 
(DO-1); p53 was detected in the BLM immunoprecipitate by western blotting.  Input indicated 
5% of the lysates used for the IP and the efficiency of the IP was verified with the BLM 
antibody.  PBS was added to the no drug treatment, HU was used at 1.5 mM and PALA was used 
at 100 M.  
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Figure 2-17. PALA treatment induces p53 binding at the Rad51 promoter.  ChIP analysis of 
p53 enrichment at the Rad51 promoter in asynchronous HCT116 cells after 24 hours of drug 
treatment.  p53-DNA complexes were immunoprecipitated from crosslinked cells and Rad51 
promoter levels in the immunoprecipitate were quantitated with Q-PCR.  Non-specific binding 
was immunoprecipitated with IgG.  Standard error is depicted by the bars from two biological 
repeat with triplicate Q-PCR samples.  Vehicle was PBS, HU was used at 1.5 mM and PALA 
was used at 100 M.  
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containing abundant DNA damage may require the repression of homologous recombination 
(Ivanov et al., 2003).  If this is true, it could explain that the enrichment of p53 at the Rad51 
promoter is repressing transcription of the homologous recombination protein Rad51 in order to 
induce apoptosis.     
 
Mechanism of the failure of PALA to induce Chk1 phosphorylation 
PALA treatment activates the transcription of the Wip1 phosphatase 
 Although HU and PALA treatment slowed S-phase progression, the activities of the S-
phase checkpoint were found to be conflicting.  That is, HU-treatment resulted in Chk1 
phosphorylation and p53 interaction with BLM, while Chk1 was not phosphorylated after 
PALA-treatment, yet p53 associated with BLM and regulated Rad51 transcription.  In order to 
clarify the complexity of the cellular responses, we focused on the transient nature of Chk1 
phosphorylation during PALA treatment.  The increase in Chk1 phosphorylation in the absence 
of p53 in PALA-treated HCT116 p53-/- cells suggested that p53 was preventing Chk1 
phosphorylation (Fig 2-14).  In combination with the p53 dependency and the transient nature of 
Chk1 phosphorylation during PALA treatment, we hypothesized that the p53-dependent gene, 
Wip1, was dephosphorylating Chk1.  The presence of p53 at the Wip1 promoter after 24 hours of 
drug treatment was investigated using ChIP.  There was a massive (> eight fold) enrichment of 
p53 binding to the Wip1 promoter after PALA treatment that was not observed after HU 
treatment (Fig 2-18A).  RT-QPCR demonstrated that the high occupancy of p53 at the Wip1 
promoter after PALA treatment was strongly activating transcription as is seen by a 12-fold 
increase in Wip1 transcript levels.  There was about a four-fold increase in Wip1 transcript after  
HU treatment.  The Wip1 transcriptional activation was p53 dependent: in HCT116 cells that are 
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Figure 2-18. PALA treatment activates Wip1 transcription.  A, ChIP analysis of p53 
enrichment at the Wip1 promoter in asynchronous HCT116 cells after 24 hours of drug 
treatment.  p53-DNA complexes were immunoprecipitated from crosslinked cells and Wip1 
promoter levels present in the immunoprecipitate were quantitated with Q-PCR.  Non-specific 
binding was assessed by a parallel immunoprecipitate with IgG.  Standard error is depicted by 
the bars from one biological repeats with triplicate Q-PCR samples.  The same trend was 
observed in subsequent biological repeats.  B, Wip1 transcript levels quantitated using RT-Q-
PCR in asynchronous HCT116 p53 +/+ and HCT116 p53 -/- cells treated with drug for 24 hours.  
Transcript levels were normalized to -actin.  Standard error is depicted by the bars from two 
biological repeat with triplicate Q-PCR samples.  C, Western blot analysis of the p53-dependent 
activation of Wip1 in asynchronous HCT116 p53 +/+ and HCT116 p53 -/- cells exposed to drug 
for 24 hours.  Equal levels of total protein (25 g) were loaded in each lane. Vehicle was PBS, 
HU was used at 1.5 mM, PALA was used at 100 M and VP16 was used at 10 M. Protein 
loading was assessed with-Actin. 
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null for p53, the Wip1 transcript levels are down to basal (Fig 2-18B).  Wip1 protein levels 
correlated with the transcript levels; there is a large induction of Wip1 protein after PALA 
treatment and only a small, if any, induction of Wip1 protein after HU treatment.  There was no 
significant Wip1 protein in HCT116 p53 null cells (Fig 2-18C).  
  In order to determine the functional significance of the enhanced Wip1 levels found in 
PALA-treated cells, Wip1 was knocked down with pools of siRNA and the phosphorylation 
status of Chk1 was investigated to determine the role of Wip1 in preventing Chk1 
phosphorylation during PALA treatment.  Drug treatment began 48 hours after transfection of 
the Wip1 siRNA.  Lysates were made 72 hours after transfection.  Wip1 knock-down was 
remarkably efficient; Wip1 protein was undetectable in all samples following siRNA treatment.  
Chk1 phosphorylation was not restored during PALA treatment in the absence of Wip1 (Fig 2-
19).  The amount of Wip1 knockdown effectively abolished phosphatase activity as is observed 
by the increase in phosphorylation at serine 15 of p53, a residue that Wip1 is known to 
dephosphorylate.  This suggests that Wip1 was playing a minor role in the failure to activate 
Chk1 following PALA treatment and, hence, in assembling the S-phase checkpoint.   
Interestingly, there was a substantial increase in the level of phosphorylation of p53 at serine 15 
in all siRNA treated samples, an indication of the role of Wip1 in control of the steady-state 
levels of this phosphorylation.  
 The protein phosphatase 2A (PP2A) has been shown to dephosphorylate Chk1 at serine 
345 maintaining a hypophosphorylated Chk1 during unperturbed S-phases (Leung-Pineda et al., 
2006). To rule out the possibility that PP2A was compensating for the loss of Wip1 phosphatase 
activity during these knock down experiments okadaic acid was used as a pharmacological  
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Figure 2-19. Wip1 does not dephosphorylate Chk1 during PALA treatment.  This figure 
shows a western blot analysis of Wip1, total and phosphorylated Chk1 at serine 345 and total and 
phosphorylated p53 at serine 15 in asynchronous HCT116 cells transiently transfected with Wip1 
siRNA pools.  Cells were exposed to drug 48 hours post transfection for 24 hours.  Non-targeting 
siRNA pools were used as a control.  Equal levels of total protein (25 g) were loaded in each 
lane. Vehicle was PBS, HU was used at 1.5 mM, PALA was used at 100 M and VP16 was used 
at 10 M.  
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inhibitor of the PP2A.  Treatment of HCT116 cells prior to knocking down Wip1 with 50 nM 
okadaic acid alone or in combination with PALA did not change Chk1 phosphorylation levels; 
they were similar to what was observed with PALA treatment (Fig 2-20).  In HCT116 cells in 
which Wip1 was knocked down, okadaic acid treatment did not restore Chk1 phosphorylation 
following PALA treatment.  The phosphorylation of Chk1 was not detectable during okadaic 
acid and PALA treatment suggesting PP2A is not responsible for the lack of Chk1 
phosphorylation in the absence of Wip1 (Fig 2-20B). 
 
PALA treatment fails to recruit ATR to the chromatin  
 The other explanation for the lack of Chk1 phosphorylation during PALA treatment could be that 
ATR is not activated by recruitment to replication forks during the slowed S-phase progression.  If ATR 
is not present at stalled replication forks, Chk1 will not become phosphorylated and activated and, as a 
result, the S-phase checkpoint will not be intact.  This question of the recruitment of ATR to nucleotide 
deficiency-induced stalled replication forks was addressed by fractionating chromatin away from the 
soluble nuclear proteins in synchronized HCT116 cells and determining whether ATR was bound to 
chromatin in HU and PALA treatment.  The fractions were blotted for the presence of ATR.  In whole 
cell and soluble nuclear fractions the levels of ATR are relatively consistent over the treatments, ruling 
out transcriptional or post-transcription effects on total cellular levels of ATR by PALA.  Yet, there is no 
detectable ATR accumulating in the chromatin-bound fraction during PALA treatment, while there is a 
significant level of ATR recruited to the chromatin after HU treatment, indicating that Chk1 is not 
phosphorylated during PALA due to the lack of ATR chromatin recruitment (Fig 2-21).  Interestingly, the 
S-phase checkpoint proteins phosphorylated Chk1 and BLM were also not recruited to the chromatin 
during PALA treatment, yet there were equivalent levels of p53 at the chromatin during HU and 
PALA treatment (Fig 2-21).  The lack of S-phase proteins at the chromatin during PALA  
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Figure 2-20. PP2A does not compensate for the absence of Wip1.  A, This figure shows a 
western blot analysis of total and phosphorylated Chk1 at serine 345 in asynchronous HCT116 
cells.  The arrow indicates the band specific for phosphorylated Chk1.  The PBS vehicle 
corresponds to the HU and PALA samples and the EtOH vehicle corresponds to the PALA with 
OA and OA alone samples.  B, This figure shows a western blot analysis of  Wip1 and 
phosphorylated Chk1 in asynchronous HCT116 cells transiently transfected with Wip1 siRNA 
pools.  Cells were exposed to drug 48 hours post transfection for 24 hours.  Non-targeting siRNA 
pools and a mock transfection were used as a control.  HU was used at 1.5 mM, PALA was used 
at 100 M and OA at 50 nM.  
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Figure 2-21. S-phase checkpoint proteins are not recruited to the chromatin after PALA 
treatment.  This figure shows a western blot analysis of the assembly of S-phase checkpoint 
proteins on chromatin. G0/G1 synchronized HCT116 cells were released into drug containing 
medium for 24 hours and the chromatin was fractionated from whole cell lysates as described by 
(Mendez and Stillman, 2000).  Equal protein levels (25 g) of whole cell, nuclear soluble and 
chromatin fractions were analyzed by western blot for ATR, phospho Chk1, BLM and p53.  
H3K4 me3 was used to demonstrate the purity of the fractions. Vehicle was PBS, HU was used 
at 1.5 mM and PALA was used at 100 M.  
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treatment suggests that, due to the failure of ATR recruitment, the S-phase checkpoint is not 
activated and therefore, these proteins were not being actively recruited to stalled replication 
forks.  The equivalent levels of chromatin-bound p53 observed during the two treatments 
suggests that, during PALA treatment, p53 is involved in other cellular processes occurring at the 
chromatin, possibly at the level of transcription, i.e. binding at p53RES in promoters.     
 
The Cellular Consequences of the Differential Chk1 Phosphorylation  
PALA treatment is cytotoxic while HU treatment is cytoprotective 
 Colony formation assays were used to test the ability of cells to recover and survive after 
HU and PALA treatment.  A classical colony formation assay was performed, allowing cells to 
adhere for five hours and then replacing the growth medium with medium containing increasing 
concentrations of drugs for 24 hours.  Both HCT116 p53 +/+ and HCT116 -/- cells lines were 
used in this assay.  PALA treatment had a steeper decline in cell survival over the range of 
concentrations tested; this trend was observed in both cell lines.  HU treatment did not decrease 
cell survival as steeply as did PALA treatment, but at concentrations ≥ 3mM HU, cell survival 
decreased in both cell lines.  In both treatments, cells were unable to survive at a higher drug 
concentration and cells without p53 were less sensitive to the cytotoxicity of both drugs.  
However, the most important aspect of this analysis is that, at concentrations of HU that were 
markedly inhibitory to cell progression through S-phase, i.e. 1.5 mM, HU was without 
cytotoxicity whereas a concentration of PALA that impeded S-phase progression (100 M) was 
grossly cytotoxic (Fig 2-22).   
 To determine the time course of commitment to cell death, synchronized cells were 
released into either HU or PALA for various lengths of time.  At each time point, adherent and  
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Figure 2-22.  HCT116 cells containing wild-type p53 are more sensitive to cell kill induced 
by HU or PALA treatment than HCT116 null of p53.   HCT116 p53 +/+ (solid symbols) and 
HCT p53 -/- (open symbols) were plated and allowed to adhere for 5 hours.  Medium containing 
10% dFBS and various concentrations of HU (circles) or PALA (triangles) were added for 24 
hours.  Cells were maintained in drug free medium after the exposure for an additional 8 days 
and colonies were stained and counted and plotted as survival of drug treated cells compared to 
vehicle treated cells.  Points indicate the mean of three plates within a single experiment and 
standard error is depicted by the bars.     
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floating cells were collected and counted.  Both ND and HU treated cells were plated in fresh 
drug-free medium at 150 cells/60 mm
2
 dish while PALA treated cells were plated at 150, 1,500 
and 15,000 cells/60 mm
2
 dish and allowed to attach and grow for 7 days.  HU-treated cells were 
protected from nucleotide deficiencies for 36 hours, after 48 hours of drug treatment cell survival 
decreased slightly.  However, the cell survival observed during HU treatment never decreased 
below 10% survival throughout the 72 hour time course (Fig 2-23).  Conversely, the cytotoxicity 
of PALA treatment was observed within 6 hours of treatment; cell survival decreased to ~10% 
and continued to decrease with time.  By 48 hours, PALA treatment was cytotoxic with ≤ 0.1% 
cell survival (Fig 2-23).  The cytotoxicity of PALA treatment can easily be seen in Fig 2-23A; 
very few colonies out of the total of 15,000 plated cells survived after 12 hours of PALA 
treatment, while HU and untreated cells contained a similar number of colonies at 12 hours (Fig 
2-23A).  The S-phase checkpoint appeared to be protecting HU-treated cells from cytotoxicity 
while the lack of S-phase checkpoint resulted in cytotoxicity within 6 hours of PALA treatment.   
 
PALA treatment promotes a p53-dependent apoptosis 
 The post-translational phosphorylation of p53 during PALA treatment at serine 46 
suggested that these cells may be undergoing p53 dependent apoptosis (Mayo et al., 2005).  This 
proved to be the case: after 24 hours, PALA-treatment resulted in apoptosis as observed by 
cleaved caspases 7 and 9, as well as by PARP1 (Fig 2-24).  Treatment with HU did not cause 
cleavage of any of these proteins crucial to the apoptotic response.  The PARP1 cleavage during 
PALA treatment was shown to be dependent on p53, in concordance with the data in Fig 2-14.   
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Figure 2.23. The imposition of an S-phase checkpoint by HU protects HCT116 cells from 
cytotoxicity for an extensive period, whereas PALA exposure is rapidly cytotoxic. G0/G1 
synchronized HCT116 cells were released into drug-containing medium for the indicated times 
and adherent and non-adherent cells were re-plated at 150 cells/plate in drug free medium 
allowing for colony formation.  B, Quantitation of the colony formation assay in HCT116 cells 
after treatment with HU or PALA at the indicated times.  Points indicate the mean of two 
biological repeats containing two plates within a single experiment and standard error is depicted 
by the bars.  Colony number was plotted as survival of drug- treated cells compared to vehicle-
treated cells.  Vehicle was PBS, HU was used at 1.5 mM, PALA was used at 100 M. 
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Figure 2-24. PALA treatment induced p53 dependent apoptosis while the HU-induced S-
phase checkpoint protects cells from apoptosis. This figure shows a western blot analysis of 
cleaved caspases 7 and 9, PARP1 and cleaved PARP1 in asynchronous HCT116 cells treated 
with drug for 24 hours. B,  Lysates from asynchronous HCT116 p53 +/+ and HCT116 p53 -/- 
cells were probed for PARP1 to determine the p53 dependency of apoptosis.   Equal levels of 
total protein (25 g) were loaded in each lane.  Vehicle was PBS, HU was used at 1.5 mM, 
PALA was used at 100 M and VP16 was used at 10M. 
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Using the p53 HCT116 isogenic cell lines, PARP1 cleavage was not observed after PALA 
treatment in the absence of p53.  The p53 dependency of this apoptosis was further investigated 
by examining the presence of p53 at a panel of known p53-dependent pro-apoptotic promoters 
after 24 hours in drug.  Five promoters were chosen based on their known p53RE affinities for 
p53.  The p53RE in the BAX, PIG3, and AIP1 promoters are known to have weaker p53 binding 
affinities while that in the PUMA and FAS promoters have higher p53 promoter affinity (Inga et 
al., 2002; Kaeser and Iggo, 2002; Weinberg et al., 2005).  PALA treatment promoted enhanced 
binding of p53 at all of these promoters at or exceeding levels seen with the highly cytotoxic 
dose of VP16 used as the control, indicating that after 24 hours in drug, PALA treatment 
facilitated p53 binding to pro-apoptotic promoters (Fig 2-25).  This is in agreement with the 
apoptosis observed by the cleavages of caspases 7, 9 and PARP1 and the cytotoxicity measured 
by colony formation assays.  The species of p53 accumulating in HU-treated cells was 
apparently much less active at entering the nucleus and binding at either high- or low-affinity 
p53REs. 
 H2AX formation is a rapid cellular response for DNA double strand breaks and 
therefore to determine if apoptosis resulting from PALA treatment was due to DNA damage, 
levels of H2AX were measured (Rogakou et al., 1998).  There were no significant differences in 
the levels of H2AX between HU and PALA treatment and both were less than the positive 
control for DNA damage, VP16 (Fig 2-26).  
 Another hypothesis was tested in the experiments that investigated rescue of HU 
treatment with the addition of 2-deoxyadenosine (AdR) and 2-deoxyguanosine (GdR), the purine 
deoxyribonucleotides discussed above.  The apoptosome formed by the intrinsic apoptotic 
pathway responsible for cleavage of caspase 9 and initiating the downstream signaling has been  
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Figure 2-25. PALA treatment induces p53 binding at promoters of pro-apoptotic proteins.  
ChIP analysis of p53 enrichment at pro-apoptotic promoters in asynchronous HCT116 cells after 
24 hours of drug treatment.  p53-DNA complexes were immunoprecipitated from crosslinked 
cells and PUMA, FAS, PIG3, BAX, AIP1 promoter levels were quantitated with Q-PCR.  Non-
specific binding was immunoprecipitated with IgG. PUMA and FAS promoters correspond to 
the left ordinate while PIG3, BAX and AIP1 promoters correspond to the right ordinate.  
Standard error is depicted by the bars from one biological repeat with triplicate Q-PCR samples.  
The same trend was observed in subsequent biological repeats.  Vehicle was PBS, VP16 was 
used at 10 M, HU was used at 1.5 mM and PALA was used at 100 M.  
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Figure 2-26. HU and PALA-treatment induce the same level of H2AX in asynchronous 
HCT116 cells. This figure shows a western blot analysis of levels of H2AX after exposure to 
10 M VP16, 1.5 mM HU or 100 M PALA for 24 hours.  Total cell lysate protein (25 g) was 
subjected to SDS-PAGE and immunoblotted with antibodies against H2AX and -Actin.  VP16 
was used as the positive control.  Protein loading was assessed with -Actin.  
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shown to be dependent on cytochrome c and dATP (Zou et al., 1999).  Since HU depletes all 
dNTPS (Bianchi et al., 1986; Rosenthal et al., 1928), it was hypothesized that HU treatment 
cannot promote apoptosis due to the lack of availability of dATP for apoptosome assembly. 
PARP1 cleavage was immunoblotted for in these samples.  There was no change in cleavage 
between the HU sample alone and the HU supplemented with AdR and GdR.  Therefore, the 
depletion of dATP is not preventing apoptosis in HU treatment (Fig 2-15 B).  Ultimately, the 
supplementation experiments with AdR and GdR did not explain the differences in the cellular 
responses between HU and PALA treatment. 
 
Discussion 
 We have found that HCT116 cells respond very differently to two drugs that both cause 
an inhibition of nucleotide synthesis pathways and a subsequent slowed progression of S-phase 
and stalling of replication forks.  The ribonucleotide reductase inhibitor HU activates the S-phase 
checkpoint through ATR recruitment to the chromatin and Chk1 phosphorylation and is not 
appreciably cytotoxic for several generation times.  PALA, an inhibitor of aspartate 
transcarbamylase in the de novo pyrimidine synthesis pathway, fails to activate the S-phase 
checkpoint resulting in commitment to a p53-dependent apoptosis without a lag time.  One 
would hypothesize that these two drugs essentially stress the cells in the same manner, by 
causing an imbalance of nucleotides, and would be expected to result in similar cellular 
responses.  This is clearly not the case in HCT116 colon carcinoma cells.  
 
Why does HU induce the S-phase Checkpoint and PALA does not?  
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 Flow cytometry analysis of G1 synchronized cells released into HU and PALA 
demonstrated that the cells are slowly progressing though the S-phase (Fig 2-12).  The nearly 
comparable rates of S-phase progression suggested that the two drug treatments were causing 
similar cell cycle signaling; this was shown to not be true.  The S-phase checkpoint effector 
kinase Chk1 was phosphorylated during HU treatment indicating an activated S-phase 
checkpoint, while PALA treatment resulted in minimal phosphorylation of Chk1 (Fig 2-13).  The 
differential Chk1 phosphorylation was found to be due to the levels of ATR recruited to the 
chromatin (Fig 2-21).  PALA treatment did not cause ATR recruitment to the chromatin, 
explaining the lack of Chk1 phosphorylation; the upstream kinase was not recruited and 
therefore, Chk1 could not become phosphorylated and activated.  Interestingly, another S-phase 
checkpoint protein, BLM, was also not at the chromatin after PALA treatment, while HU 
treatment resulted in BLM recruitment.  It is clear that PALA treatment did not activate the 
signaling pathway involved in the S-phase checkpoint (Fig 2-5), but the question remains as to 
why there is such a disparity between HU and PALA treatment?  Why is ATR recruited to the 
chromatin only after HU treatment?  ATR recruitment was shown to be dependent on ATRIP 
loading onto RPA coated ssDNA and that the long stretches of RPA-coated ssDNA is the 
molecular trigger initiating the S-phase checkpoint (Zou and Elledge, 2003).  It is possible that 
PALA treatment does not result in long stretches of exposed ssDNA at replication forks. Since 
the recruitment of ATRIP and ATR depends on RPA bound ssDNA, if this event is not 
occurring, then the differences in ATR recruitment between HU and PALA treatment could be 
explained be examining the RPA levels at stalled replication forks.   
 
Why is PALA cytotoxic and HU is not? 
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 Cell kill was obvious early studies of PALA treatment.  After cells were treated with 
PALA for extended lengths of time (> 24 hours) the majority of the cells were falling off the 
tissue culture dish and floating.  Throughout the time course studies, it was difficult to obtain 
enough cells at the later time points for flow cytometry or western blot analysis.  The answer 
became clear when I discovered that the HCT116 cell death after PALA was apoptotic (Fig 2-
24).  PALA induces apoptosis and HU does not at equivalent functional effects on S-phase 
traverse.  Interestingly, there appeared to be no lag time in the observed apoptosis.  Within 6 
hours of PALA treatment, 90% of the cells were unable to survive and by 36 hours no significant 
cell survival was observed (Fig 2-23).  This was not true for HU-treated cells; almost all plated 
cells were still able to survive and form visible colonies after 48 hours of HU treatment.  When 
the dependency of cell survival on p53 was investigated, it was shown that at the working 
concentration of PALA (100 M), 50% of  HCT116 cells null for p53 could survive while cells 
wild-type for p53 could not (Fig 2-22).    
 The mode of cell death was first suggested by analysis of the PTMs of p53 after HU and 
PALA treatment.  The PTMs of the accumulated p53 were completely opposite following HU or 
PALA treatment (Fig 2-8).  During HU treatment serines 15 and 20 were phosphorylated.  ATR 
is known to phosphorylate p53 at serine 15 and Chk1 is known to phosphorylate p53 at serine 20 
(Shieh et al., 2000; Tibbetts et al., 1999); therefore these modifications correlate with the 
observed activation of the S-phase checkpoint in HU but not in PALA.  The modifications on 
serines 37, 46 and 392 during PALA treatment are informative of the cellular activities of p53: 
phosphorylation of serine 46 has been shown to favor p53-dependent apoptosis (Mayo et al., 
2005), serine 392 phosphorylation enhances p53 tetramerization and subsequent DNA binding 
(Hupp et al., 1992; Keller et al., 2001; Sakaguchi et al., 1997), and phosphorylation of serine 37 
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promotes sequence-specific DNA binding of p53 (Sakaguchi et al., 1998).  During HU treatment 
none of these sites were phosphorylated to the extent observed during PALA treatment, 
suggesting that the p53 accumulated during PALA treatment was activated to bind to DNA and 
promote apoptosis whereas the p53 in HU-treated cells was not.  This was found to be true; 
PALA-stabilized p53 was bound to all investigated pro-apoptotic promoters at levels greater than 
that of the HU-stabilized p53 (Fig 2-25).  It was later discovered that PALA induces apoptosis 
which is dependent on p53; cleavage of PARP1 was not observed after PALA treatment in 
HCT116 cells null for p53 (Fig 2-24).   The dependency on  p53 for  inducing apoptosis after 
PALA treatment and the fact that HCT116 cells null for p53 are able to survive after 24 hours of 
PALA treatment while HCT116 cells wild-type for p53 are not, indicated that the key factor in 
this decision for apoptotic cell death appeared to be p53.   
 
Does p53 determine cellular fate? 
  It appears that p53 is involved in the differing cellular responses to HU and PALA.  The 
total amount of accumulated p53 between the two treatments is significantly different and the 
post-translational modifications of the accumulated p53 are completely opposite when 
comparing drug treatments.  Secondly, the apoptotic response was found to be p53-dependent 
and the colony formation assays demonstrated that p53 null cells are better able to survive after 
PALA treatment, all implicating the involvement of p53. 
 It was consistently observed that PALA treatment resulted in the accumulation of twice 
as much p53 than seen after HU treatment (Figs 2-11, 2-13, 2-14, 2-15).  This was observed in 
synchronous cells, asynchronous cells and over a range of time points.  Why is there a difference 
in the p53 levels accumulated after HU and PALA treatment? It has been shown that the nuclear 
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export sequence (NES) that is located at amino acids 340-351 within the oligomerization domain 
is masked by p53 tetramerization resulting in nuclear retention of p53 (Stommel et al., 1999).  
The PTMs of p53 after PALA treatment, specifically phosphorylation of serine 392, suggested 
that after PALA treatment, the accumulated p53 forms tetramers more readily than the HU-
stabilized p53.  If this is found to be true, then during PALA treatment the tetramerization of p53 
may be masking the NES and therefore trapping p53 in the nucleus and protecting it from 
degradation, while the p53 accumulated during HU treatment is not.   
   
How do the differing levels of accumulated p53 ultimately determine the cellular fate of 
PALA-treated cells?     
 Although the exact answer to this question remains to be elucidated, the experiments 
presented throughout this chapter have led to some interesting hypotheses.  The role of p53 in the 
S-phase checkpoint is complex and there is no known required transcriptional role for p53 in the 
S-phase checkpoint.  It is thought that p53 interacts with BLM and Rad51, enhancing their 
recruitment to stalled replication forks independent of transcriptional activation.  Previous 
literature has suggested that the p53 stabilized during HU treatment has decreased transcriptional 
activity when compared to IR-stabilized p53 as determined by northern blot analyses of RNA 
levels of several p53 dependent genes including, p21, gadd45, hdm2 and cyclin G (Gottifredi et 
al., 2001).  In this chapter, we showed that HU treatment activates a functional S-phase 
checkpoint as shown by ATR recruitment to the chromatin and phosphorylation of Chk1.  This 
would suggest that the transactivating ability of p53 is dispensable for a functional S-phase 
checkpoint.  Furthermore, it appears that, during PALA treatment, promoters are enriched with 
p53 to a greater extent than during HU treatment.  In the ChIP assays described throughout this 
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chapter, PALA-stabilized p53 was found to bind to large range of promoters, as observed in the 
panel of pro-apoptotic promoters and the p21 promoter (Fig 2-7 & Fig 2-25).  Conversely, during 
HU treatment the upstream binding site of the p21 promoter, which is known to have the highest 
affinity for p53 (Inga et al., 2002; Kaeser and Iggo, 2002; Weinberg et al., 2005), was the only 
promoter that had significant levels of p53 enrichment. These data suggest that the PALA-
stabilized p53 is able to bind p53RE within promoters better than that of the HU-stabilized p53.   
The PALA-stabilized p53 is capable of transactivating genes, as is evident from the robust 
stimulation of Wip1 transcription (Fig 2-18).  Therefore, these data raise the possibility that a 
stabilized p53 that is able to bind and transactivate genes is capable of inducing apoptosis while 
the p53 accumulated during HU treatment is not capable of activating the genes required for 
apoptosis.  However, stabilization of p53 caused by HU treatment may enhance the recruitment 
of BLM and Rad51 to stalled replication forks in the S-phase checkpoint. 
 
Is p53 differentially recruited to replication forks in HU and PALA treatment? 
 Although the levels of p53 recruited to the chromatin during HU and PALA treatment 
appeared to be similar (Fig 2-21), the chromatin fractionation isolated all nuclear chromatin.  
Replication forks as well as promoters of p53-dependent genes were both included in this 
chromatin fraction, making it difficult to differentiate the levels of p53 recruited to the chromatin 
from that of p53 bound to p53REs in promoters.  The p53 accumulated after PALA treatment 
was shown to be more capable of binding to promoters than the HU-stabilized p53 (Fig 2-25), so 
it is logical to hypothesize that a large majority of the chromatin bound p53 is indeed p53 bound 
to promoters, not p53 at replication forks.  To determine if HU and PALA treatment 
differentially recruit p53 to replication forks, colocalization studies of p53 and BrdU in HU and 
PALA treated cells could be performed.  Treating cells with DNase after a brief pulse with BrdU 
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has been shown to lead to BrdU incorporation at stalled replication forks (Kennedy et al., 2000).  
This methodology would allow the identification of stalled replication forks by 
immunofluorescence and colocalization of p53 with the replication forks could then be 
determined. 
Is the S-phase checkpoint activated by HU treatment cytoprotective? 
 It was clear that PALA treatment resulted in marked cytotoxicity, but did the S-phase 
checkpoint activated by HU treatment protect the cells from nucleotide deficiencies?  The data 
presented within this chapter centrally proves that HCT116 cells are protected from cytotoxicity 
during HU treatment.  After 36 hours of HU treatment, cells were able to survive as well as the 
untreated control and even after 72 hours of HU treatment, cells showed some toxicity but a 
small percentage (~17%) of them still were able to survive and form colonies (Fig 2-23).  
Interestingly, HCT116 cells null for p53 and HCT116 wild-type for p53, were able to survive to 
the same extent when treated with HU at the working concentration of 1.5 mM for 24 hours (Fig 
2-22).  The p53 dependency of Chk1 phosphorylation during HU treatment also demonstrated 
that Chk1 was phosphorylated at serine 345 and 317 in HCT116 p53 -/- cells to the same extent 
as HCT116 cells containing wild-type p53 (Fig 2-14).  Both observations suggest that p53 is not 
required for a functional checkpoint and the resulting cytoprotectivity that the S-phase 
checkpoint provides during HU treatment.  The exact role of p53 during the S-phase checkpoint 
activated by HU treatment remains to be elucidated and the cell line, which will be described in 
the next section was generated to address this question.   
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Chapter 3: Development and Characterization of an Endogenously TAP-tagged p53 Locus 
 
Introduction 
The p53 tumor suppressor is known to be involved in several cellular pathways that are in 
place to protect the cell from tumorigenesis.  p53 is one of the main regulators in cell cycle 
control and apoptosis pathways yet it is mutated in half of all human cancers resulting in 
dysregulation of the cell cycle and of apoptosis.  For this reason, the cellular and molecular 
functions of p53 have been thoroughly investigated to understand its cellular roles and to better 
comprehend the changes that cancer cells undergo following mutation of p53. 
p53 exerts its tumor suppressor activity through two main functions; by binding to gene 
promoters recruiting transcriptional machinery activating (or repressing) transcription, and by 
directly binding to and modulating protein functions.  The transcriptional regulation activity of 
p53 has been extensively investigated while the modulation of protein functions by p53 is less 
well characterized.   There are examples in both cell cycle regulation and apoptosis pathways 
where p53 exerts its tumor suppressor activity by both mechanisms.   
p53 was first implicated in homologous recombination when p53 null mammalian cells 
were shown to have elevated levels of spontaneous homologous recombination (Mekeel et al., 
1997).  Since then, the proteins involved in homologous recombination have been identified and 
the role of p53 in this pathway has been further elucidated.  Rad51 is induced in late S-phase and 
G2 and binds to single stranded DNA during the initial steps of homologous recombination 
(Benson et al., 1994; Flygare et al., 1996).  Rad51 possesses DNA-dependent ATPase activity 
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which supplies the energy needed for the homologous pairing and strand exchange steps during 
homologous recombination (Baumann et al., 1996).  p53 was shown to inhibit homologous 
recombination through binding to and modulating the function of Rad51 (Linke et al., 2003; 
Sturzbecher et al., 1996). Rad51 and p53 co-localize to stalled replication forks induced by HU 
and their interaction stabilizes the replication fork through inhibition of the Rad51-driven branch 
migration (Sengupta et al., 2003; Yoon et al., 2004).  During VP16-induced DNA damage, p53 
binds to the Rad51 promoter inhibiting the transcription of this gene.  Therefore, p53 controls 
homologous recombination at two levels when the genome integrity is compromised; through 
protein-protein interactions and through transcriptional repression (Arias-Lopez et al., 2006).   
 This duality of p53 in control of a cellular process also occurs during apoptosis.  It was 
shown that p53 had a role in apoptosis when p53 null tumor cells underwent spontaneous cell 
death after the introduction of wild-type p53 (Yonish-Rouach et al., 1991).  Bax has been well-
defined as an apoptotic protein that inserts into the outer mitochondrial membrane to form a 
pore, releasing cytochrome c and activating cytosolic events in the apoptotic pathway (Rosse et 
al., 1998). The restoration of p53 in murine leukemia cells caused an increase of Bax mRNA and 
protein levels (Selvakumaran et al., 1994). Bax was found to be a direct transcriptional target of 
p53 and it was the first example of a proapoptotic gene that is directly regulated by p53 
(Miyashita and Reed, 1995).  Almost ten years after the discovery of the transcription activation 
of Bax by p53, p53 was found to bind to Bax directly, promoting mitochondrial 
permeabilization, a characteristic of apoptosis (Chipuk et al., 2004).  Homologous recombination 
and apoptosis are two examples of very different cellular processes in which p53 exerts tumor 
suppressor activity through effects at both the level of transcriptional control and at the level of 
protein-interactions.  
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  There are several examples where p53 exerts only one level of control by binding to and 
modulating protein functions.  One such example is the control of the function of the RecQ 
helicase, BLM, the product of the gene responsible for causing Bloom‟s syndrome when 
mutated.  Cells from Bloom Syndrome patients exhibit chromosomal instability due to an 
elevated rate of sister-chromatid exchange, suggesting that a protein involved in recombination is 
mutated in these cells (Chaganti et al., 1974).  The sequence of BLM has high homology with the 
RecQ family of helicases and was shown to have 3′-5′ helicase activity (Ellis et al., 1995; Karow 
et al., 1997).  BLM selectively recognizes Holliday junctions and promotes the branch migration 
of these junctions, preventing homologous recombination events from occurring (Karow et al., 
2000).  It has been hypothesized that when replication forks stall, Holliday junctions arise and 
that resolution of these structures would result in a double-strand DNA break (Sharples et al., 
1999).  p53 has been shown to bind directly to BLM, modulating the helicase activity.  By 
inhibiting the resolution of the Holliday junctions at stalled replication forks, modulation of 
BLM by p53 prevents the collapse of replication forks, as well as further DNA damage and the 
threat of tumorigenesis (Yang et al., 2002).   
 
The problem addressed in this chapter 
 With the myriad mechanisms of action of p53 that occur, the question arises of how to 
suitably study the binding of p53 to various proteins and promoters in the cell while also 
conserving the ability to determine whether various PTMs drive p53 to these various nuclear, 
cytosolic and mitochondrial compartments.  Specifically, the role of p53 in the S-phase 
checkpoint has been recently proposed and the question arises whether p53 is binding to other 
checkpoint proteins.  In order to address this question, p53 has to be isolated at endogenous 
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levels with all interacting proteins during nucleotide deficiencies to determine what proteins bind 
p53.  To address these questions, we have designed and created a HCT116 cell line in which a 
tandem affinity purification tag has been inserted into one of the endogenous p53 alleles by 
homologous recombination.  
 
The use of TAP tag to study protein-protein interactions 
 Until recently, the methodology to ask non-biased questions about protein interactions 
within mammalian cells has been limited.  Co-immunoprecipitation experiments only provide 
data answering specific questions such as, „does protein x interact with protein y?‟ and usually 
are confined to analysis of such events in whole cell lysates.  The ability to ask „what are all of 
the proteins that interact with protein x?‟ has not been easily feasible until the introduction of the 
tandem affinity purification (TAP) tag technology combined with mass spectrometry.  This tag 
was designed to allow the target protein to be purified with all interacting proteins using mild, 
non-denaturing, purification conditions.  The two step purification tag consists of a protein A tag 
and a calmodulin binding peptide separated by a tobacco etch virus (TEV) protease cleavage site 
(Fig 3-1) (Rigaut et al., 1999).  This cleavage site was found to be advantageous over others 
because the TEV nuclear inclusion A protein encoded by the tobacco etch virus is stable and 
active over a range of pH, ionic strengths and temperatures and recognized a short peptide 
sequence rarely found in mammalian tissues.  The proteinase has stringent sequence specificity 
for the TEV cleavage site, decreasing proteolysis of cryptic sites within mammalian proteins 
(Parks et al., 1994).    IgG beads are used as the first affinity adsorption matrix to select any 
protein bearing the protein A tag.  The complex is removed from the beads by cleavage with the 
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TEV protease.  The complex is then subjected to the second affinity matrix absorption onto 
beads covalently attached to calmodulin in the presence of Ca
2+
 which selectively binds to the 
calmodulin binding peptide.  The protein complex is eluted and isolated through chelation of the 
Ca
2+
 with EGTA (See Figure 3-1) (Rigaut et al., 1999).  The tandem purification approach is 
superior to single purification tags for two reasons; the two purification steps allow for a purer 
isolated product with less contaminants, and the design of the TAP tag allows for stringent, non-
denaturing purification conditions making it possible to isolate protein binding partners. 
 
Gene Targeting Allows Protein Interactions to be studied at endogenous levels 
 Protein interactions are driven by association constants (Ka) and therefore protein-protein 
interactions should be studied at endogenous levels to rule out any false positives resulting from 
the over expression of the target protein of interest.  With the use of the TAP tag, isolation of 
these interactions are now possible, and in combination with gene targeting, the TAP tag 
sequence can be inserted by homologous recombination at the end of the endogenous gene locus 
coding the protein of interest.  This would result in the transcription and translation of the target 
gene and the incorporated TAP tag in one contiguous transcript, allowing protein interactions to 
be studied at natural endogenous levels.  This was first achieved in yeast in 1999 and, in 2002, 
Seraphin‟s group used the TAP tag to identify 234 multiprotein complexes and proposed new 
roles for 344 of the proteins, 231 of which had no previously known function.  Function could be 
assigned for most of these unassigned open reading frame proteins by a “guilt-by-association” 
logic, demonstrating the power of this technology (Gavin et al., 2002; Rigaut et al., 1999).       
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Figure 3-1. Overview of Tandem Affinity Purification Procedure.  Cellular lysates are 
incubated with IgG beads that bind to protein A in the TAP tag.  The target protein and binding 
partners are eluted from the IgG beads with TEV protease.  The eluate is then bound to 
calmodulin beads in the presence of CaCl2, which will bind to the calmodulin binding peptide.  
The target protein and binding partners are eluted by chelating the CaCl2 with EGTA.   
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rAAV as the mode for gene delivery 
 For successful gene targeting events to occur, the targeting vector must pair up with the 
homologous sequence in the chromosome.  Considering that the human genome is three million 
base pairs, the frequency of this occurring is exceptionally low (Vasileva and Jessberger, 2005).  
Previous methodologies to introduce targeting vectors into mammalian somatic cells consisted of 
lipid based transfections or electroporation of double-stranded DNA plasmid, which resulted in 
frequencies of one cell out of a million transfected cells incorporating the targeting sequence into 
their genomes by homologous recombination, but substantial frequencies of incorporation at 
random locations within the genome occurred (Sedivy and Sharp, 1989).  This low frequency of 
correct insertion against a very high background made manipulating the endogenous genetic 
locus of mammalian cells difficult, and required screening tens of thousands of cell clones to find 
one clone in which correct sequence-specific integration had occurred.  The introduction of 
recombinant adeno-associated viruses (rAAV) as the mode of gene delivery greatly improved 
these frequencies (Kohli et al., 2004).  AAV were first used in the early 2000‟s as a method to 
introduce genetic modifications into homologous human chromosomes.  Vectors containing 1.5 
kb of homologous sequence could be inserted into the correct location of the targeted gene at a 
frequency of 1%, a vast improvement from previous methodologies (Hirata et al., 2002). 
 AAV is a single-stranded linear DNA virus with a 4.7 kb genome containing a rep gene 
and a cap gene encoding proteins required for viral replication and encapsidation of the viral 
genome.  Inverted terminal repeats (ITR) are also required for replication.  The ITR sequences 
are 145 bp palindromic sequences which allow the virus to fold into a hairpin, these sequences 
are required for integration into the host genome and viral replication.  In recombinant rAAVs, 
the rep and cap genes are replaced with homologous sequence to the gene to be targeted and the 
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viral genes are supplied in trans through helper vectors during the viral packaging step.  The 
packaging limit of AAV is approximately 4.9 kbs and the ITR sequence is the only viral 
sequence required to be provided in cis, providing space for 4.4 kb homologous sequence to be 
cloned into the vector.  These longer stretches of homologous sequences increase the frequency 
of homologous recombination with the targeted genome (Reviewed in (Carter, 1992)).  
 It is not well understood why rAAV yield higher frequencies of gene targeting than 
previous methodologies, but there are several hypotheses.  Since a large number of intact viral 
vectors are delivered to each cell, this increases the probability of homologous recombination 
occurring.  In addition, the single stranded viral genome is highly recombinogenic and is thought 
to promote homologous pairing better than double stranded substrates similarly to homologous 
recombination frequently seen with stretches of single-stranded DNA at replication forks and, 
lastly, the hairpin structure of the genome may decrease random integration (Russell and Hirata, 
1998).      
 
Steps involved in generating human somatic knock-ins  
 Generating human somatic knock-ins consists of four steps: (i) designing and creating a 
targeting vector containing homologous sequence to the gene to be targeted, (ii) delivery of the 
targeting vector by rAAV to the cells, (iii) selecting for cells which underwent homologous 
recombination with the targeting vector and (iv) screening cell clones for gene knock-in at the 
correct location in the genome.  Although this process is laborious, when compared to creating 
cell lines where the sequence transfected randomly integrates into the genome, the advantages of 
studying endogenously altered genes far outweighs the time involved in the creation of the cell 
line.  
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 To understand the function of p53 at the replication fork during nucleotide deficiencies 
we have inserted a TAP tag into the p53 genomic locus at the C-terminus in human colon cancer 
HCT116 cells.  The protein product of this allele appears to be fully functional in comparison 
with the wild-type p53 protein translated from the unaltered allele.  We have used this cell line to 
isolate p53 with its binding partners under the cellular stress of DNA damage induced by VP16 
and nucleotide imbalances induced by HU and PALA.   This cell line is a powerful tool for 
studying p53 in various cellular compartments, when combined with physical subfractionation of 
the cell and/or immuno-selection of megacomplexes, as well as in studying the protein-protein 
interactions of p53 during any form of cellular stress.     
 
Materials & Methods 
 Prior to deciding to use the rAAV as the method of delivery of the TAP tag sequence into 
the HCT116 cells, the sequence encoding the TAP tag and 3kb of the p53 coding sequence 
directly upstream from the stop codon were cloned into the pIRES-neo2 vector.  The cloning of 
this vector will be explained first (Fig 3-2), and then the use of this vector as the template for 
PCR in cloning the vector which was ultimately used in the gene targeting by rAAV will be 
described.  The final vector used for inserting the TAP tag sequence into the p53 genomic locus 
was named pAAV-MCS p53 TAP (Fig 3-3).   
 
Generating the template sequences used to clone the pAAV-MCS p53 TAP 
Amplifying the TAP tag sequence and the 3 kb p53 coding sequence 
 The sequence encoding the calmodulin peptide, TEV cleavage site and protein A of the 
TAP tag was amplified from the p-Zome-1-C plasmid using TAP tag pZome sense primer 
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Figure 3-2. Overview of cloning the pIRES-TAP-p53 vector.  A, The sequence encoding the 
TAP tag peptide was amplified from the pZOME-1-C vector with a sense primer with a 5′- HpaI 
restriction site and an antisense primer with a 3′-NotI restriction site.  The amplified TAP tag 
PCR product and the pIRES-neo2 vector were digested with HpaI and  NotI and ligated, 
generating the pIRES-TAP vector.  B, The p53 coding sequence upstream from the stop codon 
was amplified from genomic HCT116 DNA with a sense primer containing a 5′- AlfII site and an 
antisense primer containing a HpaI site.  The amplified p53 upstream PCR product and the 
pIRES-TAP vector were digested with AlfII and HpaI and ligated generating the pIRES-TAP-
p53 vector.  This vector was used as the PCR template in amplifying the left homology arm 
required for the cloning of the vector required for rAAV gene targeting.   
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Figure 3-3. Overview of the insertion of a TAP tag into the endogenous p53 locus by 
homologous recombination.  A, This figure shows the vector designed, cloned and transfected 
in the generation of the cell line.  The plasmid backbone is in rust, the right and left homology 
sequences required for homologous recombination are in turquoise and the resistance cassettes 
are in peach. B, The two p53 genomic loci after homologous recombination with the transducing 
vector.  Grey boxes indicate the endogenous exons and white indicates the exogenous sequence 
inserted through homologous recombination. 
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containing a HpaI restriction site and TAP tag pZome antisense primer containing a NotI 
restriction site  (Table 3-1, Fig. 3-2A) (Euroscarf, Frankfurt Germany).  The 25 L PCR reaction 
contained  20 mM Tris-HCl, 50 mM KCl (pH 8.4; MgCl2 Free 10x PCR Reaction Buffer),  200 
M deoxynucleotides, 1.5 mM MgCl2, 0.6 M of each primer, 1 U Taq DNA Polymerase, 0.25 
U PfuTurbo DNA Polymerase, 5% DMSO and 100 ng of p-Zome-1-C.  The PCR program 
consisted of a 10 minute incubation at 94ºC, followed by 35 cycles of 94ºC for 45 second, a 
range of temperatures from 45ºC-42ºC
 
to determine the optimal annealing temperature of the 
primers for 45 seconds, and 72ºC for 3 minutes, and finished with a final extension at 72ºC for 5 
minutes.  PCR products were run on a 1% agarose gel with ethidium bromide and the 600 bp 
product was extracted and purified using the Promega Wizard SV gel and PCR Clean-Up 
System.  The concentration of the purified product was determined by sample absorbance at 260 
nm and the sequence of the purified product was checked.   
 A 3 kb fragment of the genomic p53 coding sequence was amplified from 50 ng genomic 
DNA isolated from HCT116 cells by Fiona Turner with the Upstream p53 sense primer 
containing a AlfII restriction site and the Upstream p53 antisense primer containing a HpaI 
restriction site (Table 3-1).   The 25 L PCR reaction contained 12.5 L Hot StartTaq Master 
Mix, 0.5 U PfuTurbo DNA Polymerase and 0.3M of each primer.  The PCR program started 
with a 15 minute incubation at 95ºC followed by a 10 cycles of 94ºC for 45 seconds, a range of 
temperature from 70ºC -60ºC for 45 seconds to optimize the annealing temperature of the 
primers and 72ºC for 3 minutes.  This was followed with an additional 35 cycles of 94ºC for 45 
seconds, 59.3ºC
 
for 45 seconds and 72ºC for 3 minutes, and finished with an extension for 15 
minutes at 72ºC
 
 (Fig 3-2B).  The 3 kb band was purified as stated above and the sequence was 
checked.   
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Table 3-1. The primers used in cloning the pAAV-MCS p53 TAP vector and in screening 
for the correct insertion of the TAP tag into the p53 genomic locus by homologous 
recombination. 
  
Primer Sequence
TAP tag pZome sense 5′-AGTCTAGTTAACATGGAAAAGAGAAGATGG-3′
TAP tag pZome antisense 5′- TATTATGCGGCCGCATAACTTCGTATAATGTATGCTATACGAA
GTTATCTAATTAGCGTCTACTT-3′
Upstream p53 sense 5′-CACTACTTAAGTCCCAAGTTGCTTCAACTACAGGC-3′
Upstream p53 antisense 5′-TAGATAGTTAACGTCTGAGTCAGGCCCTTCTGTC-3′
Downstream p53 sense 5′-TAACTAGTCGACATAACTTCGTATAGCATACATTATACGAAGTT
ATCATTCTCCACTTCTTGTTCCCCACTG-3′
Downstream p53 antisense 5′-GTCAATCAGCTGCTGAAGCCATGAGGAAATTGGG-3′
Left homology arm sense 5′-ATACATACGCGGCCGCCATGGTCAAAGGCAGCTG-3′
Left homol arm antisense 5′-GCTCCAGCTTTTGTTCCCTTTAGCTAATTAGCGTCTACTTT-3′
Right homology arm Sense 5′-CGCCCTATAGTGAGTCGTATTACCATTCTCCACTTCTTGTTC-3′
Right homol arm antisense 5′-ATACATACGCGGCCGCTTGGCTGGCCATGGTGGCATGA-3′
Left homol-Neo sense 5′-ATACATACGCGGCCGCCATGGTCAAAGGCAGCTG-3′
Left homol-Neo antisense 5′-GCGTAATACGACTCACTATAGGGCGAATTGGGTACC-3′
Neo-right homol sense 5′-CTAAAGGGAACAAAAGCTGGAGCTCCACCGCGG-3′
Neo-right homol antisense 5′-ATACATACGCGGCCGCTTGGCTGGCCATGGTGGCATGA-3′
Exon 10 screening sense 5′-AGA GCTGAATGAGGCCTTGGAACT-3′
TAP screen antisense 5′-TAGCGCTTTGGCTTGGGTCATCTT-3′
3′-screening sense 5′-AGTCTAGTTAACATGGAAAAGAGAAGATGG-3′
3′-screening antisense 5′-CTTCCCAGCACCTCCTCACTCACCCCTG-3′
  
116 
 
Cloning the sequence encoding the TAP tag and p53 sequence into the pIRES-neo2 vector 
 The TAP tag PCR product and pIRES-neo2 vector (Clontech) were digested with HpaI 
and NotI at 37ºC for 1 hour in a 20 L reaction containing 50 mM NaCl 10 mM Tris-HCl, 10 
mM MgCl2, 1 mM dithiothreitol (pH 7.9), 0.1 g/L BSA, 10 U of NotI and 10 U HpaI (Fig 3-
2A).  Following the digestion the products were electrophoresed, purified and their 
concentrations were determined as stated above.  Ligation of 25 ng of the pIRES-neo2 vector 
with 9.9 ng of the TAP tag PCR product (a 3:1 molar ratio) was carried out at 16ºC for 16 hours 
in a 10 L volume reaction containing 66 mM Tris-HCl, 5 mM MgCl2
 
, 1 mM dithiothreitol, 1 
mM ATP (pH 7.5) and 1 U T4 DNA ligase.  
 TOP10 chemically competent E. coli cells were transformed with the ligation product.  
TOP10 cells were removed from the -80ºC and thawed on ice; 4 L of the ligation reaction was 
added to the TOP10 cells and mixed gently.  This mixture was incubated on ice for 15-30 
minutes and then heat shocked at 42ºC for 30 seconds.  S.O.C. medium (2% tryptone, 0.5 % 
yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4 and 20 mM glucose) 
was warmed to 25ºC and 250 L was added to the tubes and the tubes were shaken vertically at 
225 rpm at 37ºC for 1 hour in an orbital shaker.  The transformed TOP10 cells were plated on 
Luria-Bertani (LB) plates with 100 g/ml carbenicillin added and the plates were incubated at 
37ºC for 16 hours.  Only TOP10 cells which were successfully transformed would survive since 
the pIRES-neo2 vector contained an ampicillin resistance cassette.  Eight surviving colonies 
were picked for expansion, inoculated into 4mL of LB medium containing carbenicillin and the 
tubes were shaken vertically at 225 rpm at 37ºC for 16 hours in an orbital shaker.  Bacterial cells 
were pelleted by centrifugation at 4,000 x g and the plasmid DNA was isolated using a Promega 
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Wizard Plus SV Miniprep kit.  All purified plasmids were digested with NotI and HpaI as 
described above to check for the appropriately sized insert.  
 The cloned pIRES-neo2 vector, now containing the TAP tag sequence was named 
pIRES-TAP, and the purified p53 sequence were digested with HpaI and AflII for 1 hour at 37ºC
 
in a 20 L reaction containing 50 mM potassium acetate, 20 mM Tris-acetate, 10 mM 
magnesium acetate, 1 mM dithiothreitol (pH 7.9), 0.1 g/L BSA, 10 U AflII and 10 U HpaI.  
Following the digest, the products were electrophoresed, purified and their concentrations were 
determined as stated above.  The pIRES-TAP plasmid and the purified p53 sequence insert were 
ligated as stated above with 43.7 ng of the insert and 25 ng of the plasmid.  The ligation was 
transformed into TOP10 cells, surviving colonies were picked and mini-prepped as described 
above.  The eight purified plasmids were checked for the correct size insert with a digestion 
including HpaI I and AflII as described above.  This vector was named pIRES-TAP-p53 (Fig 3-
2B). 
 
Amplifying the 3kb p53 UTR fragment 
 A 3kb fragment of the p53 non-coding sequence directly after the stop codon was 
amplified from 50 ng of genomic DNA isolated from HCT116 cells by Fiona Turner with the 
Downstream p53 sense primer and the Downstream p53 Antisense primer (Table 3-1) in a 25 L 
reaction containing 12.5 L Hot StartTaq Master Mix, 0.5 U PfuTurbo DNA Polymerase and 0.3 
M of each primer.  The PCR program started with a 15 minute incubation at 95ºC followed by 
35 cycles of 94ºC for 45 seconds, 60ºC for 45 seconds and 72ºC for 3 minutes, and finished with 
an extension for 15 minutes at 72ºC.  The product was electrophoresed, purified and the 
concentration was determined as previously described and the sequence was checked.    
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Cloning the pAAV-MCS p53 TAP vector 
Homology Arm Amplification 
 The left homology arm was designed to contain 900 bp of p53 sequence upstream from 
the stop codon and the sequence encoding the TAP tag which would provide sufficient 
homologous sequence with the endogenous p53 allele to allow for homologous recombination to 
occur with the vector.  These sequences were amplified from the pIRES-TAP-p53 vector which 
contained 3kb of p53 coding sequence upstream from the endogenous stop codon and the TAP 
tag sequence.  The primers used for this amplification contained a NotI restriction site in the Left 
homology arm sense primer and a 23 bp sequence referred to as a linker sequence which is 
required for subsequent PCR reactions in the Left homol. arm antisense primer (Fig 3-4, Table 3-
1).  The right homology arm was designed to contain 900 bp of p53 sequence directly 
downstream of the p53 stop codon to allow homologous recombination to occur with the 
endogenous p53 genomic locus.  This sequence was amplified from the purified PCR product 
containing 3kb of p53 sequence directly after the stop codon.  The primers used for this 
amplification contained a 23 bp sequence referred to as a linker sequence in the Right homol 
sense primer and a NotI restriction site in the Right homol arm antisense primer (Fig 3-5, Table 
3.1).  Both PCR reactions contained 12.5 L Hot Start Taq Master Mix, 0.5 U PfuTurbo DNA 
Polymerase and 0.3 M of each primer.  The PCR program started with a 15 minute incubation 
at 95ºC followed by 35 cycles of 94ºC for 45 seconds, a range of temperatures from 59ºC to 64ºC
 
for 45 seconds was used to optimize the annealing temperature of the primers and 72ºC for 1 
minute, and finished with an extension for 15 minutes at 72ºC.  A total of 25 PCR reactions were 
done for each template to obtain sufficient PCR product for subsequent ligation steps.   The  
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Figure 3-4. Left Homology Arm Amplification. A, Left Panel, This figure shows an agarose 
gel analysis of a digest of the 600 bp TAP tag sequence with NotI and HpaI from the pIRES-
TAP-p53 vector. Right Panel, This figure shows an agarose gel analysis of a digest with HpaI 
and AflII of the 3 kb p53 upstream homologous sequence from the pIRES-TAP-p53 vector.  
Clone 2 contained the insert of the correct size.  Bottom panel, This figure is a depiction of the 
PCR amplification step of the Left homology arm using the sequences cloned into pIRES-TAP-
p53 as template.  Primer design included a sense primer with a 5′-Not1 restriction site and 
antisense with the 3′-23 bp linker.  B, This figure is a depiction of the amplification product and 
agarose gel analysis of the amplified 1.5 kb product. 
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Figure 3-5. Right Homology Arm Amplification. A, Top panel, This figure is an agarose gel 
analysis of the 3 kb PCR product of the p53 3′-UTR sequence amplified from HCT116 genomic 
DNA.  Primer design included an antisense primer with a 3′-Not1 restriction site and the sense 
primer with the 5′-23 bp linker. Bottom panel, This figure is a depiction of the PCR amplification 
of the right homology arm using the 3 kb PCR product as the PCR template. B, This figure is a 
depiction of the amplification product and agarose gel analysis of the amplified 900 bp product. 
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products were pooled, electrophoresed, purified and the concentrations were determined as 
previously described. 
 
Digest Neomycin Cassette from pNeDaKO-Neo   
 The pNeDaKO-Neo vector (2 g) (Kohli et al., 2004) was digested with PvuI in a total 
volume of 20 L containing 300 mM NaCl, 50 mM Tris-HCl, 10 mM MgCl2, 1 mM 
dithiothreitol (pH 7.9), 5 U PvuI, and 0.1 g/L BSA for 1 hour at 37ºC.  The digest reaction 
was run on a 1% agarose gel with ethidium bromide and the 4 kb product was excised, purified 
and the concentration was determined as previously described.  This fragment carried sequence 
complementary to the 23 bp linker sequence present in the primers used to amplify the homology 
arms. 
 
Fusion PCR of Homology Arms and Neomycin Cassette 
 Figure 3-6B depicts how the linker sequences in the homology arms and neomycin 
cassette allowed for a 3-way PCR fusion.  An equimolar PCR fusion with 30 ng of the left 
homology arm product and 33 ng of the neomycin cassette were incubated with the Left homol-
neo sense primer designed to anneal to the 5′-end of the left homology arm sequence and the Left 
Homol-Neo antisense primer to anneal to the 3′-end of the neomycin cassette (Table 3-1).  The 
23 bp linker sequences within the homology arm and neomycin cassette acted as primers and 
annealed during the reaction (Fig 3-6C).  The 25L PCR reaction contained 12.5 L Hot 
StartTaq Master Mix, 0.5 U PfuTurbo DNA polymerase and 0.3 M of each primer.  The PCR 
program started with a 15 minute incubation at 95ºC followed by 35 cycles of 94ºC for 45 
seconds, a range of temperatures from 61ºC to 64ºC
 
for 45 seconds and 72ºC for 3.5 minutes, and  
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Figure 3-6. Fusion PCR of the Homology Arms with the Neomycin Resistance Cassette. A, 
This figure is an agarose gel analysis of a digest with PvuI of the 2.2 kb neomycin cassette from 
the pNeDaKO-Neo vector. B, This figure is a depiction of the 3 way PCR fusion of the 
homology arms with the neomycin cassette which was not successfully accomplished C, This 
figure is a depiction of the separate PCR fusion reactions, the black rectangles depicts the 23 bp 
linker sequences.  The agarose gel analysis of each fusion reaction is below the respective 
depiction.     
  
Left Homology Arm Fusion
Uncut     Cut
p53 
Exon11
TAP
Neo
p53 
UTR
Neo
A
C
2 kb
3 kb
Right Homology Arm Fusion
3 kb
3 kb
p53 
Exon11
TAP
Neo
B
p53 
UTR
  
123 
 
finished with an extension for 15 minutes at 72ºC.   The PCR reaction was analyzed on an 1% 
agarose gel, the 3.7 kb product was excised, purified and the concentration was determined as 
previously described.  The fusion between the neomycin cassette and the right homology arm 
was performed in a similar fashion.  The Neo-right homol sense primers were designed to anneal 
to the 5′-end of the neomycin cassette and the Neo-right homol antisense primer was designed to 
anneal to the 3′-end of the right homology arm (Table 3-1).  The PCR reaction was set up as 
described above and the PCR program was also the same with the exception of the range of 
temperature used to optimize the primer annealing temperature, which was changed to 62ºC to 
68ºC for this PCR fusion.  The 3kb product was found to be efficiently amplified at an annealing 
temperature of 63ºC, it was analyzed and purified as previously stated.   Both fusion products 
were sequenced and the sequences were compared with the known sequences of p53, the 
sequence encoding the TAP tag, and the known sequence of the neomycin resistance cassette. 
 Both resulting PCR fusions contained neomycin resistant cassettes and only one 
neomycin cassette is required in the final vector needed for homologous recombination. Hence, 
the neomycin cassette from the right homology arm was removed with a digest containing KpnI.  
The left homology arm was also cut with KpnI to generate compatible sticky ends required for 
the subsequent ligation with the right homology arm (Fig 3-7).  The KpnI digestions were 
performed for one hour at 37ºC in a reaction volume of 50 L containing 10 mM Tris HCl, 10 
mM MgCl2, 1 mM dithiothreitol (pH 7.0), 10 U KpnI and 0.1 g/L BSA.  The reaction were 
analyzed on a 1% agarose gel and the 3.6 kb left homology arm and the 943 bp right homology 
arm were gel purified and their concentrations were determined.  The two purified homology 
arms were ligated together for 16 hours at 16ºC in a solution contain T4 ligase and ligase buffer  
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Figure 3-7. Generation of the Cloned Insert Necessary for Gene Targeting.  The top half of 
the figure demonstrates how the left homology arm was digested with KpnI to remove the 23 bp 
linker and right homology arm was digested with KpnI to remove the neomycin cassette.  
Analysis by agarose gel is the right of the depiction. The bottom half demonstrates the ligation of 
the left and right homology arms creating the 4.5 kb insert necessary for gene targeting.  Prior to 
cloning the fragment into the pAAV MCS vector the insert was digested with NotI generating 
compatible ends.  Agarose gel analysis of the ligation is to the right of the figure, the total 
volume of the ligation was loaded into the four lanes.    
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as previously described.  The ligation product was run on a 1% agarose gel and the 4.5 kb band 
was excised and purified as described above.   
 
Cloning the insert into the pAAV-MCS vector 
 The pAAV-MCS vector was digested with NotI for two hours at 37ºC in a 200 L 
reaction containing 300 mM NaCl, 50 mM Tris-HCl, 10 mM MgCl2, 1 mM dithiothreitol (pH 
7.9), 40 U NotI, 0.1 g/L BSA and 2g of the vector.  NotI was heat inactivated for 20 minutes 
at 65ºC and the vector was dephosphorylated with 20 U calf intestinal alkaline phosphatase for 
one hour at 37ºC.  The vector was phenol:chloroform extracted by adding one volume of 
phenol:chloroform (ratio 1:1) to the reaction, the tube was vortexed and centrifuged at 16,100 x g 
for 15 minutes at 4ºC in a tabletop centrifuge.  The top (aqueous) layer was recovered and 1/10 
volume of 3 M NaOAc and 2 volumes of 100% ethanol were added, the tubes were vortexed and 
incubated at -80ºC for one hour to precipitate the DNA.  The sample was thawed and spun down 
at 16,100 x g for 15 minutes at 4ºC
 
to pellet the DNA.  The supernatant was poured off and 
washed with one volume of 70% ethanol.  The DNA was pelleted by centrifugation at 16,100 x g 
for 15 minutes at 4ºC.  The supernatant was poured off and the pellet was dried for 5 minutes.  
The pellet was resuspended in 20 L H2O and the dissolved cut plasmid was purified on a 1% 
agarose gel and the 3 kb cut vector was isolated (Fig 3-8).  The 4.5 kb insert containing the left 
homology arm-TAP tag sequence-right homology arm was cut with NotI and gel-purified.   
 The insert and vector were ligated at a 3:1 molar ratio as described above.  The ligation 
reaction was transformed into TOP10 chemically competent E. coli cells and plated on LB 
plates.  Fifty colonies were picked, each was inoculated in LB containing 50 g/mL carbenicillin  
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Figure 3-8. Cloning the Insert into the pAAV-MCS vector.  A, This figure is an agarose gel 
analysis of a digest with NotI of the pAAV-MCS vector.  The 3kb vector backbone was gel 
purified and used in the subsequent ligation.  B, This figure is an agarose gel analysis of a digest 
with NotI to verify the 4.5 kb insert after the ligation, transformation in TOP10 competent E. coli 
cells and vector purification from the surviving colonies. 
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and 40 g/ml zeocin and the cultures were incubated for 16 hours at 37ºC with shaking.  Mini-
prepped plasmids were prepared from each culture.  The purified plasmids were digested with 
NotI to check for the correct size insert (Fig 3-8).  The pAAV MCS p53TAP vectors were 
sequenced.   
 
Packaging and isolating the rAAV 
 HEK293 cells (ATCC) were grown in DMEM supplemented with 10% dFBS and 100 
U/mL of penicillin and 100 mg/mL of streptomycin at 37ºC
 
with 5% CO2.   Cells were grown to 
80% confluency in a T-75 flask prior the transfection.  A mixture of 2.5 g of pAAV MCS 
p53TAP and 2.5 g of each helper plasmid, pAAV-RC and pHelper was diluted in Opti-MEM 
reduced serum medium to a total volume of 750L.  Lipofectamine 2000 reagent (54g) was 
mixed with Opti-MEM medium to a total volume of 750L.  The two tubes were combined and 
incubated at 25ºC for 15 minutes.  The HEK293 cells were washed with 10 mL Hank‟s Balanced 
Salt solution and 7.5 mL of Opti-MEM medium was added to the flask.  The transfection mixture 
was added drop-wise to the flask and incubated for four hours.  The Opti-MEM medium was 
removed and replaced with DMEM medium and the flask was incubated at 37ºC.  Forty-eight 
hours after the transfection, the packaged adeno-associated virus was collected from the HEK293 
cells (Fig 3-9).  The DMEM medium was aspirated and the cells were scraped off into 1.5 mL of 
PBS.  The cells were freeze thawed three times in a 70% ethanol and dry ice bath for 10 minutes 
with intermediate thaws in a 37ºC water bath.   The cells were pelleted at 12,000 x g at 25ºC for 
10 minutes and the supernatant was stored in three 500 L aliquots at -80ºC.   
 
Transducing HCT116 cells with the packaged rAAV   
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Figure 3-9. The process of packaging the rAAV with the pAAV-MCS p53 TAP vector.  The 
cloned pAA-MCS p53 TAP vector, pHELPER and pAAV-RC helper vectors were cotransfected 
into HEK 293 cells.  The rAAV was extracted from the cells after 48 hours and an aliquot of the 
isolated virus was used to transduce HCT116 cells. 
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 HCT116 cells (ATCC) were grown in RPMI 1640 supplemented with 10% dFBS and 
100 U/mL of penicillin and 100 mg/mL of streptomycin at 37ºC
 
with 5% CO2.  A 75% confluent 
culture in a T-75 flask was washed once with Hanks Balanced Salt Solution, an aliquot of the 
isolated rAAV was thawed on ice and added to the culture mixed with 4 mL of RPMI 1640.  
After two and a half hours, the virus mixture was removed and 8 mL of fresh RPMI 1640 was 
added to the flask.  The cells were plated out under 0.4 mg/mL geneticin (G418) selection in ten-
96 well plates at 200 L per well, 48 hours after transduction.  The plates were wrapped with 
parafilm to minimize evaporation and placed in the incubator for 10 days.  Wells clearly 
containing only one cell clone were marked.  The medium was aspirated and 100 L of trypsin 
was added to each marked well and incubated at 37ºC for two minutes.  Duplicate plates were 
made with the trypsinized clones by adding 50 L of each cell suspension to 150L RPMI 1640 
with 10% dFBS, 100 U/mL of penicillin and 100mg/mL of streptomycin and 0.4 mg/mL G418 
(complete medium) in new 96-well plates.  A total of 144 single cell clones were re-plated in 
duplicate.  After four days the cells were expanded into duplicate 24-well plates by 
trypsinization.  One set of 24 well plates were used for screen the clones for correct 
recombination while the other duplicate plate was placed in -80ºC after addition of 300 L of 
freezing medium (10% DMSO in dFBS). 
 
Screening cell clones for correct insertion of the TAP tag into the endogenous p53 locus   
 The Exon 10 screening sense primer was designed to anneal to exon 10 in the 
endogenous p53 genomic locus and the TAP screen antisense primer was designed to anneal to 
TAP tag sequence within the insert (Fig 3-10, Table 3-1).  The primer placement allowed for 
screening for the correct orientation of the TAP tag insertion by homologous recombination  
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Figure 3-10. PCR screening for the correct insertion of the TAP tag into the p53 genomic 
locus by homologous recombination.  The top of the figure depicts the screening process 
including the strategic placement of the black screening primers with one primer located in the 
genomic sequence outside of the cloned insert and the other placed inside the insert.  The orange 
primers denote the 3′ screening process.  The bottom figure is the agarose gel analysis of 140 
clones screened with the 5′-screening primers (black).  The plus sign denotes the lanes 
containing the positive control, the asterisks denote clones containing the correct location of 
insertion as verified by the 1.4 kb PCR product of the insert and the X denotes a false positive 
that was determined in subsequent PCR reactions.     
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since one screening primer was located outside of the insert and the other was placed within the 
insert.  The pIRES-p53-TAP vector was used as the positive control for the screening process.  
The PCR program was optimized with the positive control vector in a 25 L reaction volume 
containing 12.5 L Hot StartTaq Master Mix and 0.6 M of each primer.  The PCR program 
started with a 15 minute incubation at 95ºC followed by 30 cycles of 94ºC for 45 seconds, 57ºC
 
for 45 seconds and 72ºC for 1.5 minutes, and finished with an extension for 10 minutes.  The 
reaction was analyzed on a 1% agarose gel containing ethidium bromide.  Genomic DNA was 
isolated from the 24-well plates using the Promega Wizard SV genomic DNA purification 
system and the concentration was determined by sample absorbance at 260 nm.  All genomic 
DNA samples were diluted down to a concentration of 50 ng/mL with H2O; 1 L of each gDNA 
sample was added to the previously described PCR reaction.  A positive control and a blank 
reaction containing water was including in all screening reactions.  The PCR products were run 
out on a 1% agarose gel and analyzed for a 1.4 kb product indicating correct homologous 
recombination.  The PCR product from the screening procedure from 4 clones containing the 
TAP tag at the correct orientation were excised from the agarose gel and purified as previously 
described.  The purified PCR screening product was cloned into the pCR4-TOPO vector for 
sequencing using the TOPO TA Cloning Kit for Sequencing (Invitrogen).  A 6 L reaction 
containing 0.2 M NaCl and 10 mM MgCl2 (Salt Solution), 4 L of purified DNA and 1 L 
pCR4-TOPO was incubated at 25ºC for 30 minutes.  TOP10 chemically competent E. coli cells 
were transformed with 2 L of each reaction.  Bacteria were plated, expanded and mini-prepped.  
The purified plasmids were cut with EcoRI to check for the correct insert size.  The reactions 
were run on a 2% agarose gel containing ethidium bromide and one plasmid containing the 
purified product from each of the four cell clones that containing the correct insert was 
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sequenced.  Clone number AA5 contained no mutations, the duplicate plate containing this well 
was removed from the -80ºC and was thawed in a water bath.  A volume of 2 mL of complete 
medium was added to the well containing this clone and placed into a 15 mL conical tube and 
spun down.  The pellet was resuspended in 5 mL of complete medium and plated into a T-25 
flask.  This cell line was named AA5 TAP.  The 3′-end of this clone was screened by PCR to 
make sure that only the insert and no other parts of the vector homologously recombined with the 
p53 locus.  The 3′-screening sense primer was designed to anneal within the TAP tag and the 3′ -
screening antisense primer was designed to anneal within the 3′ UTR of p53 outside of the insert 
(Fig 3-10, Table 3-1).  The PCR reaction contained primers at a concentration of 0.3 M and 
started with a 15 minute incubation at 95ºC followed by 35 cycles of 94ºC for 45 seconds, 
53.9ºC
 
for 45 seconds and 72ºC for 2 minutes, and finished with an extension for 10 minutes.  
The PCR product was electrophoresed and the 1.3 Kb product was excised, purified and 
sequenced.  
 
Western Blotting 
Cellular Lysate preparation 
 HCT116 and AA5 TAP cells were plated at 8 x 10
5
 cells/10 cm dish and allowed to 
adhere 24 hour prior to drug treatment.  Etoposide (VP16, Sigma) was dissolved in DMSO 
making a 10 mM stock and then diluted in PBS to 100 M prior to use.  The 100 M solution of 
VP16 was filter sterilized with a 0.22 Mfilter, 1 mL of it was added to 9 mL complete medium 
added to the treatment plates.  The no treatment plates received 9 mL complete medium with the 
same dilution of DMSO used in the VP16 plates.  Preparations of cellular lysates and Western 
blotting were performed as described in Chapter 2.  Briefly, 25 g of total cellular protein was 
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resolved by electrophoresis on a 7.5% -polyacrylamide gel (BioRad) and transferred to a PVDF 
membrane.  Non-specific protein binding was blocked with Blotto solution containing 5% milk, 
0.1% Tween 20, 0.01 M Tri, pH 7.4, 0.15 M NaCl for 1 hour at 25ºC with gently rocking.  
Primary antibody was diluted in 5% milk in TBS-T and incubated with the membrane overnight 
at 4ºC.  Primary antibodies used were p53 monoclonal Ab-6 (Calbiochem) at 1:100, p21 
monoclonal Ab-1 (Calbiochem) at 1:100, TAP polyclonal (Open Biosystems CAB1001) at 1:500 
and monoclonal beta Actin (Abcam) at 1:5000.  Membranes were incubated with secondary 
antibodies conjugated to horseradish peroxidase (Pierce) diluted in 5% milk in TBS-T for 1 hour 
at 25
º
C.  Complexes were detected by enhanced chemiluminescence using the Supersignal West 
Pico Chemiluminescent Substrate Kit (Pierce).   
 
Removing the neomycin cassette with cre recombinase 
 Dr. Jolene Windle generously provided a plasmid, pMC1 CRE, in which the cre 
recombinase can be expressed in mammalian cells under the control of a thymidine kinase 
promoter.  This plasmid was transformed into TOP10 chemically competent E. coli cells and 
purified using with the Promega Pure Yield Plasmid Midiprep System and checked with a 
digestion for one hour at 37ºC in a 20 L reaction containing 10 U EcoRV, 10 U SalI, NEB3, 
and 0.1 g/L BSA.  The reaction was run on a 1% agarose gel to check correct product size.  
AA5 TAP cells were plated in a 60 mm dish with RPMI 1640 with 10% dFBS and allowed to 
reach 90% confluency. A total of 8 g of pMCI CRE was diluted into 500L Opti-MEM 
medium and 20 g of Lipofectamine 2000 was added to 480 L Opti-MEM medium; both 
mixtures were incubated at 25ºC for 5 minutes, then combined, gently mixed and incubated for 
20 minutes at 25ºC before adding the mixture to the cells.  Twenty-four hours after transfection 
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the transfected cells were trypsinzed and plated at 0.25 cell/well in five 96-well plates in RPMI 
1640 with 10% dFBS and 100 U/mL of penicillin and 100 mg/mL of streptomycin.  The plates 
were wrapped in parafilm and placed in the incubator for 12 days.  Wells containing only one 
cell clone were marked and trypsinzed and split into duplicate sets of 24-well plates as 
previously described.  Cells were allowed to adhere for 24 hours, the medium was then replaced 
on both sets of plates.  One set received complete medium containing 0.4 mg/mL G418 while the 
duplicate set received complete medium without G418.  Five days after selection clones that 
were not G418 sensitive were trypsinized and expanded in T-75 flasks with complete medium 
not containing G418.  This cell line was named CRE2 TAP.       
 
Chromatin Immunoprecipitation  
 The ChIP assay was performed as described in Chapter 2.  Briefly, 1 x 10
7
 HCT116 cells 
or CRE2 TAP cells per treatment were crosslinked at room temperature with 1% formaldehyde.  
Aliquots of 2 x 10
6 
washed cells were lysed and sonicated with the Diagenode bioruptor for a 
total of 18 minutes in consecutive duty cycles of 30 seconds on, 30 seconds off (for a total of 3 
cycles, each being 6 minutes). These conditions were found to yield DNA fragments less than 
1000 bp in size.  Lysate volumes corresponding to 2 x 10
6 
cells were precleared and blocked with 
8 g of BSA and 5 g of sonicated lambda DNA, then were incubated with 2 g of p53 Ab-6 
(Calbiochem) antibody, 2 g TAP antibody directed against the calmodulin peptide (Open 
Biosystems) or 2 g IgG (Millipore) antibody overnight.  Antibody-protein-DNA complexes 
were captured by the addition of 30 L of 50% protein G-Sepharose bead slurry. Beads were 
extensively washed as previously described.  Protein-DNA complexes were eluted with elution 
buffer containing 2% SDS, 10 mM DTT, 0.1 M NaHCO3 and incubated at 65ºC overnight to 
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reverse the crosslinks.  DNA was treated with RNase, Proteinase K, phenol-chloroform 
extracted, ethanol-precipitated as previously described, and dissolved in 100L of TE.  
 
Quantitative PCR  
 Q-PCR was performed with 1 L of input DNA or ChIP DNA per a 25 L reaction 
containing 12.5 L Quantitect SYBR Green PCR Master Mix (Qiagen), 0.3 M of each primer.  
The sequences of the primers for the upstream p53 consensus binding site on the p21 promoter 
were 5′-CTTTCCACCTTTCACCATTCC-3′ (sense) and 5′-
AAGGACAAAATAGCCACCAGC-3′ (antisense).  The amplification conditions were 95ºC for 
15 minutes, 40 cycles of 95ºC for 45 seconds, 53ºC for 45 seconds, 72ºC for 45 seconds with a 
plate read between cycles followed by a 5 minute extension at 72ºC and a determination of the 
melting curve from 45ºC to 100ºC.  Quantities were calculated using a standard curve ranging 
from 100 ng to 0.8 ng of input DNA.   
 
Tandem Affinity Purification of p53 
Cellular Lysate Preparation 
 Approximately 8 x 10
8
 CRE2 TAP cells were used for each purification.  CRE2 TAP 
cells were plated at 4 x 10
6
 cells/15 cm dish in forty dishes per drug treatment containing RPMI 
1640 with 10% dFBS and allowed to adhere for 24 hours.  Cells were treated for 24 hours with 
either VP16, HU or PALA as previously described.  Cells were trypsinzed, washed twice with 
PBS containing 1x protease inhibitor complete cocktail (Roche) and resuspended in 8 mL 
Tween-20 lysis buffer containing 50 mM HEPES pH 7.5, 150 mM NaCl, 1 mM EDTA, 2.5 mM 
EGTA 0.1% Tween-20.  All purification buffers contained 1 g/mL aprotinin, 1 g/mL 
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leupeptin, 1 mM PMSF, 1 mM Na3VO4, 1 mM NaF.  Lysates were sonicated on ice using the 
Misonix Sonicator 3000 with the 1/16” microtip for 40 cycles of 1 second on, 5 seconds off at 4 
ºC while on ice and then incubated on ice for 30 minutes. 
   
IgG Purification and TEV Cleavage 
 Cell debris was spun down at 16,100 x g for 15 minutes at 4ºC.  An aliquot (200 L) IgG 
Sepharose 6 Fast Flow beads (GE Healthcare) that were washed with Tween-20 Lysis buffer and 
a 50 % bead slurry was added to the clarified supernatant.  The IgG bead suspension was 
incubated at 4ºC
 
 for 4 hours while rotating end-over-end.  The beads were pelleted at 2,500 x g 
for 1 minute at 4ºC and washed three times with Tween-20 lysis buffer and three times with TEV 
buffer containing 50 mM Tris pH 8.0, 0.5 mM EDTA.  The p53 complex was cleaved from the 
IgG beads in a 300 L reaction containing 50 mM Tris, pH 8.0, 0.5 mM EDTA, 1.0 mM DTT 
and 100 U AcTEV Protease (Invitrogen) TEV protease cleavage proceeded for 16 hours at 4ºC 
rotating end-over-end.   
 
Calmodulin Purification 
 The IgG beads were pelleted at 2,500 x g for 2 minutes at 4ºC and the supernatant was 
removed and added to 200 L of the 50% slurry of Calmodulin Sepharose 4B (GE Healthcare).  
The IgG beads were washed three times with 300 L calmodulin binding buffer containing 10 
mM Tris pH 8.0, 150 mM NaCl, 1 mM magnesium acetate, 1 mM imidazole, 0.1% NP-40, 2 
mM EGTA, 10 mM 2-mercaptoethanol and each wash was added to the saved supernatant.  
Aliquots of a concentrated stock of 1M CaCl2 was added to the lysate-calmodulin slurry to 
achieve a final concentration of 4 mM and the mixture was incubated for 4 hours at 4ºC while 
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rotating end-over-end.  The beads were pelleted by centrifugation at 2,500 x g for 2 minutes at 
4ºC and washed three times with calmodulin binding buffer.  The p53 protein complex was 
eluted in eight 200 L fractions with calmodulin eluting buffer (10 mM Tris pH 8.0, 150 mM 
NaCl, 1 mM magnesium acetate, 1 mM imidazole, 0.1% NP-40, 2mM EGTA, 10 mM 2-
mercaptoethanol).  Aliquots of IgG Beads and Calmodulin beads from this procedure were 
resuspended in 100 L SDS sample buffer containing 62.5 mM Tris pH 6.8, 5% glycerol, 2% 
SDS, 5% 2-mercaptoethanol, boiled for five minutes, pelleted and the supernatant was saved 
along with samples from each step of the purification for further analysis.  All samples were 
stored at -80ºC for further analysis. 
 
Analysis of Tandem Affinity Purification 
 The concentrations of the soluble and insoluble fractions after sonication were 
quantitated with the Bradford assay as previously described.  Samples collected throughout the 
purification process and eluted fractions were resolved on a 4-15% gradient SDS polyacrylamide 
gel.  Soluble and insoluble starting materials (25 g) were used while the remaining samples 
were loaded onto this gel based on estimations of their protein concentrations and equal volumes 
of eluted fractions were added to each well.  One set of gels underwent silver staining using the 
Bio-Rad Silver Stain plus according to manufacturer‟s instructions (161-0449) while the other 
set was immunoblotted for the presence of p53.  
 
Results 
 The experiments in Chapter 3 describe the design, development, and characterization of a 
HCT116-derived cell line in which one endogenous p53 locus has been manipulated to include 
  
138 
 
the TAP tag sequence in frame at the 3′ end of the p53 coding sequence.  This cell line was 
created to allow a proteomic analysis of the molecular role of p53 during nucleotide pool 
imbalances.  Specifically, we wished to investigate how p53 is involved in the decision to 
promote apoptosis or a cytostatic S-phase arrest.   
 
Design and Molecular Cloning of the pAAV vector that will allow insertion of the TAP-tag 
sequence in the p53 gene 
 The vector that was designed and constructed in order to insert the TAP tag into the 
endogenous p53 locus is shown in Figure 3-3 and the strategy for construction of this targeting 
vector is show in Figure 3-2.  Two fragments of DNA identical to regions of the p53 genomic 
sequence were amplified from HCT116 genomic DNA and inserted into a pAAV vector, one on 
each side of a sequence encoding the TAP-tag peptides.  To obtain high efficiencies of gene 
targeting, a minimum of 900 bp of homologous sequence upstream and downstream from the 
gene targeting site was previously shown to be required (Kohli et al., 2004).  The TAP tag 
sequence and approximately 3 kb of sequence upstream from the stop codon in the p53 genomic 
sequence was isolated by PCR and ligated into the pIRES vector (See Methods, Fig 3-2), 
including all of the coding sequence of exon 11 (79 nucleotides) and 2921 nucleotides of intron 
10.  The sequence encoding the TAP tag was excised from the pIRES-TAP vector with NotI and 
HpaI to verify the correct size (Fig 3-4A, left panel).  After the TAP tag sequence was ligated 
into pIRES, the 3 kb of p53 sequence upstream from the stop codon in the p53 genomic sequence 
was ligated into the vector upstream of the TAP tag sequence to create the pIRES-TAP-p53 
vector (Fig 3-2).  This 3 kb fragment was excised from pIRES-TAP-p53 vector with HpaI and 
AflII to verify the correct size (Fig 3-4A, right panel).  The pIRES-TAP-p53 vector was used as 
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the template for amplifying the left homology arm needed for the targeting vector.  This 
homology arm contained 900 bps of the upstream p53 coding sequence, which includes 79 
nucleotides from exon 11 ending immediately upstream of the stop codon, 821 nucleotides of 
intron 10 and the TAP tag sequence.  The primers for this PCR reaction were designed to contain 
a NotI restriction site on the 5′-end of the sense primer and to include a 23 bp linker sequence on 
the 3′-end of the antisense primer that would be required for future cloning reactions.  The 
resulting 1.5 kb fragment amplified with these primers contained 900 bps of homologous p53 
sequence followed by the TAP tag sequence, with a NotI site at the  5′-end and the linker 
sequence at the 3′-end (3-4B).  The right homology arm contained 900 bp of homologous 
sequence from the p53 3′-untranslated region (UTR) sequence directly following the stop codon.  
Previously, a 3 kb fragment was amplified from HCT116 genomic DNA with primers starting 
after the stop codon and extending for 3 kb (Fig 3-5A). This PCR fragment was used as the 
template for the amplification of the 900 bp needed for the right homology arm.  New primers 
were designed to include the 23 bp linker sequence and a NotI restriction site for this 
amplification.  The resulting PCR product was a 900 bp product with the linker sequence at the 
5′-end and a NotI restriction site at the 3′-end (Fig 3-5B).   The neomycin selection cassette was 
digested out of the pNeDaKO-Neo plasmid obtained from the Vogelstein group (Kohli et al., 
2004) with PvuI (Fig 3-6A).  The resulting 2.2 kb fragment contained a mammalian neomycin 
selection marker and a zeocin bacterial selection marker flanked with loxP sites and the 23 bp 
linker sequence on both ends.  The 23 bp linker sequences on each end of the neomycin cassette 
and the complementary linker sequences on the left and right homology arms were designed to 
allow for a three-way PCR fusion using primers designed to anneal at the 5′-end of the left 
homology arm and at the 3′-end of the right homology arm (Fig 3-6B).  Many variations of this 
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PCR fusion were attempted with several combinations of primer sets, yet the product was never 
amplified, so two two-way fusions with the neomycin cassette were performed (Fig 3-6C).  The 
left homology arm was fused with the neomycin cassette with primers designed against the 5′-
terminus of the left homology arm and against the 3′-end of the neomycin cassette.  The 3.7 kb 
fusion product was amplified and purified (Fig 3-6B left).  A similar reaction was performed 
with the right homology arm and neomycin cassette.  The 3.2 kb fusion product was amplified 
and purified (3-6B, right panel).  Each homology arm contained a neomycin cassette and only 
one cassette was needed in the final product, so the neomycin cassette was digested off the right 
homology arm fusion with KpnI (Fig 3-7, top panel).  The left homology arm fusion also was 
digested with KpnI to remove the 23 bp linker (Fig 3-7).  As a result from the digest, the purified 
products both contained complementary sticky ends and they were easily ligated together to form 
the 4.5 kb insert necessary for the gene targeting (Fig 3-7, bottom panel).  The insert was 
digested with NotI as was the pAAV MCS vector (Fig 3-7, 3-8A).  The 3 kb vector backbone 
was mixed with an equimolar amount of the 4.5 kb insert and joined with DNA ligase.  To verify 
that the correct ligation took place, the insert was cut from the pAAV MCS vector with NotI and 
sized on an agarose gel (Fig 3-8B).  Four out of 50 screened clones contained the correct size 
insert.  The resultant vector was named pAAV MCS p53 TAP   
 
Generation and Characterization of the p53 TAP-tagged Cells 
 The cloned pAAV MCS p53TAP vector in combination with two helper vectors were 
transfected into HEK 293 cells for viral packaging.  The virus was collected from the HEK 293 
cells after 48 hours and used to transduce HCT116 cells (see methods and Fig 3-9).  A total of 
140 neomycin resistant cell clones were propagated and screened by PCR for correct integration 
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of the TAP tag in the p53 locus.  Two different primer sets were used for the PCR screening for 
homologous recombinants; one set tested the 5′- insertion site and the other tested the 3′-insertion 
site.  Each set contained one primer corresponding to the TAP sequence and one outside of the 
insert to verify insertion specifically into the p53 gene locus in the correct orientation (Fig 3-10).  
Out of the 140 screened cell clones, 11 contained the TAP tag inserted into the correct location 
within the p53 gene locus as is seen by the 1.4 kb product amplified for a 7.9% efficiency of 
homologous recombination (Fig 3-10).  Several clones containing the TAP tag were expanded 
and then sequenced to ensure proper insertion and presence of all essential sequence elements.  
Clone A-A5 was used for all subsequent experimentation (Fig 3-11).     
 The sequence that was inserted into the p53 genomic locus added about 25 kDa to the 
mass of the expressed p53.  Data from western blot experiments should show two bands when 
probed for p53, a band at 53 kDa for the un-altered p53 allele and one band at 78 kDa for the 
TAP-tagged allele.  Initial experiments with the TAP tag cell line showed that the p53 that was 
transcribed and translated from the TAP tagged allele, was able to be stabilized, following VP16-
induced DNA damage.  However, the protein levels made from the TAP tagged p53 allele were 
not comparable to the p53 protein transcribed and translated from the wild-type, un-altered allele 
(Fig 3-12).   
 We hypothesized that insertion of the 2.2 kb neomycin resistance cassette moved the 
polyadenylation tail further away from the p53 coding sequence thus altering the stability of the 
mRNA.  Since the neomycin resistance cassette had been designed to be flanked with loxP sites 
in the case this happened, it was removed by a transient transfection of the pMC1 CRE vector 
containing the cre recombinase gene.  Duplicate plates of single cell transfected clones were 
propagated.  One set of plates was exposed to G418 while the other set contained no selection 
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Figure 3-11. Sequence analysis of the PCR product from the screening process.  The top 
sequence is the reference sequence and the bottom is the sequence of the screened product.  A 
line between the two sequences indicates a match.  The green highlighted sequence denotes exon 
10 of p53, the non-colored sequence represents intron 10, blue denotes exon 11 of p53 and pink 
denotes the TAP tag sequence.   
  
Known Seq.   AAAATACAAAAGTAGCCGGGCGTGGTGATGCATGCCTGTAATCCCAGCTACCTACTCGGG   
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Cloned Seq   AAAATACAAAAGTAGCCGGGCGTGGTGATGCATGCCTGTAATCCCAGCTACCTACTCGGG   
 
Known Seq.   AGGCTGAGGCAGGAGAATCGCTTGAACCCGGGAGGCAGAGGTTGCGGTGAGCTGAGATCT   
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Cloned Seq   AGGcTGAGGCAGGAGAATCGCTTGAACCCGGGAGGCAGAGGTTGCGGTGAGCTGAGATCT   
 
Known Seq.   CACCATTACACTCCAGCCTGGGCAACAAGAGTGAAACTCCGTCTCAAAAAAGATAAATAA   
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Cloned Seq   CACCATTACACTCCAGCCTGGGCAACAAGAGTGAAACTCCGTCTCAAAAAAGATAAATAA   
 
Known Seq.   AGTAAAATGGGGTAAGGGAAGATTACGAGACTAATACACACTAATACTCTGAGGTGCTCA   
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Cloned Seq   AGTAAAATGGGGTAAGGGAAGATTACGAGACTAATACACACTAATACTCTGAGGTGCTCA   
 
Known Seq.   GTAAACATATTTGCATGGGGTGTGGCCACCATCTTGATTTGAATTCCCGTTGTCCCAGCC   
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Cloned Seq   GTAAACATATTTGCATGGGGTGTGGCCACCATCTTGATTTGAATTCCCGTTGTCCCAGCC   
 
Known Seq.   TTAGGCCCTTCAAAGCATTGGTCAGGGAAAAGGGGCACAGACCCTCTCACTCATGTGATG   
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Cloned Seq   TTAGGCCCTTCAAAGCATTGGTCAGGGAAAAGGGGCACAGACCCTCTCACTCATGTGATG   
 
Known Seq.   TCATCTCTCCTCCCTGCTTCTGTCTCCTACAGCCACCTGAAGTCCAAAAAGGGTCAGTCT   
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Cloned Seq   TCATCTCTCCTCCCTGCTTCTGTCTCCTACAGCCACCTGAAGTCCAAAAAGGGTCAGTCT   
 
Known Seq.   ACCTCCCGCCATAAAAAACTCATGTTCAAGACAGAAGGGCCTGACTCAGACGTTAACATG   
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Cloned Seq   ACCTCCCGCCATAAAAAACTCATGTTCAAGACAGAAGGGCCTGACTCAGACGTTAACATG   
 
Known Seq.   GAAAAGAGAAGATGGAAAAAGAATTTCATAGCCGTCTCAGCAGCCAACCGCTTTAAGAAA   
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Cloned Seq   GAAAAGAGAAGATGGAAAAAGAATTTCATAGCCGTCTCAGCAGCCAACCGCTTTAAGAAA   
 
Known Seq.   ATCTCATCCTCCGGGGCACTTGATTATGATATTCCAACTACTGCTAGCGAGAATTTGTAT   
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Cloned Seq   ATCTCATCCTCCGGGGCACTTGATTATGATATTCCAACTACTGCTAGCGAGAATTTGTAT   
 
Known Seq.   TTTCAGGGTGAGCTCAAAACCGCGGCTCTTGCGCAACACGATGAAGCCGTGGACAACAAA   
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Cloned Seq   TTTCAGGGTGAGCTCAAAACCGCGGCTCTTGCGCAACACGATGAAGCCGTGGACAACAAA   
 
Known Seq.   TTCAACAAAGAACAACAAAACGCGTTCTATGAGATCTTACATTTACCTAACTTAAACGAA   
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Cloned Seq   TTCAACAAAGAACAACAAAACGCGTTCTATGAGATCTTACATTTACCTAACTTAAACGAA   
 
Known Seq.   GAACAACGAAACGCCTTCATCCAAAGTTTAAAAGATGACCCAAGCCAAAGCGCTA   
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Cloned Seq   GAACAACGAAACGCCTTCATCCAAAGTTTAAAAGATGACCCAAGCCAAAGCGCTA   
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Figure 3-12. TAP tagged p53 accumulates in response to DNA damage levels lower than 
that of untagged p53.  This figure is a western blot analysis of p53 levels in HCT116 and AA5 
TAP cells exposed to 10 M VP16 for24 hours.  Total cell lysate protein (25 g) was subjected 
to SDS-PAGE and immunoblotted with antibodies against p53 or the calmodulin peptide in the 
TAP tag were used.   
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(Fig 3-13).  The cells which did not survive when exposed to G418 no longer contained the 
neomycin resistance cassette and, hence, had excised the neomycin cassette and also not fixed 
the pMCI CRE plasmid in the genome since this vector also carried the neomycin resistance 
cassette.  The corresponding wells in the duplicate set without selection, were grown for further 
analysis.  Following growth of neomycin sensitive single cell populations, p53 protein levels 
were assessed by western blotting.  The removal of the neomycin resistance cassette from the 
TAP tag insert completely restored the TAP tag protein levels to wild-type p53 protein levels 
both in unstressed cells and also in cells treated with the topoisomerase II inhibitor, VP16 (Fig 3-
14).  The equivalent levels of accumulated p53 from the TAP tagged allele and the wild-type 
allele indicates that the TAP tag did not interfere with p53 stabilization and accumulation after 
DNA damage.  The levels of p21 activated upon DNA damage were similar to the untagged cells 
suggesting that insertion of the TAP tag did not interfere with the transactivating ability of p53.    
 The functionality of the TAP tagged p53 was further investigated to determine whether 
the tag interferes with the cellular functions of the p53 encoded by the tagged allele.  To assess 
the capability of the TAP tagged p53 to bind to gene promoters, the presence of p53 at the p21 
promoter was investigated using ChIP.  Two antibodies were used for the immunoprecipitation; 
the DO-1 antibody to pull down all cellular p53, and an antibody against the calmodulin binding 
peptide in the TAP tag to pull down only TAP tagged p53.  Total p53 and TAP tagged p53 are 
poised at the upstream p53 binding site on the p21 promoter under no drug conditions and after 
VP16-induced DNA damage, the levels of both total and TAP-tagged p53 increase more than 
threefold indicating that the TAP tag does not interfere with the ability of p53 to bind to DNA 
(Figure 3-15).   
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Figure 3-13. Selection of neomycin sensitive clones post transfection of a cre recombinase 
containing vector.  Cre2 TAP cells were plated in duplicate post transfection.  The cells which 
could not survive under G418 selection were propagated from the duplicate well in the no 
selection plate.    
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Figure 3-14. Removal of the neomycin cassette restores TAP tagged p53 levels to that of the 
untagged p53.  This figure is a western blot analysis of p53 and p21 levels in HCT116, AA5 
TAP and CRE2 TAP cells exposed to 10 M VP16 for 24 hours.  Total cell lysate protein (25 
g) was subjected to SDS-PAGE and immunoblotted with antibodies against p53 or p21 were 
used. Protein loading was assessed with-Actin.     
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Figure 3-15. TAP tag does not interfere with the ability of p53 to bind to the p21 promoter.  
This figure is a ChIP analysis of p53 enrichment at the Rad51 promoter in CRE2 TAP cells after 
24 hours of drug treatment.  p53-DNA complexes were immunoprecipitated from formaldehyde 
crosslinked cells with either  the DO-1 p53 or antibody against the calmodulin peptide in the 
TAP  tag and p21 promoter levels were quantitated with Q-PCR.  Standard error is depicted by 
the bars from two biological repeats each with triplicate Q-PCR samples.  Non-specific binding 
was estimated using immunoprecipitation with non-specific IgG. Vehicle was PBS, VP16 was 
used at 10 M.   
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Tandem Affinity Purification of p53 
  The ability of the TAP tag to pull down and isolate p53 binding partners through the 
tandem affinity purification protocol was evaluated using an adapted version of the published 
purification protocol (Bertwistle et al., 2004).  TAP-tagged p53 was tandem affinity purified 
from VP16-treated cells, along with it any associated proteins.  An aliquot from each step in the 
purification was saved to assess the efficiency of the protocol; the level of p53 in each fraction 
was determined by western blot using the DO-1 p53 antibody (Fig 3-16).  There was loss of p53 
at both of the binding steps.  TAP tagged p53 was found in samples from the lysates that did not 
bind to the IgG beads.  The majority of the TAP tagged p53 was lost after TEV cleavage as 
observed by a significant amount of p53 remaining bound to IgG beads after TEV cleavage and 
after the final elution from the calmodulin beads, suggesting the use of more TEV protease and 
more calmodulin beads would result in a larger yield of p53 (Fig 3-16). 
 Western blot analysis of the eight eluted fractions from the purification, probed with the 
DO-1 p53 antibody, resulted in two bands indicating that the TAP-tagged p53 is pulling down 
the wild-type p53 as a protein binding partner, an interesting result since it implies that the 
majority of p53 pre-exists as multimers of equal parts transcribed from each allele (Fig 3-17).  
The purification functionally isolated a portion of the TAP-tagged p53.  Silver staining analysis 
of the eluted fractions revealed numerous proteins being pulled down with p53 during VP16-
induced DNA damage (Fig 3-17).  This purification procedure was next performed on cells 
which were exposed to HU to ask questions about the binding partners of p53 during nucleotide 
pool imbalances in comparison to the binding partners during DNA damage.  A control of non-
tagged HCT116 cells was also included to determine the background proteins being pulled down  
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Figure 3-16. Recovery of p53 during tandem affinity purification.  This figure shows a 
western blot analysis of the steps of the TAP purification of p53 from CRE2 TAP cells treated 
with VP16 for 24 hours and immunoblotted with DO-1 p53 antibody.  Twenty-five g of total 
protein was loaded for the insoluble fraction and soluble lysate, while the concentrations of the 
other fractions were estimated.  Off IgG Beads is the supernatant that resulted after the IgG 
beads were boiled; the material remaining on IgG beads after TEV cleavage. VP16 was used at 
10 M.   
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Figure 3-17. TAP tag purifies p53 with several protein binding partners.  This figure is a 
western blot and silver stain analysis of 8 EGTA-eluted fractions from the TAP purification of 
p53 from CRE2 TAP cells treated with VP16 for 24 hours.  18.75% of each eluted fraction was 
subjected to SDS page: one polyacrylamide gel was immunoblotted with DO-1 p53 antibody 
while the other was silver stained.   VP16 was used at 10 M.   
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by the purification protocol. The silver stain of the eluted fractions showed differential binding 
patterns when comparing untreated cells to HU and VP16 treated cells (Fig 3-18).  Although we 
are unable to confirm that there are indeed different proteins by mass spectrometry binding to 
p53 during nucleotide pools imbalances than during DNA damage, these data are encouraging.  
A similar purification was performed from HU- and PALA-treated cells.  This was performed to 
investigate the different p53 binding partners during the observed S-phase arrest induced by HU 
treatment and the apoptosis induced by PALA treatment.  In the previous purification, an equal 
number of cells were used in the purification, in contrast to using an equivalent amount of 
protein, which was done in the HU and PALA purification.  PALA treatment resulted in a five-
fold increase in p53 purification over that of the HU treated cells while the silver stain of the 
eluted fraction showed surprisingly similar protein banding patterns (Fig 3-19).     
 
Discussion    
 The creation of this cell line marked the first time our lab has successfully manipulated a 
mammalian genomic locus by homologous recombination in a cell line.  Previous attempts were 
made by Dr. Fiona Turner using different technologies but the screening process was laborious 
and after screening thousands of clones, the attempts were abandoned.  This chapter 
demonstrates that this powerful AAV technology is possible and, indeed, highly efficient; it is a 
vast improvement over previous methodologies.  From the cloning process to the completion of 
the cell line, the most challenging aspect was the cloning process, specifically attempting the 
three-way-fusion.  This three-way fusion was never successfully accomplished in the cloning of 
the pAAV MCS vector.  Other methodologies were used without adding significant labor to the  
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Figure 3-18. TAP tag purifies p53 with different protein binding partners after nucleotide 
deficiencies than after DNA damage.  This figure is a western blot and silver stain analysis of 
the second eluted fraction from the TAP purification of p53 from CRE2 TAP cells treated with 
VP16 or HU for 24 hours.  Purification of p53 from nontagged, HCT116 cells were used as a 
negative control for non specific proteins.  18.75% of each eluted fraction was subjected to SDS 
PAGE one polyacrylamide gel was immunoblotted with DO-1 p53 antibody while the other one 
was silver stained.   VP16 was used at 10 M and HU was used at 1.5 mM   
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Figure 3-19. TAP tag purifies p53 with protein binding partners after nucleotide 
deficiencies induced by HU and PALA treatment.  This figure is a western blot and silver 
stain analysis of the second eluted fraction from the TAP purification of p53 from CRE2 TAP 
cells treated with HU or PALA for 24 hours.  18.75% of each eluted fraction was subjected to 
SDS PAGE: one polyacrylamide gel was immunoblotted with DO-1 p53 antibody while the 
other was silver stained.   HU was used at 1.5 mM and PALA was used at 100 M.  
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process.  The screening step which previously has caused the most problems was the least 
problematic step.  With a targeting efficiency of 7.9%, it would be theoretically possible to 
screen fifteen clones and find one that was correct.  This alone makes this methodology powerful 
enough to allow questions to be asked which previously were not within reach.   
 
Does the neomycin cassette interfere with the stability of the TAP tagged p53? 
 The initial analysis of the stability of the TAP tagged p53 AA5 cells by western blot 
analysis showed for the first time that the tagged p53 is able to be stabilized and accumulated 
after VP16-induced DNA damage,  suggesting that the large 25 kDa TAP tag is not interfering 
with the stabilization of p53 after genotoxic stress.  The levels of accumulated p53 were not 
equivalent between the tagged allele and the wild-type allele (Fig 3-12).  If the protein produced 
from a tagged allele does not reflect the behavior of the protein product from the wild-type allele, 
it would be difficult to draw conclusions about the protein binding partners of p53.  Hence, the 
protein level disparity had to be addressed.  Since insertion of the neomycin cassette moved the 
endogenous polyadenylation tail 2.2 kb further away from the end of the coding sequence, we 
suspected that the neomycin cassette was altering with the stability of the mRNA.  Although the 
function of the polyadenylation tail is somewhat complex, there are several hypotheses of how it 
affects the stability of mRNA and the initiation of protein synthesis (reviewed in (Millevoi and 
Vagner, 2010)).  Moving the polyadenylation tail over 2 kb downstream from its original 
location most likely interfered with protein binding and subsequent signaling events involved in 
the splicing, translocation and translation initiation of the p53-TAP mRNA.  The pAAV MCS 
vector was designed to have loxP sites flanking the neomycin resistance cassette allowing the 
removal of the cassette from the endogenous p53 in the eventuality that this type of problem 
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arose.  After the pMCI CRE plasmid containing the cre recombinase gene was transfected into 
the AA5 cells, cells were selected for the acquisition of sensitivity to G418 (Fig 3-13).  In cell 
lines which the cre excision removed the drug resistance cassette, the protein levels of the TAP 
tagged p53 was restored to the endogenous levels of the wild-type protein, implying that the 
hypothesis that the neomycin cassette was altering translation or mRNA stability was correct 
(Fig 3-14).               
 
Does the TAP tag interfere in the molecular properties of p53? 
 The ability of the TAP tagged p53 to accumulate after DNA damage was encouraging, 
but to prove that the TAP tag did not interfere in the molecular properties of p53, further 
experimentation was done.  The ChIP analysis of the binding of both alleles of p53 at the p21 
promoter demonstrated that the TAP tag did not interfere with the ability of p53 to bind to 
promoters.  Since different antibodies were used for the TAP- and p53-immunoprecipitates, we 
cannot quantitatively determine the amount of TAP tagged p53 versus wild-type p53 that is at 
the p21 promoter.  To assess the ability of the tagged p53 to bind to and modulate proteins, both 
BLM and HU-stabilized tagged p53 could be purified and the helicase activity of BLM could be 
measured.  To do so, both purified proteins would be incubated with a radiolabeled X-junctions 
mimicking a Holliday junction where BLM is known to promote branch migration (Karow et al., 
2000).  If the HU stabilized p53 is able to bind to and inhibit BLM, then the X-junction would 
not be disrupted.  If p53 does not inhibit BLM, then the X-junction would be disrupted, and two 
products would result; a one armed product (single stranded DNA) and a two armed product 
(half of the holiday junction) (Yang et al., 2002).     
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Purification of TAP tagged p53 along with its binding partners 
 The purification of tagged p53 along with interacting proteins was successful and the 
silver stain analysis showed that many proteins of various masses (Fig 3-18) are interacting with 
p53 and that these interactions change depending on the genotoxic stressor.  When the western 
blot analysis of the eluted fraction was probed with the p53 antibody two bands resulted: the 
TAP tagged p53, which after the TEV protease cleavage has a mass of 59 kDa, and the band 
from wild-type p53.  Since TAP tagged p53 is pulling down equimolar wild-type p53 in the 
purification, this indicates that the tag does not interfere with p53 oligomerization. 
 A second TAP tag could have been inserted into the wild-type p53 locus through gene 
targeting in the same manner as the other locus.  This would have resulted in all cellular p53 
being TAP tagged.  Since p53 acts as a tetramer and we demonstrated that the tagged p53 
interacts with the wild-type p53, there is no real desire to tag the other locus.  Having an 
unaltered locus is a useful internal control when determining the functionality of the tagged p53. 
 
Possible Uses for the TAP tagged p53 
Post-translational Modifications  
 p53 is a highly post translationally modified protein.  These modifications include 
phosphorylation, methylation, acetylation, sumoylation, neddylation and ubiquitylation and are 
thought to act as a barcode governing the activity of p53 (reviewed by (Murray-Zmijewski et al., 
2008) (Fig 2-2).  Extensive research has been done to identify the upstream kinases responsible 
for modifying p53 and how certain modifications impact the cellular activities of p53.  The TAP 
tag cell line could be used to purify p53 and through mass spectroscopy, all of the PTMs could 
be identified under any given set of circumstances.  Since the focus of this thesis is on the 
  
157 
 
different cellular responses to HU and PALA treatment, the p53 purified from CRE2 TAP cells 
treated with HU and PALA can be used to identify the PTMs of p53.  As discussed in the 
previous chapter, some of the modifications of p53 during HU and PALA treatment have been 
investigated with western blots; the results are striking.  The PTMs were asymmetrically 
opposed; if a specific serine was phosphorylated in HU treatment it was not phosphorylated in 
PALA treatment (Fig 2-8).  Using the nonbiased approach of mass spectroscopy, an all inclusive 
PTM map of the p53 accumulated by HU- and PALA-treatment could be constructed.  The 
upstream kinases could be elucidated and possibly give direction to the next experiment needed 
to understand the upstream cellular events promoting the oppositely modified p53 and 
subsequent different cellular outcomes.      
 
Protein Binding Partners 
Mitochondrial Fractionation 
 Not only can p53 be isolated from whole cells to determine what is binding to p53 but it 
could be purified from sub-cellular fractions to ask more specific questions.  p53 has been found 
in the mitochondria and is known to induce mitochondrial outer membrane permeabilization 
triggering the release of pro-apoptotic molecules (Chipuk et al., 2004).  Intact mitochondria 
could be fractionated from drug-treated cells and the protein binding partners of p53 could be 
identified.  Previously, we found that PALA-treatment promoted p53-dependent apoptosis while 
HU-treatment did not.  Thus, it would be interesting to compare the mitochondrial binding 
partners of p53 during these two treatments.  Hypothetically, one would expect to find p53 
associating with the pro-apoptotic Bcl2 family proteins during PALA treatment, such as Bax, 
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Bak, Bad and Bid while during HU treatment p53 may be associated with anti-apoptotic 
molecules Bcl-2 and Bcl-XL.  The TAP tag cell line could be used to ask such questions.   
 
Cytosolic Fractionation 
 The function of cytosolic p53 has recently been investigated and it has been linked to 
both inhibition of autophagy and to energy conservation.  During metabolic stress, it is thought 
that AMPK phosphorylates and activates p53 (Feng et al., 2005).  The accumulated p53 activates 
the transcription of sestrin 1 and sestrin 2.  Both sestrins preferentially activate AMPK towards 
phosphorylating TSC2 which inhibits mTOR (Budanov and Karin, 2008).  mTOR suppresses 
autophagy, so through its inhibition, p53 has been linked to activating autophagy during 
metabolic stress while basal levels of cytosolic p53 have been implicated in the inhibition of 
autophagy (Tasdemir et al., 2008).  Through inhibition of mTOR the cell is able to conserve 
energy and prolong viability.  This is fairly new and rapidly growing field, and with the TAP tag 
cell line, the involvement of p53 could be further examined.  Questions about the direct 
interactions between p53 and AMPK could be addressed, as well as identifying all proteins 
which interact with p53 in the cytosol.  Since cytosolic p53 has been associated with AMPK 
signaling, one would imagine at least some of the proteins binding to p53 will have a role in this 
signaling pathway.   
 
Nuclear Fractionation 
 The majority of p53 research has been focused on the nuclear functions of the tumor 
suppressor, specifically its functions as a transcription factor activating the transcription of cell 
cycle and apoptosis regulatory proteins.  The mechanism involved in determining which set of 
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genes p53 activates is not fully understood.  There are two theories: one is the p53-centric theory, 
in which the cellular fate of the cell depends on the activities of p53 which are regulated by the 
PTMs and protein interactions of p53.  The other theory is the p53-autonomous model that states 
that the cellular fate is determined independently of p53 activity and that, although p53 may be 
found at the promoter, the activation of transcription is dependent on other transcription factors 
(Gomes and Espinosa, 2010).  TAP purification of nuclear p53 from cells undergoing apoptosis 
(PALA-treated) versus cell cycle arrested cells (HU-treated) could be used to compare the PTMs 
and protein interaction of p53 between both cellular fates.  The similarities and differences may 
lead to further understanding of how the cellular fate is decided and if indeed p53 is a key 
regulator in the decision.          
 
Transcriptional Regulation 
 The enrichment of p53 at promoters does not necessarily indicate that transcription is 
activated.  There are instances where p53 is found at the p21 promoter yet it is not activating 
transcription.  Previously in our lab, Julie Bronder identified one of these instances where, during 
DDATHF treatment, p53 was found at the p21 promoter but due to the lack of PTMs of p53 and 
the closed chromatin structure of the promoter, transcription was not activated (Bronder and 
Moran, 2003).  During this dissertation work, two more instances were found, both HU and 
pemetrexed treatment resulted in a defect in significant p21 transcription even though p53 was 
found at the p21 promoter (Heyer, Racanelli and Moran, unpublished results and (Gottifredi et 
al., 2001), and Figs 2-6, 2-7).  This was not found during PALA treatment.  The hydroxyurea 
observation was previously identified and thought to be due to a decrease in the phosphorylation 
of RNA polymerase II which is required for transcriptional elongation (Mattia et al., 2007).  The 
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causative event for this defect was never identified.  Prior to any cellular stress, basal levels of 
p53 are at the p21 promoter and establish a gradient of paused RNA polymerase II at the 
promoter.  Upon stress, the RNA polymerase is converted to the elongation form via CTD 
phosphorylation, resulting in gene transcription.  This process requires the recruitment of several 
elongation factors including P-TEFb, FACT, DSIP, TPIIF and TFIIH.  This suggests that gene 
transcription of p53-dependent promoters depends on the protein complexes recruited after 
cellular stress (Espinosa et al., 2003; Gomes et al., 2006).  Nuclear purified TAP tagged p53 
from both HU- and PALA-treated cells would help to investigate the different protein complexes 
associating with p53 at promoters where in one instance p21 transcription is activated and in the 
other, it is not.  Promoter complexes could first be isolated through immunoprecipitation of a 
component of the preinitiation complex and then subjected to the TAP purification to isolate p53 
binding proteins.  With mass spectroscopy, the identities of the protein that are present or 
missing in both treatments could be achieved.  The PTMs of promoter bound p53 could also be 
identified and may possibly lead to an understanding of the signaling events required for 
transcriptional activation.     
 
S-phase Checkpoint 
 Another nuclear role of p53 is the S-phase checkpoint, which was described in depth in 
the previous chapter.  Since the role of p53 is still to be elucidated in this pathway, the TAP tag 
would be useful in expanding the knowledge in this field.  It appears that p53 exerts its tumor 
suppressor activity as a protein modulator in this pathway more than as a transcription factor.  By 
isolating p53 and all interacting proteins from nuclear extracts, or specifically from chromatin, 
the protein complexes could be identified.  To further enrich for stalled replication forks, an 
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initial immunoprecipitation could be performed with an antibody against a specific replication 
fork protein such as BLM, RPA or Rad51.  Then this pool of proteins could be subjected to the 
TAP purification resulting in isolation of the proteins which interact with p53 solely at stalled 
replication forks.  Identification of these proteins may lead to discovering new proteins 
previously not identified in the S-phase checkpoint, leading to further understanding of the 
signaling events occurring after a replication fork stalls.    
 
Modifications of the TAP tag 
 Since the development of the CRE2 TAP cell line, several other tandem affinity tags have 
been developed.  The weakness of the TAP tag was found to be the calmodulin binding peptide.  
TAP tagged p53 was not completely captured by the calmodulin beads as it was found in all the 
washes and a larger amount of protein remained on the calmodulin beads after the elution 
(Calmodulin supernatant (unabsorbed) and Cal Wash #1 & #2, Fig 3-16).  Since a large amount 
of the purified protein complex was lost at this step, upwards of 800 million cells had to be used 
to yield enough protein for analysis.  Different versions of the TAP tag have been engineered.  
The calmodulin peptide has been replaced with a FLAG tag or a streptavidin binding peptide.  
Protein A has been replaced with Protein G which is thought to have a slightly higher binding 
affinity for a broader range of IgGs (Sauer-Eriksson et al., 1995).  The modified TAP tag where 
the calmodulin binding peptide was replaced with the FLAG tag and the completely changed tag 
where both protein G binding units replaced the protein A units and the streptavidin binding 
peptide replaced the calmodulin peptide had a significant increase in purified protein yield 
(Burckstummer et al., 2006; Tsai and Carstens, 2006).  Recovery increased to 80% and 50 
million cells were used to obtain protein yields similar to what were achieved in my studies with 
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1 billion cells with the original TAP tag.  Interestingly, the original TAP tag paper tested 
combinations of calmodulin binding peptide, FLAG tag, histidine tag, streptavidin binding 
peptide, and chitin-binding domain and found the protein A and protein calmodulin binding 
peptide combination to yield the most efficiently recovered protein complexes in yeast cells 
(Rigaut et al., 1999).  Although there have been significant modifications in the TAP tag, the 
CRE2 TAP cells still have endless possibilities, the starting cell number simply needs to be 
adjusted to account for a lower efficiency of purification.       
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Chapter 4: Perspectives 
  
 Through the course of this dissertation, I have identified that human colon carcinoma 
cells respond differently to two nucleotide synthesis inhibitors, HU and PALA.  The difference 
lies at the level of activation of the S-phase checkpoint: whereas HU treatment activates the 
checkpoint resulting in Chk1 phosphorylation, PALA treatment fails to, resulting in p53-
dependent apoptosis.  Despite the wealth of information obtained regarding the molecular events 
occurring after treatment with both antimetabolites, several fundamental questions remain 
unanswered about why these differences exist.  These questions will be addressed within this 
chapter from a specific standpoint as well as from a global standpoint in regards to the clinical 
utility of antimetabolites.  
 
Why do colon carcinoma cells respond differently to an inhibitor of dNTP synthesis versus 
an inhibitor of pyrimidine synthesis?  
 The nucleotide concentrations after drug treatment were not measured in the course of 
this dissertation work.  These concentrations may lead to a better understanding of why the 
HCT116 cells responds in such different manners to HU and PALA treatment.  There is some 
evidence that nucleotide levels may affect the DNA binding capacity of p53 in that increased 
levels of ADP and dADP stabilize p53-DNA complexes whereas ATP, dATP, GTP and dGTP 
facilitate the release of p53 (Okorokov and Milner, 1999).  Further investigation would be 
  
164 
 
necessary to determine if the pyrimidine dNTPs would have an impact on the DNA binding 
capacity of p53 as well as to determine the nucleotide levels in HCT116 cells after HU or PALA 
treatment.  The original suggestion that p53 is capable of sensing nucleotide levels concluded 
that antimetabolites primarily affecting dNTP levels arrest early in S-phase, independent of p53 
status, while CTP, UTP and GMP synthesis inhibitors induce a p53-dependent G1 arrest (Linke 
et al., 1996).  Therefore, the idea that p53 is able to detect nucleotide levels is not universal, and 
is only relevant for some nucleotides.  A more probable explanation is that p53 senses changes in 
the signal transduction pathways rather than the direct changes in nucleotide levels.  The changes 
in the signal transduction pathways after treatment with nucleotide synthesis inhibitors ultimately 
could determine the cellular fate.  Interestingly, we observed a difference in phosphorylation of 
p53 between HU, PALA and the DNA damaging agent VP16.  p53 was phosphorylated at all 
investigated serines when cells were treated with VP16, a topoisomerase II inhibitor, which does 
not inhibit nucleotide synthesis.  Only a fraction of these residues were phosphorylated after 
either HU or PALA-induced nucleotide synthesis inhibition, suggesting that the signal 
transduction pathways after nucleotide deficiencies were different than that after DNA damage.   
 Why during PALA treatment is there a greater level of stabilized p53 than during HU 
treatment?  The dissimilar PTMs of p53 after treatment with HU or PALA may help to gain 
insight to as to why there is a difference in the total amount of accumulated p53.    During HU 
treatment, p53 is modified at serines 15 and 20, the hallmark sites known to inhibit MDM-
induced degradation of p53, while these residues are not modified during PALA treatment.  
Serine 392 is phosphorylated in PALA-treated cells (Fig 2-8).  This phosphorylation is known to 
enhance tetramerization which masks the nuclear export signal, possibly trapping PALA-
stabilized p53 within the nucleus and therefore protecting it from degradation.  If the level of p53 
  
165 
 
is the causative event promoting apoptosis or S-phase arrest, then understanding why there is a 
differing level is crucial for our understanding and the clinical implications of this dissertation 
work. 
 To further address the differences observed between HU treatment and PALA treatment 
in HCT116 cells, the question of how cells are traversing through S-phase with a limited pool of 
nucleotides should be addressed.  Are the cells accumulating DNA damage while synthesizing 
DNA with limiting nucleotides?  Does this DNA damage differ between drugs?  If so, is this the 
signal that causes the activation of the two different pathways?  The studies performed 
throughout this dissertation work suggest that cells are progressing through S-phase at a much 
reduced rate compared with the untreated cells.  HU treatment does not completely exhaust the 
nucleotide pools, but it is hard to imagine the small percentages remaining during treatment are 
enough to provide the nucleotides required to progress through an entire S-phase (Koc et al., 
2004).  If extensive DNA damage was occurring, the measured H2AX levels would be higher, 
similar to what was observed during VP16 treatment.  Also, during PALA treatment, if cells 
were accumulating DNA damage, why did they bypass the G1 arrest and enter S-phase?  Further 
experimentation to address these questions will build on the observations made during this 
dissertation, as well as understanding how drugs inhibiting enzymes within the nucleotide 
synthesis pathway can have such dissimilar cellular consequences.            
 The events responsible for the differing responses to HU and PALA treatment remain to 
be completely elucidated.  It may be due to the levels of nucleotides within the cell, the differing 
levels of accumulated p53, or it may be peculiar for HCT116 cells. Either way we discovered 
that colon carcinoma cells do not respond equally to nucleotide synthesis inhibitors and the 
clinical implications of these findings will now be discussed. 
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Clinical Implications 
 The hypothesis that the level of accumulated p53 may cause the differential cellular 
response to HU and PALA treatment could aid in targeted chemotherapy.  PALA treatment 
resulted in a p53-dependent apoptosis, a higher level of accumulated p53 and higher levels of 
p53 bound to all investigated promoters compared to promoter residence after VP16 or HU 
treatment.  Conversely, HU treatment resulted in a cytostatic S-phase arrest, a lower level of 
accumulated p53, and significant p53 enrichment only at high affinity promoters.  Overall, it 
appears that the high level of accumulated p53 during PALA treatment is able to bind specific 
promoters and transactivate these genes, resulting in programmed cell death.  Cancer in which 
p53 is over expressed due to deletion of Mdm2, might be pushed towards apoptosis while the 
normal stem cells would arrest in S-phase until treatment subsides.  If it is true that the level of 
accumulated p53 determines the cellular fate during nucleotide stress, then cancer cells over 
expressing a wild-type form of p53 could be treated with a nucleotide synthesis inhibitor.  Prior 
to any treatment, p53 would be poised at proapoptotic promoters, and after nucleotide synthesis 
is inhibited, p53 levels would increase activating the transcription of these genes causing 
apoptosis.  In the normal cells, p53 levels would be low prior to any treatment; after treatment, 
p53 levels would increase, but not to the extent observed in the cancer cells, resulting in S-phase 
arrest, similar to what we observed after HU treatment.  This would result in cytotoxicity of the 
cancer cells and a reversible cytostatic arrest in the normal cells. 
 In light of the current ability to sequence the cancer genome, identifying the upstream 
pathways regulating p53 after inhibition of nucleotide synthesis would be very informative.  The 
genetics of cancer is exhaustively being studied in hopes of finding common mutational trends 
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within cancer types.  If the upstream modulators of p53 after HU and PALA treatment are 
identified, then cancers known to contain mutations of these modulators perhaps will have a 
higher response rate to nucleotide synthesis inhibitors.  The PTMs of p53 after treatment with 
either HU or PALA suggest different upstream signaling pathways are activated during the two 
treatments, resulting in the diametrically opposed pattern of phosphorylation.  If our hypothesis 
is true that p53 does not directly sense nucleotide levels but does sense changes in signaling from 
stalled replication intermediates, then the identification of the specific p53 activating pathway 
being activated would be beneficial.  Specifically, in the case of PALA treatment, where the 
PTMs of p53 stimulate sequence-specific DNA binding and transcription of apoptotic genes, the 
upstream kinases responsible for phosphorylated serines 37, 46 and 392 would advance our 
understanding of the resulting apoptotic response.  CK2 is thought to be a cancer driver since it 
was found at elevated levels in a number of cancers and cells containing elevated CK2 have a 
selective advantage for oncogenesis (reviewed in (Ruzzene and Pinna, 2010)).  CK2 is known to 
phosphorylate p53 at serine 392 and this phosphorylation was found to enhance p53 tetramer 
stability, increase DNA binding and transcriptional activity of p53 (Meek et al., 1990).  In cancer 
cells that have an elevated level of CK2, it is logical to think that CK2 is readily available to 
phosphorylate p53 at serine 392 after nucleotide deficiencies, promoting DNA binding and 
transcription, and in the case of PALA treatment, apoptosis.  This concept can be extended to 
inactive mutant forms of ATR or Chk1; treatment with HU would hypothetically drive cells to 
apoptosis since the S-phase cell cycle checkpoint would not be intact, while normal surrounding 
cells would reversibly arrest in S-phase.  Through sequencing of the cancer genome, the 
knowledge of probable mutations within cancer types will be available, thus allowing for 
chemotherapies to be designed according to the genetics of an individual cancer case, 
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significantly improving the treatment of cancer.  Therefore, the signaling pathways involved in 
the cellular responses to HU and PALA need to be identified, as well as the proteins 
phosphorylating p53, to better understand how inhibitors of nucleotide synthesis can be used in 
the treatment of cancer.  With the use of the TAP tagged p53 cell line generated during this 
dissertation work, this may now be possible.     
 The p53 TAP tagged cell line can also be used to identify S-phase specific p53 binding 
partners.  A large part of the function of the S-phase checkpoint is to modulate homologous 
recombination proteins to ensure DNA repair does not occur in times of replicative stress. With 
the use of the TAP tag, new proteins can be identified which may have a high incidence of 
mutations within human cancers.  Cancers containing mutation in S-phase proteins would be 
more sensitive to S-phase specific drugs since the checkpoint would not be intact.  Constitutively 
active mutants of pro-recombinogenic proteins would result in the S-phase checkpoint losing 
control of DNA repair activity.  If these cancer cells are treated with HU, or another S-phase 
specific drug, apoptosis would be induced due to increased homologous recombination at a time 
of genomic instability.  The homologous recombination protein Rad51 has been implicated in 
cancer.  Decreased Rad51 expression was found in 30% of the investigated 179 breast cancer 
cases and in sporadic invasive ductal breast cancer.  In pancreatic adenocarcinoma, Rad51 was 
found to be over expressed (reviewed in (Thacker, 2005)).  Together with the finding that cells 
containing a Rad51 mutant preventing phosphorylation by Chk1 are more sensitive to HU 
treatment, suggests that targeted therapeutics in cancers containing Rad51 mutations is possible 
(Sorensen et al., 2005).  It is also likely that there are other proteins involved in the S-phase 
checkpoint which still remain to be identified and with the use of the p53 TAP tagged cell line, 
these multi-protein complexes can be isolated and identified.     
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